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SUMMARY.
An overview of the noradrenergic system, including the identification of 
norepinephrine (NE) in animal tissue, its synthesis and metabolism, 
adrenoceptor classification, peripheral and central actions, uptake and 
storage, and mechanisms of NE release are presented.
After characterizing the kinetic, ion dependence and inhibitor sensitivity of the 
norepinephrine transporter (NET) expressed in a recombinant cell line (LLC- 
NET cells), the influence of catecholamine (CA) metabolizing enzymes on 
studies of transport was assessed. Inhibitors of catechol-0-methyltransferase 
(COMT) potentiated the apparent uptake and retention of [^H]NE and [^H]DA. 
COMT inhibition had a greater influence on pH]DA than [^H]NE uptake and 
retention, which corresponds to the higher spontaneous loss of radiolabel from 
cells exposed to [^H]DA than pH]NE ([^HJmethoxytyramine, is more lipophilic 
than [^H]normetanephrine). The monoamine oxidase inhibitor, pargyline, had 
no augmentary action on [^H]CA uptake, but actually inhibited substrate influx 
by blocking the NET.
[^Hjsubstrate specific differences were demonstrated for [^H]NE, [^H]DA and 
[^HjlVIPP^. For a given length of exposure to low Na^ or tyramine, [^H]NE 
release was the lowest, but most sensitive to NET inhibitors. Disparities in the 
kinetics of each [^H]substrate for the inwardly facing NET may account for this. 
Inhibitors of the NET were found to stimulate the efflux of [^H]substrates from 
preloaded cells incubated in a physiological HEPES buffer. Efflux was NET-
IV
dependent and differed greatly for each [^H]substrate. Inhibitor-induced 
release was greatest for pHJMPP'^ and least for [^HjNE.
Finally, a functional model of carrier-mediated NE release in myocardial 
ischemia, was developed in this study. Release of [^H]MPP^ was stimulated 
by Na’^ -H’*’ exchanger (NHE) activation and modulated by inhibitors of the NET, 
NHE, Na’^ .K '^-ATPase, and via a receptor-operated pathway. Excessive NE 
release contributes to severe myocardial arrhythmias, therefore an improved 
understanding of the carrier-mediated NE release process will ultimately 
enhance our ability to intervene and prevent the deleterious effects of 
excessive NE release.
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CHAPTER 1
INTRODUCTION
List of commonly used abbreviations.
AR, adrenoceptor; CA, catecholamine; COMT, catechol-O-methyltransferase; 
DA, dopamine; DAT, dopamine transporter; DMI, desipramine; E, 
epinephrine; EIPA, 5-(A/-ethyl-Af-isopropyi)-amiloride; LLC-NET, LLC-PKi 
cells transfected with human norepinephrine transporter cDNA; MAO, 
monoamine oxidase; MPP*, [^H]A/-methyl-4-phenylpyridinium, NE, 
norepinephrine; NET, norepinephrine transporter; NHE, NaVH^ exchanger, 
PKA, cAMP-dependent protein kinase; PKC, protein kinase C; TH, tyrosine 
hydroxylase; VMAT, vesicular monoamine transporter.
1.1 The discovery of norepinephrine.
In 1905, Elliot made the first proposal of chemical transmission at synapses 
(Elliot, 1905). He suggested that epinephrine (E) might be released from 
sympathetic nerve endings and that it may then act at the junction of 
sympathetic nerve endings and effector organs. Experimental confirmation of 
this hypothesis did not occur until 1921, when responses to sympathetic nerve 
stimulation and those of E on target organs were shown to be very similar 
(Cannon and Uridil, 1921). Subsequent findings, that postganglionic 
stimulation of nerves of the rabbit’s ear, released what appeared to be E 
(Gaddum and Kwiatkowski, 1939) and that certain organs and their 
sympathetic nerves contained E (Cannon and Lissak, 1939; Lissak, 1939), 
supported the original hypothesis leading to its firm acceptance.
It was not until 1946, when the presence of norepinephrine (NE) was 
identified in the animal body, that the credibility of the original hypothesis and 
identity of the transmitter involved was seriously challenged (Von Euler, 
1946a; Von Euler, 1946b). Identification of NE in mammalian tissue, renewed 
interest in a chemical that had been artificially synthesized several years 
earlier (Stolz, 1904). At the time of its synthesis, the first observations of the 
biological properties of NE were made. Probably the most notable finding, 
was the similarity of the action of NE to E on the blood pressure of animals. 
Its activity was comparable to E in terms of ability to raise blood pressure, yet 
it was less toxic (Stolz, 1904). Despite the findings of Stolz, little interest was
shown in NE between the years of its synthesis and identification in the 
animal body. However, with hindsight, the few papers that investigated the 
actions and properties of NE, did suggest NE as a tentative candidate for 
sympathetic nerve transmission. A paper entitled chemical structure and 
sympathomimetic action of amines (Barger and Dale, 1910), actually suggests 
a role for NE in neurotransmission. The discussion implies that the actions of 
some artificially synthesized catecholamines (CAs) resemble those of 
stimulated sympathetic nerves more closely than E. A major finding was the 
inability of ergotoxine (a substance known to inhibit the pressor response of E 
by adrenoceptor blockade) to reverse the pressor response after stimulation 
of sympathetic nerves or addition of NE. The differences found between E 
and the action of the substance liberated from sympathetic nerve endings, led 
one group of investigators (Cannon and Rosenbleuth, 1933) to suggest a 
theory of two sympathins (sympathin E and sympathin I). They proposed that 
the common mediator released from sympathetic nerves combined with an 
excitatory or inhibitory substance in the effector cell to form sympathin E or 
sympathin I (excitatory and inhibitory, respectively). The possible existence 
and involvement of intermediate substances in sympathetic nervous 
transmission was not fully accepted. Greer and coworkers (1938) proposed 
an alternative theory, after experiments which compared the results of 
injections of DL-NE (the synthetic compound), L-E and stimulation of the 
hepatic nerves in the cat before and after ergotoxine treatment. Rather than 
the involvement of intermediate substances, they suggested that either of two 
transmitters, which have direct actions on effector cells, could be released
from sympathetic nerves (Greer et al., 1938). It was suggested that the 
excitatory transmitter might be NE and the inhibitory one E. The discovery of 
the enzyme L-DOPA decarboxylase in mammalian tissues (Holtz et al., 1938), 
which converts L-DOPA to dopamine (DA), led to another line of evidence that 
NE is an endogenous substance in mammalian tissue. The suggestion that 
NE might be formed as an intermediate in mammalian tissues during the 
synthesis of E (Blaschko, 1939), was made on the basis of structural 
similarities between DA and NE (the only difference being the presence of a 
(3-hydroxyl group in NE). In 1946, a detailed comparison of extracts from 
splenic nerves and spleen (ox), and mammalian heart with E showed a 
number of differences and suggested that the CA in such extracts was NE 
(Von Euler, 1946a; Von Euler, 1946b). Shortly after this discovery, several 
groups confirmed the presence of NE in mammalian tissue and nerves. NE 
was detected in extracts of blood vessels from several different species 
(Schmiterlow, 1948) and was recognized as the transmitter in the liver 
(Gaddum and Goodwin, 1947). After synthetic NE was resolved into the 
optical isomers (Tullar, 1948), the naturally occurring form of NE was 
identified as L-NE in splenic nerves (Von Euler, 1948). Direct evidence for the 
release of NE by postganglionic sympathetic nerve stimulation occurred soon 
after its identification in mammalian tissues (Peart, 1949; Outschoorn and 
Vogt, 1952). It is now firmly established that NE is the major transmitter 
present in sympathetic neurones.
1.2 Biosynthesis of catecholamine neurotransmitters.
The first and rate-limiting step in the biosynthesis of NE is the hydroxylation of 
the aromatic amino acid tyrosine to 3,4-dihydroxyphenylalanine (DOPA; see 
figure 1) (Levitt et al., 1965). Tyrosine hydroxylase (TH), the enzyme 
responsible, is found only in the cytoplasm of CA containing cells (Levitt et al., 
1965). As the catalyst of the rate-limiting step in CA biosynthesis, TH is 
subject to multiple controls, both short and long term regulation (Alousi and 
Weiner, 1966; Shen and Abell, 1983; Nagatsu, 1995; Kumer and Vrana, 
1996). Moment to moment regulation of TH includes activation in response to 
increased nerve traffic (Alousi and Weiner, 1966) and negative feedback 
through end product inhibition (Kumer and Vrana, 1996). One mechanism for 
short-term activation of TH is believed to be mediated in part by 
phosphorylation of the enzyme. Four phosphorylation sites have been 
identified, corresponding to serine residues (ser) 8 , 19, 31 and 40 in the rat 
TH amino acid sequence (Campbell etal., 1986; Haycock, 1990). All of these 
sites can be phosphorylated by several of the common multiprotein kinases 
(Nagatsu, 1995) and it has been shown that phosphorylation of ser 31 and 40 
leads to significant enzyme activation in vitro. Extensive studies of ser 40 
have revealed that phosphorylation of this amino acid results in a 
conformational change of TH that triggers the release of inhibitory CA bound 
to the active site iron (Muga et ai., 1998).
An obligatory cofactor for TH is tetrahydrobiopterin (BH4) which is synthesized
and regenerated from quinonoid dihydrobiopterin (qBHz) by dihydropteridine 
reductase (DHPR) (Kaufman, 1957). DHPR therefore plays an essential role 
in CA biosynthesis by providing adequate concentrations of BH4 for TH. 
Similarly to its end product regulation of TH activity, dopamine has been 
illustrated to be a potent noncompetitive inhibitor of DHPR, hence suggesting 
a possible dual regulatory mechanism of DA on tyrosine hydroxylation (Shen 
and Abell, 1983). In addition to increasing the inhibitory constant (Kj) for CA 
feedback inhibition, phosphorylation of TH by protein kinase A (PKA) reduces 
the affinity of the enzyme for BH4, allowing more efficient utilization of limited 
amounts of BH4 (Kumer and Vrana, 1996).
TH protein and activity levels can be modulated in the long-term by changes 
in TH mRNA concentrations and translational regulation. In the intact animal, 
electrical stimulation, environmental stress and drugs such as reserpine 
(Pasinetti et a i, 1990) elicit a long-term increase in TH activity. In such 
cases, enhanced TH activity is not a result of the activation of a pre-existing 
pool of enzyme but is due to the synthesis of new enzyme molecules 
(Pasinetti etal., 1990).
The second step in the biosynthetic pathway of CAs is the conversion of 
DOPA to DA (Holtz et a!., 1938). DOPA decarboxylase catalyses this 
reaction, it is also found in the cytosol, but unlike TH is not confined to CA 
synthesizing cells and is a relatively nonspecific enzyme (Mallet, 1996). 
Aswell as decarboxylating DOPA, DOPA decarboxylase acts on various other
L-aromatic amino acids, such as L-histidine and L-tryptophan (which are 
precursors in the synthesis of histamine and 5-HT respectively). This enzyme 
is not rate-limiting for the production of NE and does not appear to be a target 
for effective regulation of CA synthesis.
The hydroxylation of DA to form NE is catalyzed by the enzyme dopamine 13- 
hydroxylase (DBH) (Kumer and Vrana, 1996). Although this enzyme is 
relatively non-specific in terms of substrate specificity, its distribution is limited 
to CA-synthesizing cells. DBH is localized in membrane-bound (77-kDa) and 
soluble (73-kDa) forms in neurosecretory vesicles of the noradrenergic 
neurons of the central and peripheral nervous systems and in the chromaffin 
granules of the adrenal medullary cells (Sabban and Nankova, 1998). When 
NE is released from noradrenergic nerve terminals, a small amount of DBH 
accompanies it (De Potter et a/., 1971). This is presumably the soluble form 
of the enzyme. Unlike NE, DBH is not subject to rapid uptake or subsequent 
degradation so its concentration is often measured in samples of plasma and 
body fluids to establish an index of overall sympathetic nerve activity (De 
Potter et al., 1971). DBH gene expression is elevated in vivo in response to a 
variety of stimuli, including, hormones, growth factors, trans-synaptic signals 
and stress (Sabban and Nankova, 1998). Data for mRNA levels, 
immunoreactive protein and DBH activity all indicate that conditions which 
stimulate prolonged CA biosynthesis, also lead to a marked elevation in DBH 
expression (Sabban and Nankova, 1998). Some of the conditions which are 
known to regulate TH gene expression, also, alter DBH gene expression in a
similar fashion (Sabban and Nankova, 1998).
Phenylethanolamine-N-methyltransferase (PNMT) is the enzyme responsible 
for converting NE to E (Kumer and Vrana, 1996). It catalyzes the transfer of a 
methyl group from S-adenosylmethionine to NE or other p-hydroxylated 
phenylethylamines. This enzyme is highly localized in the cytoplasm of the 
chromaffin cells of the adrenal medulla and in certain neurons in the CNS.
Figure 1. Catecholamine biosynthesis.
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1.2.1 Degradation of norepinephrine.
Monoamine oxidase (MAO) and catechoi-O-methyl transferase (COMT) are 
the 2 main enzymes responsible for the metabolism of CAs (see figure 2) 
once they have been removed from the extracellular fluid by uptake-1 and/or 
uptake-2 (Boulton and Eisenhofer, 1998). Both of these enzymes are located 
intracellularly, MAO being bound to the surface membrane of mitochondria. 
MAO exists in 2 forms called MAO A and MAO B (Denney et al., 1982; 
Denney et al., 1983). The main differences between the 2 isozymes are 
substrate specificity, distribution and drug inhibition profiles (Abell, 1986; 
Boulton and Eisenhofer, 1998). Any NE that is displaced from or leaks out of 
the storage vesicles, or excess NE that is taken up by the prejunctional 
membrane, can be deaminated by MAO to the corresponding aldehyde. In 
the periphery, aldehyde dehydrogenase rapidly metabolizes NE-aldehyde to 
the carboxylic acid dihydroxymandelic acid (DHMA; see fig. 2). The principle 
subtype responsible for this is MAO A, whereas both subtypes catalyze DA 
(Abell, 1986). Méthylation of one of the catecholamine -OH groups to give 
the methoxy derivative is catalyzed by COMT. As well as acting on the CAs, 
metabolites produced by MAO are methylated by COMT. O-methylation of 
NE gives rise to the metabolite normetanephrine. Subsequent action of MAO 
on normetanephrine and of COMT on DHMA produces the main final 
metabolite of NE in the periphery, vanillylmandelic acid (VMA).
10
Figure 2. Pathways of catecholamine metabolism.
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The most active pathways are shown by the more solid arrows and the least 
active by dashed arrows. DBH, dopamine /^-hydroxylase; PNMT, 
phenylethanolamine-N-methyltransferase; COMT, catechol-0-
methyltransferase; MAO, monoamine oxidase; AR, aldehyde reductase; AD, 
aldehyde dehydrogenase; DOPET, dihydroxyphenylethanol; DHPG, 
d i hyd roxy pheny Ig lycol ; DOPAC, dihydroxyphenylacetic acid; MOPET, 
methoxyhydroxyphenylethanol; DHMA, dihydroxymandelic acid; MHPG, 
methoxyhydroxyphenylglycol; HVA, homovanillic acid; VMA, vanillylmandelic 
acid. Figure taken from Boulton and Eisenhofer (1998).
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1.3 Adrenoceptors.
Dale (1906) was the first to demonstrate that epinephrine (E) elicited two 
distinct responses in isolated vascular beds, vasoconstriction (which was the 
case for the majority) and vasodilatation, resulting in a respective rise or fall of 
arterial pressure. An even more surprising finding was the disappearance of 
the vasoconstrictor component of E in animals injected with an ergot 
derivative. Epinephrine actually caused a fall rather than a rise in arterial 
pressure in these experiments (Dale, 1906). Although it is now easy to 
interpret these results as an unmasking of the p-adrenoceptor-mediated 
effects of E, by a-adrenoceptor blockade. Dale avoided this explanation at the 
time of these findings.
Ahlquist reported the first clear evidence of adrenoceptor heterogeneity more 
than 50 years ago (Ahlquist, 1948). He studied the effects of six 
sympathomimetic amines on several different tissue types and functions. His 
work (from potency orders) indicated that there were 2 classes of 
adrenoceptor (which he named a and p), but he concluded that the responses 
they mediate could not simply be described as excitatory or inhibitory, as 
either receptor may have either kind of action depending on the location. The 
major differences in agonist potency order for the two receptor classes 
described by Ahlquist, were the affinities for NE and the synthetic CA, 
isoprenaline. A simplified version of his potency order for a- and p-
12
adrenoceptors (AR) is as follows: a-AR, E> NE> isoprenaline and for p-AR, 
isoprenaline > E > NE (Ahlquist, 1948).
1.3.1 a-Adrenoceptor heterogeneity.
Experiments by Brown and Gillespie (1957) demonstrated a positive effect of 
the a-AR antagonist phenoxybenzamine on NE overflow from stimulated 
nerves of the perfused cat spleen (Brown and Gillespie, 1957). They 
postulated that this increase in NE overflow was a result of a-AR blockade on 
the effector organ, which was thought to be an important site of loss of the 
released transmitter. This hypothesis was initially challenged when it was 
discovered that phenoxybenzamine could also inhibit the transporter 
responsible for the reuptake of released NE (Iversen, 1965). However, further 
studies with compounds that inhibit the NET without blocking ARs, such as 
cocaine and desipramine, elicited very little or no increase in NE overflow 
during nerve stimulation (Geffen, 1965; Dubocovich and Langer, 1973). As 
NE is also removed from the synaptic cleft by an extraneuronal uptake 
system, the possible significance of phenoxybenzamine on blockade of this 
system was tested. Indeed, it was shown that a significant amount of [^H]NE 
released by nerve stimulation was composed of [^H]NE metabolites in 
phenoxybenzamine treated groups (Eisenfeld et al., 1967; Iversen and 
Langer, 1969), though this did not fully account for the enhanced NE overflow 
seen with a-AR blockers (Langer, 1980). Subsequently it was shown that 
concentrations of a-AR antagonists that do not inhibit neuronal or
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extraneuronal uptake of NE still enhanced NE overflow during nerve 
stimulation (Starke et a i, 1971; Enero et a i, 1972). Furthermore, the release 
of dopamine-/?-hydroxylase, an enzyme found in storage vesicles that is 
released with NE during exocytosis, was shown to be enhanced in 
phenoxybenzamine treated tissues. This enzyme cannot be metabolized or 
removed by reuptake systems, indicating an actual increase in release of 
transmitter (De Potter et a i, 1971; Cubeddu and Weiner, 1975). Similar 
results (i.e. a potentiation of NE overflow during nerve stimulation, with a-AR 
blockade) were obtained in experiments using guinea-pig isolated atria, where 
the response to nerve stimulation is mediated by a postjunctional p-AR 
(McCulloch et a i, 1972). If the increase in NE overflow were due to a-AR 
occupation by the a-AR antagonist phenoxybenzamine, no increase would be 
expected in experiments with tissues known to possess the p-AR subtype. 
This lead to the hypothesis that a-AR are present in the outer surface of 
noradrenergic nerve endings, where they are involved in the regulation of NE 
release through a negative feedback mechanism (Langer, 1977). The finding 
that a-AR agonists inhibit NE overflow during nerve stimulation further 
supported this hypothesis (Langer, 1977).
It is currently accepted that 3 main AR families (ai, a2 , and p) exist. All 
belong to the large G-protein-linked superfamily of receptors that have seven 
transmembrane domains and share a striking similarity in secondary structure 
to bacteriorhodopsin (Kobilka et a i, 1987a; Hein and Kobilka, 1997). The 
development of more selective drugs and the use of molecular cloning
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technology have enabled the identification and cloning of several distinct 
subtypes for each family of AR (see tables 4 and 5).
1.3.2 ai-Adrenoceptors.
Activation of ai-AR leads to an increase in intracellular levels of free Ca^^. 
This is achieved by coupling of the receptor to phopholipase C (P L C ) through 
the Gq G-protein (Smrcka et a i, 1991). Once activated, PLC  initiates the 
hydrolysis of phosphatidylinositol bisphosphate (a membrane phospholipid), 
producing two second messengers, diacylglycerol (DAG) and inositol 1,4,5- 
triphosphate (IPs). DAG is a potent activator of protein kinase G (P K C ) and 
IPs mediates the release of sequestered Ca^^ from internal stores via a 
specific receptor (Berridge and Irvine, 1989). ai-AR are also coupled directly 
to the receptor operated Ca^  ^channel (Han et a/., 1987).
Heterogeneity of ai-ARs was first suggested by Morrow and Creese (1986) 
on the basis of radioligand binding studies in rat brain. They found that the 
ai-AR antagonists phentolamine and WB 4101 competed for [^H]prazosin 
binding with shallow and biphasic curves, whereas prazosin exhibited a steep 
and monophasic competition curve (Morrow and Creese, 1986). In a different 
study, only about half of the ai-AR binding sites of the rat cerebral cortex 
were inactivated by the site-directed alkylating agent, chloroethylclonidine 
(CEC) (Han et al., 1987). Subsequent studies with other tissues revealed 2 
populations of a-AR binding sites and responses, CEC-sensitive and CEC-
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insensitive sites. It was found that sites with a high affinity for the competitive 
antagonist WB 4101 and its congeners, correlated with the CEC-insensitive 
site (aiA-AR) (Minneman et al., 1988). The existence of these 2 
pharmacologically distinct ai-ARs is widely accepted.
The first a i-A R  to be cloned was the aib-AR (Cotecchia et al., 1988) from a 
hamster vas deferens cell line (DDi-MF2). The expressed clone has 
properties consistent with the pharmacological profile of a^-AR in native 
tissues, having low affinity for WB 4101 and other selective œia“AR. The 
cloned aib-AR was also sensitive to irreversible alkylation by CEC, consistent 
with aiB-ARs. A rat homolog of this receptor was identified using a cDNA 
probe derived from the hamster clone (McGehee et al., 1990). The rat 
homolog showed a greater than 98% amino acid identity with the hamster aib- 
AR clone and had a similar pharmacological profile. mRNA corresponding to 
these clones is readily detectable in a variety of tissues known to possess 
homogenous populations of aie-ARs, including rat liver (Price et al., 1994). 
Cloning of the aia-AR proved much more difficult and controversial. In 1990, 
Schwinn et al. identified a novel cDNA encoding an a i-A R  from a bovine brain 
library that was similar to the aiA site in terms of its affinity for WB 4101 and 
phentolamine, but resembled the am site with regard to inactivation by CEC. 
One of the most puzzling findings was the low affinity of (+)-niguldipine (the 
most selective aiA-AR ligand) for this site (Schwinn et al., 1990). At the time, 
it was thought that this represented a novel subtype of ai-AR, so it was given
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the name aic-AR. Subsequently, homologs of this site were cloned from rat 
(Laz e ta i, 1994; Perez ef a/., 1994) and human tissue (Weinberg etaL, 1994; 
Schwinn et a/., 1995). When expressed, these homologs have a high affinity 
for (+)-niguldipine and are quantitatively much less sensitive to alkylation by 
CEC than aib-ARs. It should also be noted that, in more recent studies, high 
affinity for (+)-niguldipine has also been detected for the bovine aia-AR 
(Schwinn etaL, 1995).
A third subtype of ai-AR was cloned by (Lomasney et al., 1991) which shared 
common properties with both the aiA-AR and am-AR. For a long time there 
was much confusion over the identity of this subtype, which was initially 
defined as aiA-AR and then awo-AR after several pharmacological studies of 
the expressed clone. Eventually it was shown that this clone (now named aia- 
AR) is different from aiA-AR in many respects, particularly in terms of the 
affinities for particular aiA-AR selective ligands (Perez et a!., 1994; Forray et 
al., 1994; Laz et al., 1994). The aia-AR was also considerably more sensitive 
to alkylation by CEC than aia-AR (Forray et al., 1994; Laz et al., 1994). 
Comparisons of the three cloned human ai-ARs for various a-AR antagonists 
are summarized in table 1 .
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Table 1. Comparison of the affinities of a-adrenoceptor antagonists for
expressed ai-adrenoceptor clones
Clone Kj (nM) 
(chromosome)
OCia Ollb Olid
Compound (C8) (C5) (C20)
CEC 855 473 549
Prazosin 0.51 0.32 0.32
WB-4101 0.37 9.9 0.8
5-methylurapidil 2.3 92 21
ARC-239 0.16 0.95 0.38
(±)-Niguldipine 1.87 24.8 45.4
Indoramin 3.7 29 110
Human ai-adrenoceptor clones were expressed in CHO, COS-7 or rat 
fibroblast cells. Table adapted from Hieble et al. (1995). CEC, 
chloroethylclonidine; prazosin, 1 -[4-Amino-6,7-dimethoxy-2-quinazolinyl]-4-[2- 
furanylcarbonylj-piperazine; WB-4101, 2-(2,6)-Dimethyoxyphenoxyethyl)- 
aminomethyl-1,4-benzodioxane; ARC-239, [2-[2-[4(o-methoxyphenyl)- 
piperazine-l-yl]-ethyl]4,4-dimethyl-3,1(2H,4H)-isoquinolinedione]- 
dihydrochloride; (±)-niguldipine, (±)-1,4-Dihydro-2,6-dimethyl-4-(3- 
nitrophenyl)-3,5-pyridinediacarboxylic acid 3-4(4,4-diphenyl-1-piperidinyl)- 
propyl methyl ester; indoramin, N-[1-[2-(1H-lndol-3-yl)ethyl]-4- 
piperidinyl]benzamide.
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1.3.3 a2-Adrenoceptors.
The 3 subtypes of ag-AR recognized to date share many common features. 
All Œ2-AR are coupled to adenylate cyclase (AC) or ion channels by the G, G- 
protein (Summers and McMartin, 1993). Thus, they alter cellular activity by 
reducing the levels of intracellular cAMP or by directly modifying the activity of 
specific ion channels. It has been demonstrated that ion channel targets of 
Œ2-ARS include the NaVH^ antiporter, Ca^^ and K’" channels (Bylund, 1988). 
Comparisons between pH]-clonidine and pH]-yohimbine binding in a variety 
of tissues (Bylund, 1981) provided the first evidence for Œ2-AR receptor 
heterogeneity. Another study demonstrated that prazosin was significantly 
more potent in neonatal rat lung (Latifpour et al, 1982) and in rat cerebral 
cortex (Cheung et a l, 1982) than it was in the human platelet. Initially, it was 
concluded that different Œ2-AR exist in rodent and non-rodent species (the 
term isoceptors was used to describe this). Since these original findings, it 
has been demonstrated that particular regions of the human and rat brain 
contain 2 populations of Œ2-AR which differ in their affinity for prazosin by 30- 
to 40-fold (Petrash and Bylund, 1986; Bylund, 1985). In conclusion, it was 
proposed that 2 subtypes of Œ2-AR (œ2a and a2B-AR) exist in these tissues. A 
third Œ2-AR was discovered during studies to further characterize the a2A and 
Œ2B-ARS. The pharmacological profile of the Œ2-AR of opossum kidney (OK) 
cells differed to the œ2a and Œ2B-AR (Bylund, 1988; Murphy and Bylund, 1988). 
Despite being similar to the a2B-AR, in terms of its relatively high affinity for 
prazosin, the K, ratio of prazosin to yohimbine is closer to the Œ2A-AR (Bylund,
19
1988).
All 3 subtypes of a2-AR have now been cloned. The first Œ2-AR cDNA was 
isolated from human platelet (Kobilka etaL, 1987b) and designated as a2-C10 
(known as the a2A-AR), based on its location on human chromosome 10 . 
Human platelet Œ2-AR were purified and peptides obtained by cyanogen 
bromide. Oligonucleotide probes corresponding to amino acid sequences 
obtained from the purified peptides were sequenced and used to screen a 
human genomic DNA library. 2 overlapping probes (each 39 amino acids in 
length) strongly hybridized to 3 clones (plaque hybridization analysis), which 
were isolated and found to be identical. The deduced amino acid sequence 
coded for a protein 450 amino acids in length. A second subtype of aa-AR 
was cloned from a human kidney cDNA library (Regan et al., 1988) using the 
gene for the human platelet Œ2-AR (a2A-AR) as a probe. When expressed in 
COS-7 cells, competition curve analysis indicated this to be the Œ2B-AR site. 
This gene is located on chromosome 4 in humans. Subsequent studies 
comparing potencies of drugs at the expressed receptor, to data obtained 
from cell lines containing the Œ2A-, «26- and a2c-AR initially suggested the 
existence of another subtype of Œ2-AR. It has now been accepted that this 
cloned Œ2-AR corresponds to the oc2c-AR. A third Œ2-AR was cloned from a 
human placental genomic library (Lomasney et al., 1990) using the 
polymerase chain reaction (PCR) with oligonucleotide primers homologous to 
conserved regions of the cloned a2-C10 (œ2a) and Œ2-C4  receptors. Studies 
of the expressed receptor revealed a unique pharmacological profile («20)-
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Recently, neurotransmitter release in mice in which the genes encoding the 
three a2-adrenoceptor subtypes were disrupted, was investigated (Hein et a/., 
1999). It was found that both the Œ2A- and a2c-subtypes are required for 
normal presynaptic control of NE release from sympathetic nerve endings in 
the heart and central noradrenergic neurons. Inhibition of electrically-induced 
[^H]NE release by an a2 agonist, was significantly reduced in the atria of mice 
lacking the a2A-subtype. Furthermore, the inhibitory effect of the a2-AR 
agonist was abolished in mice lacking both the a2A- and a2c-subtypes. In vivo 
experiments demonstrated an increase in plasma NE levels and cardiac 
hypertrophy, illustrating the physiological importance of both receptor
subtypes in autoregulation of NE release.
Autoregulation of NE release from sympathetic nerve endings via 0C2-AR
stimulation has been shown to involve the inhibition of N-type calcium
channels by the py G-protein subunit (Ikeda, 1996; Herlitze e ta i, 1996).
Comparisons of the three cloned human a2-ARs, for various a-AR
antagonists, are summarized in table 2 .
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Table 2. Comparison of the affinities of a-adrenoceptor antagonists for
expressed az-adrenoceptor clones
Compound
clone Kj (nM) 
(chromosome)
«2a
(CIO)
«2b
(C2)
«2c
(C4)
Yohimbine 3.5 4.6 0.6
Prazosin 2133 365 95
SK&F 86466 9.4 15.8 19.8
5-methylurapidil 612 406 131
Indoramin 2240 528 476
Human aa-adrenoceptor clones were expressed in CHO or COS-7 cells. 
Table adapted from Hieble et al. (1995). Yohimbine, 17-Hydroxyyohimban-16- 
carboxylic acid methyl ester; SK&F 86466, 6-chloro-N-methyl-2,3,4,5- 
tetrahydro-1 -H-3-benzazepine.
22
1.3.4 p-Adrenoceptors.
Of the 3 families of ARs, most is probably known about the p-ARs. Three 
subtypes of p-AR have been identified to date by both molecular and classical 
pharmacological studies. All 3 subtypes of p-AR are coupled to adenylyl 
cyclase by the Gs G-protein, producing alterations in cellular activity by raising 
intracellular levels of cAMP (Summers and McMartin, 1993). A major 
consequence of increased cAMP is the activation of cAMP-dependent protein 
kinase (PKA). In cardiac cells, one of the protein targets of PKA-mediated 
phosphorylation is the L-type Ca^^ channels. Phosphorylation by PKA results 
in channel activation and subsequently a larger influx of Ca^^ during each 
action potential (Castellano and Bohm, 1997). There is also evidence to 
support the direct modulation of L-type Ca^^ channels and Na^ channels by Gs 
during p-AR stimulation (Schubert etaL, 1989).
The first suggestion of p-AR heterogeneity was proposed by Lands in 1967 
(Lands et al., 1967). The group compared the potencies of a series of 
sympathomimetic amines on a variety of tissue specific responses. They 
found a marked similarity between correlation coefficients (calculated from the 
logarithms of the relative potencies of the sympathomimetic amines) of 
cardiac stimulation/lipolysis, and of the bronchodilator/vasodepressor 
responses. They proposed that 2 subtypes of p-AR exist (Pi and P2), thus 
explaining the correlation between particular tissue responses to 
sympathomimetic amines. A number of studies using a variety of synthetic p-
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AR antagonists suggested the existence of atypical p-AR-mediated responses 
that were clearly distinct from the traditional effects mediated by the pi- and 
p2-ARs (Arch et al., 1984; Wilson et al., 1984; Emorine et al., 1989). In one 
study, the thermogenic agonist BRL 37344 stimulated lipolysis in rodent 
brown adipocytes even in the presence of the pi- and p2-AR antagonist 
propranolol (Arch et al., 1984). This and subsequent studies led to the idea 
that one or several additional receptors exist in fat and skeletal muscle. Since 
the cloning of this receptor subtype (Emorine etal., 1989), a high potency of a 
novel class of compounds initially described as potent activators of lipolysis 
and thermogenesis in white and brown adipose tissues of rodents has been 
described (Strosberg and Pietri-Rouxel, 1996). Expression of Ps-AR has been 
detected in a number of tissue types, though it is most abundant in the highly 
innervated brown adipose tissue, where high enough concentrations of NE 
develop during nerve stimulation to activate the receptor (Strosberg and 
Pietri-Rouxel, 1996).
The p2“AR from hamster lung was the first p-AR to be cloned (Dixon et al., 
1986). Hamster lung p-AR was purified to homogeneity by sequential affinity 
chromatography and molecular sieve HPLC. Sequence analysis was then 
performed on pure peptide fragments of p2-AR generated by cyanogen 
bromide cleavage and isolated by reverse HPLC. Probes derived from this 
cDNA have been used to clone P2-ARS from mouse, rat and human sources 
(Allen etal., 1988; Gocayne e ta l,  1987; Kobilka e ta i,  1987a). Attempts to 
clone the Pi-AR with P2-AR cDNA were unsuccessful. Even with the full
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length coding sequence, P2-AR cDNA did not cross-hybridize with the Pi-AR. 
However the P2-AR probe did cross-hybridize with a related receptor, which 
was subsequently identified as the S-HT-ia receptor (Fargin et al., 1988). 
When the 5-HTia receptor was used to screen a human placental cDNA, the 
pi-AR was finally identified (Frielle et al., 1987). The overall amino acid 
identity of human Pi-AR and P2-AR is 54%, with the highest amount of 
sequence identity in the hydrophobic regions postulated to represent the 
membrane spanning domains. The ps-AR was cloned by screening a human 
genomic library with probes prepared from the avian p-AR and human P2-AR 
cDNA (Emorine et al., 1989). A homologous ps-AR was cloned from rat 
brown adipose tissue (Muzzin et al., 1991). The 2 ps-AR share 80% overall 
amino acid identity. The identity in primary structure for the Ps-AR with both 
the Pi-AR and P2-AR is only 40-50%. As well as the three p-AR described 
here, the existence of other atypical p-ARs has also been suggested (Challiss 
et al., 1988; Kaumann and Molenaar, 1996). It is very likely that additional 
members of the AR family will be identified in the near future.
Comparisons of the three cloned human p-ARs, for various p-AR agonists and 
antagonists are summarized in table 3.
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Table 3. Comparison of the affinity of p-adrenoceptor agonists and
antagonists for expressed p-adrenoceptor clones.
Compound
Clone Ki (nM)
Pi P2 P3
BRL 3744 1750 1120 287
Salbutamol 74* 5.2* 266*
(-)-bupranolol 1.7 0.4 50
ICI 118551 120 1.2 257
CGP20712A 1.5 1800 2300
Human p-adrenoceptor clones were expressed in CHO cells. Table adapted 
from Strosberg (1997). * Values were calculated from adenylyl cyclase
activation studies. BRL 3744, (±)-(R*,R*)-[4-[2-[[2-(3-Chlorophenyl)-2- 
hydroxyethyl]amino]propyl]acetic acid; salbutamol, a-[(t-Butylamino)methyl]-4- 
hydroxy-m-xylene-a,a’-diol; (-)-bupranolol, 1 -(2~Chloro-5-methylphenoxy)-3- 
[(1,1-dimethylethyl)amino]-2-propanol; ICI 118551, (±)-1-[2,3-(Dihydro-7-
methyl-1 H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-butanol; CGP 20712A, 
(±)-2-Hydroxy-5-[2-[[2-hydroxy-3-[4-[methyl-4-(trifluoromethyl)-1H-imidazol-2- 
yl]phenoxy]propyl]amino]ethoxy]"benzamide.
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Table 4. Classification schema for adrenoceptors.
Subtype G- Effector Agonist Antagonist
protein
«1 Gq/Gll Phospholipase C-p Phenylephrine Prazosin
0C1A Gq/Gii Phospholipase C-p Indoramin;
5-methylurapidil
«1B Gq/Gii Phospholipase C-p WB4101 
(low affinity)
« 1D Gq/Gii Phospholipase C-p
«2 Gi, Go Inh. Adenylyl cyclase BH-T 920 Yohimbine
«2A Gj, Go Inh. Adenylyl cyclase Oxymetazoline BRL 44408
«2B Gi, Go Inh. Adenylyl cyclase Prazosin*;
ARC-239
«20 Gj, Go Inh. Adenylyl cyclase Prazosin*
P Gs Adenylyl cyclase Isoproterenol Propranolol
Pl Gs Adenylyl cyclase Dobutamine Metoprolol
P2 Gs Adenylyl cyclase Terbutaline IC1118551
P3 Gs Adenylyl cyclase BRL 37344
(*) Prazosin also blocks ai-adrenoceptors nonselectively. Table adapted from 
Goldstein (1998). B-HT 920, 5,6,7,8-Tetrahydro-6-(2-propenyl)-4H- 
thiazolo[4,5-d]azepin-2-amine; oxymetazoline, 3-[(4,5-Dihydro-1 H-imidazol-2- 
yl)methyl]-6-(1,1-diethylethyl)-2,4-dimethylphenol; dobutamine, (±)-4-[2-[[3-(4- 
Hydroxyphenyl)-1-methylpropyl]amino]ethyl]-1,2-benzendiol; Terbutaline, 2-t- 
Butylamino-1-[3,5-dlhydroxyphenyl]ethanol; propranolol, (±)-1-
(lsopropylamino)-3-(1-naphthyloxy)-2-propanol; metoprolol, 1-
[lsopropylamino]-3-[p-(p-methoxyethyl)phenoxy]-2-propanol); BRL 44408, (+)- 
2-[(4,5-dihydro-1 H-imidazol-2yl)methyl]-2,3-dihydro-1-methyl-1 H-isoindole.
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Table 5. Comparison of the affinity of epinephrine and norepinephrine
for the cloned adrenoceptors.
Clone Ki (nM)
Adrenoceptor clone Epinephrine Norepinephrine
«1a
«1b
«Id
236
122
35.1
424
290
22.1
«2a
«2b
«2c
1671
1851
318
3677
1265
606
Pi
P2
P3
18900 + 6400
4320 + 1160
20650 ±2810
24100 + 14100
11800 ±5800
475 ± 75
Human a r ,  a2 and p-adrenoceptor clones were expressed in LTK' (Hancock, 
1996), COS-7 (Lomasney et al. 1991) and CHO cells (Strosberg, 1997) 
respectively.
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1.3.5 Post-translational regulation of p-ARs.
Receptor phosphorylation by p-AR kinase and cAMP-dependent protein 
kinase (PKA) are the main processes for post-translational regulation of p- 
ARs. PKA produces a relatively slow (t%, 3.5 minutes) phosphorylation of the 
p-AR which impairs the ability of the receptor to activate Gs (Hausdorff et a i, 
1990). p-ARK only phosphorylates agonist-occupied receptor by a rapid 
process (t%, 20 seconds) that initiates the binding of p-arrestin (a cytosolic 
protein) to the receptor, resulting in uncoupling of p-AR from Gs (Hausdorff et 
ai, 1990).
1.3.6 Actions of Norepinephrine.
Adrenoceptors are widely distributed throughout the whole mammalian body 
suggesting the participation of NE and E in numerous processes underlying 
normal tissue functions (see table 6). It is often very difficult to determine 
which specific AR subtype mediates a tissue or cellular response (in terms of 
e.g. aiA or am) as often, more than one subtype of AR is expressed on the 
same cell type. However, there are examples in which the specific AR 
subtype mediating a response is known. Platelets are a good example of this, 
it has been shown that E- and NE-induced aggregation of platelets is 
mediated by the a2A-AR (Nieuwland e ta i, 1994).
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1.3.7 Central actions of norepinephrine.
The majority of the noradrenergic neurons of the central nervous system 
(CNS) arise from the brain stem nucleus, locus coeruleus (LG), which is 
located in the grey matter of the pons medulla (Amaral and Sinnamon, 1977). 
Axons that arise from these cell bodies innervate several areas of the brain 
including the hypothalamus, hippocampus, cerebral cortex, cerebellum and 
limbic system. Studies of the LG have demonstrated an important role of this 
nucleus in the control of sleep and wakefulness (Kayama and Koyama, 1998). 
NE dysfunction is believed to be a contributing factor to the occurrence of 
several clinical disorders, including stress, psychosis and depression (Grace 
et al., 1998). A large area of research has focussed on the role of NE in 
depression. The GA hypothesis of depression (Schildkraut, 1965) is based on 
the clinical observation that drugs which deplete NE in the brain lower the 
mood, whereas those drugs that increase NE availability in the synaptic cleft 
are usually clinically effective antidepressants (Leonard, 1997). Disparities 
between the inhibition of NE uptake by antidepressants and the onset of the 
therapeutic response, has provoked studies of possible adaptive changes in 
neurotransmitter receptor function (Ankier and Leonard, 1986). Unlike 
depression, excessive stimulation of noradrenergic projections, particularly to 
the cortex, has been implicated in the pathophysiology of panic disorder. This 
is believed to involve an abnormal activation of the LG. It has been 
demonstrated that the a2-AR antagonist yohimbine can induce panic attacks 
by increasing LG activation (a2-AR negatively modulate LG firing) (Williams et
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ai, 1985).
Alpha2-AR agonists are commonly used for the treatment of hypertension as 
they decrease sympathetic outflow and reduce arterial blood pressure. The 
central hypotensive effect of a2R agonists was shown to be principally 
mediated by the a2A- subtype (MacMillan etaL, 1996).
The central actions of NE described here are just a few representatives of a 
great number of central adrenoceptor-mediated functions. As demonstrated 
by the findings described above, ongoing research in this area has immense 
therapeutic implications, particularly as more subtype-selective ligands 
become available.
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1.4 The norepinephrine transporter.
Many neurotransmitters have their actions constrained by rapid clearance 
from synaptic spaces by plasma membrane transport proteins (Rudnick and 
Clark, 1993). In addition to bringing the neurotransmitter into contact with 
enzymatic pathways responsible for transmitter metabolism, reuptake is the 
first of two important steps for recycling released catecholamine (Rudnick and 
Clark, 1993; Amara and Kuhar, 1993). A second transporter (the vesicular 
monoamine transporter) is responsible for sequestering cytoplasmic NE or DA 
within synaptic vesicles, where it is stored in preparation for regulated release 
by exocytosis. The importance of plasma membrane biogenic amine 
transporters in the recycling of transmitter is clearly illustrated by experiments 
in which the actions of the transporter are blocked. Little or no NE overflows 
into perfusing fluids from various organs during sympathetic nerve stimulation, 
however, a large increase in NE overflow occurs and catecholamine (GA) 
stores become rapidly depleted if stimulation is accompanied with reuptake 
inhibition (Brown and Gillespie, 1957). Whereas inhibitors of NE metabolism 
do not potentiate noradrenergic transmission, drugs that block the uptake 
system can have marked enhancing effects, most notably by means of 
increasing both pre- and post-synaptic receptor occupation (Iversen, 1967).
Burn (1932) first suggested the possibility that exogenous GAs might be taken 
up by peripheral tissues (Burn, 1932). Several subsequent studies supported 
this notion. One such study by Axelrod and coworkers, showed that [^H]NE
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and [^H]E were removed from the circulation of animals injected with small 
doses of these labeled substrates (Axelrod et a i, 1959). The radiolabeled 
CAs were shown to accumulate in peripheral tissues, the highest amounts 
predominantly in tissues with a large degree of sympathetic innervation, 
suggesting accumulation in sympathetic neurons. Additional studies showed 
that destruction of sympathetic neurons in a variety of peripheral organs 
resulted in a reduction of NE uptake (Zaimis et al., 1965; Iversen and Kravitz, 
1966). An example of this is a study in which rodents were given nerve 
growth factor antiserum to hinder the development of the sympathetic nervous 
system. The accumulation of [^H]NE was reduced in the peripheral organs of 
these animals (Iversen and Kravitz, 1966; Sjoqvist et al., 1967; Zaimis et al., 
1965). Another study showed that lesions of ascending noradrenergic 
pathways in brain resulted in a reduction of [^H]NE uptake by synaptosomal 
fractions prepared from areas receiving these pathways (Kuhar, 1973), 
supporting the concept of NE uptake by sympathetic neurons.
1.4.1 Properties of the norepinephrine transporter.
The NET belongs to a family of plasma membrane transporters that are 
absolutely dependent on both Na^ and Cl" for their function (Iversen and 
Kravitz, 1966; Sanchez-Armass and Orrego, 1977). Increasing the 
extracellular Na^ concentration causes an increase in the apparent \/max 
(maximal transport) and decrease in the apparent Km of NE uptake and 
affinity, respectively. Similar results are seen when the extracellular Cl"
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concentration is raised in the presence of a fixed Na^ concentration. Although 
this demonstrates the dependence on Na^ and Cl' of NET function, it does not 
demonstrate co-transport of these ions with the CA. The definitive evidence 
for NET mediated co-transport of Na^ and Cl" came from saturation studies of 
NE transport. When determined at several fixed concentrations of N a\ the 
plots of Mv; vs. 1/[NE] were all linear and intersected at a common point to the 
left of the ordinate and above the abscissa. The inverse experiments (i.e. 
fixed NE concentrations) produced similar Lineweaver-Burk plots (Sammet 
and Graefe, 1979). The same has been shown for Cl", therefore both Na^ and 
Cl" must be co-transported with the catecholamine by the NET (Friedrich and 
Bonisch, 1986).
To enable co-transport of three substrates it is postulated that the NET has 
three binding sites, one for Na\ Cl" and the protonated substrate (Sammet 
and Graefe, 1979; Friedrich and Bonisch, 1986). Binding to the transporter 
occurs sequentially, N a\ Cl" and then the substrate (Friedrich and Bonisch, 
1986). That Na'*' is the leading substrate was determined by [^F1]NE efflux 
studies, in which outward transport of pH]NE was induced by the removal of 
extracellular Na^ or Cl". Omission of Na^ caused a pronounced carrier- 
mediated efflux of [^H]NE, whereas removal of Cl" from the extracellular buffer 
caused only a small enhancement of [^H]NE release. The effect of Cl" was 
identical to inhibition of reuptake. In addition, the efflux of [^H]NE induced by 
the omission of extracellular Na^ was inhibited in a dose-dependent manner 
by N a\ These findings suggest that Na^ fixes the transporter in a non­
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transported complex. The similarity in the kinetic parameters calculated for 
Cr with Na^ indicates that Cl' must bind to the transporter before the 
catecholamine. The stoichiometry for the NET was determined by measuring 
the dependence of transport on Na^ and Cl'. Initial rates of transport of NE 
into placental brush-border membrane vesicles (Ramamoorthy et al., 1993a) 
and intact PC I2 cells (Friedrich and Bonisch, 1986) revealed a simple 
hyperbolic dependence on Na^ and Cl', consistent with a Na%l"/NE 
stoichiometry of 1:1:1. Since the cloning of the NET (Pacholczyk et al., 1991), 
studies of NE transport in cells stably expressing the cDNA for the NET have 
confirmed this stoichiometry (Gu et al., 1994; Gu et al., 1996). A Na'^/CIVNE 
stoichiometry of 1:1:1 predicts that transport mediated by the NET is 
electrogenic, as a net positive charge will be carried with each transport cycle. 
This has been ascertained by transport studies of membrane vesicles from 
stably NET and serotonin transporter transfected cells (Gu et al., 1996). 
When NET expressing membrane vesicles were exposed to the K*-specific 
ionophore, valinomycin, the influx of NE was significantly increased. 
Valinomycin decreases the vesicle membrane potential by increasing the 
efflux of from membrane vesicles. As a comparison, accumulation of 
[^H]5FIT by SERT expressing membranes, which is known to be electroneutral 
due to the counter transport of K ,^ was not increased in the presence of 
valinomycin (Gu et al., 1996).
In normal physiological conditions, several factors favor inward transport of 
NE. The first and possibly most critical of these is the high concentration of
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both Na^ and Cl' outside the cell (> 100 mM) compared to the inside (10-20 
mM). In resting neuronal cells, the plasma membrane is relatively 
impermeable to both Na^ and Cl" ions (Abell, 1986), so this high diffusion 
potential becomes a major driving force for the reuptake of extracellular CAs. 
The mobility of the carrier is dependent on which of the three sites are 
occupied at any one time. When all three binding sites are free, carriers are 
mobile, however this mobility is lost as soon as Na^ binds. Mobility is 
regained with consequent binding of Cl' and NE (or other protonated 
substrate) (Trendelenburg, 1991). The high extracellular Na^ concentration 
results in the immobilization of a much larger number of transporters on the 
outside of the axonal membrane compared to the inside. This creates an 
asymmetric distribution of the carrier, resulting in a large difference between 
VmaxiN and VmaxouT for Carrier-mediated transport. VmaxiN is much greater than 
VmaxouT (Trendelenburg, 1991). Two additional factors contribute to the 
asymmetry of the transporter. The affinity of the transporter for NE is greatly 
increased by prior loading of the carrier with Na\ hence Km\u is much lower 
than KmouT for carrier mediated transport (Graefe and Bonisch, 1988). NE 
and other substrates (see table 7) must be protonated in order to bind to the 
transporter, therefore the transporter carries a positive charge, which is 
favorable with the normal resting cell potential (Harder and Bonisch, 1985; Gu 
etaL, 1996).
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Table 7. Norepinephrine transporter substrate affinities.
hNET hDAT
Km Wnax Km %nax
Cell line Substrate (|iM) (pmol/min/mg) (HM) (pmol/min/mg)
(reference)
SK-N-SH (Graefe et al., 1999)
NE 1.0 ±0.2 
1.15*
35.6
DA 0.533* 10*
tyramine 1.7 + 0.5 36.6
MIBG 1.6 ±0.8 43.4
LLC-PKi (Gu et al., 1994)
NE 0.58 ±0.06 17 ±0.7 17±1 .7 300 ± 13
DA 0.24 ± 0.02 32 ±1 5.2 ±0.8 300 ± 19
COS (PifI et al.. 1996)
NE 1.9 ±0.2 22 ± 6** 15.8± 1.5 66 ±1.8**
DA 0.42 ±0.1 10.6 ±0.4** 2.7 ± 0.4 60 ± 22**
MPP^ 0.64 ±0.1 10.6 ±2** 16.8 ±1.6 77 ± 6**
SKNMC {Pm et al., 1996)
NE 2.2 ±1.2 19 ± 4 * * 9.4 ±2 .4 7.3 ±0.1**
DA 1.7±1.1 9.12 ±0.4** 2.7 ±0 .7 7 ±3**
MPP^ 0.8 ± 0.4 9.12 ±0.8** 7.0 ±1.1 7.8 ± 0.4**
LLC-PKi and SKNMC cells were stably transfected with the human 
norepinephrine or dopamine transporter, whereas COS cells were transiently 
transfected. * Vmax and values from Richards and Sadee (1986). ** \/max 
values are for the uptake of substrates in pmol/min/1 O'® cells. MIBG, 
metaiodobenzylguanidine; MPP^, 1-methyI-4-phenylpyridnium.
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1.4.2 inhibitors of the norepinephrine transporter.
The NET is a target for many classes of drugs, including tricyclic 
antidepressants (e.g. desipramine) (Bruss et a i, 1993) and drugs of abuse, 
such as cocaine and amphetamines (Schomig and Bonisch, 1986; Ritz et a i, 
1987; Wall et al., 1995). As is the case with the substrates of the NET, the 
binding of NET inhibitors to the transporter is dependent on extracellular Na^ 
(Trendelenburg, 1991). Unlike NET substrates, binding of NET inhibitors is 
thought not to induce transporter mobility. Despite this, recently (Johnson et 
al., 1998), and in work presented here, inhibitor-induced release of CAT 
substrates has been demonstrated in recombinant cell lines expressing the 
CATs (see chapter 5).
Comparisons of the biogenic amine transporters revealed different drug 
inhibition profiles (Gu et al., 1994; Buck and Amara, 1995). The tricyclic 
antidepressant desipramine was found to be the most potent and selective 
inhibitor of the NET (Gu et al., 1994), making it a useful tool for studying this 
transporter (see table 8 and figure 3).
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Table 8. Drug inhibition profile of the norepinephrine and dopamine
transporters.
Ki (nM)
Inhibitor NET DAT
Desipramine 4 + 2 9365 + 1260
Nisoxetine 6 ± 2 1945 ± 144
Mazindol 2 + 1 60 + 5
Cocaine 612 + 53 391 ±39
GBR 12909 20 ± 2  2 ±  1
GBR 12935 21 ± 2  2 ± 1
LR1111 51 ±5  3 ± 2
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Figure 3. The structure of commonly used norepinephrine and 
dopamine transporter inhibitors.
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Studies of functional DA and NE chimeric transporters revealed structural 
domains that are involved in the selective inhibition of transport by 
antidepressants (Buck and Amara, 1995). It was found that a segment 
spanning transmembrane domains 5-7 of the NET is of principal importance 
for the high affinity binding of tricyclic and non-tricyclic antidepressants.
It is firmly accepted that the NET can exist in two conformational states, one 
in which the binding sites for Na^, Cl" and substrate are available to the 
outside of the cell and the other when they are exposed to the inside 
(Trendelenburg, 1991). This gives rise to the question, at which conformation 
do inhibitors of the NET act, the inward or outward facing conformation, or 
both? A recent study was undertaken to attempt to answer this question and 
to determine the type of inhibition elicited by cocaine at the NET: competitive, 
noncompetitve or uncompetitve (Chen and Justice, 1998). Simultaneous 
incubation of LLC-PKi cells stably expressing the NET (LLC-NET) with 
cocaine and DA, which should only allow an inhibitory effect of cocaine at the 
outward conformation of the NET, revealed a competitive inhibition pattern of 
cocaine. In the presence of cocaine, the Km of DA uptake was increased with 
no change in the V^ ax of DA transport. Pre-incubation of cocaine with LLC- 
NET cells, which results in equilibration of cocaine across the plasma 
membrane, again revealed a competitive inhibitory pattern of cocaine. If 
cocaine acted on the inward facing conformation of the NET, prior incubation 
of LLC-NET cells with cocaine should result in a noncompetitive inhibition 
pattern as external DA will not be able to displace an inhibitor bound to the
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inward facing conformation. Therefore, it appears that cocaine is a 
competitive inhibitor of the NET and acts at the outward facing conformation 
of the transporter. A previous study of the NET presumed that the NET 
returns to the outward facing conformation faster when it is loaded with 
substrate than when it is unloaded (Schomig et al., 1988a) (transporters are 
mobile when empty of Na^, Cl' and substrate). If the reorientation of the 
unloaded NET is the rate-limiting step for transport, external DA may cause 
the NET to be trapped in the inward facing conformation during initial uptake 
when there is no intracellular substrate to replace the DA released from the 
transporter. In an inward facing conformation the NET would be inaccessible 
to an inhibitor which acts on the outward facing conformation of the 
transporter, such as cocaine. This could give rise to a competitive inhibition 
pattern for a noncompetitive inhibitor acting at the outward facing 
confirmation. To rule out this possibility, initial uptake experiments were 
performed in the presence of an internal substrate, so that the reorientation of 
the transporter is iess of a rate-iimiting factor. The fact that in the presence of 
an internal substrate the inhibitory action of cocaine was not enhanced rules 
out the possibility that cocaine is a noncompetitive inhibitor at the NET (Chen 
and Justice, 1998). It was concluded that cocaine is a competitive inhibitor of 
the outward facing conformation of the NET.
A different group of compounds (amiloride and its derivatives; see figure 4) 
compete with Na^ for binding to the Na^-binding site of the NET (Schomig et 
al., 1989; Trendelenburg, 1991). The amiloride derivative 5-(N-ethyl-N-
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isopropyl)-amiloride (ElPA) is unable to bind to the Na"'-binding site of outward 
facing carriers, where it has to compete with a very high Na^ concentration. 
The high lipid solubility of El PA enables it to diffuse across the plasma 
membrane where it can easily compete with the low intracellular concentration 
of Na^ (Schomig et a/., 1989). The inhibition of NE uptake produced by EIPA 
is different to that seen with classical NET inhibitors such as cocaine, which 
compete for the substrate-binding site of the NET. EIPA reduces the Km and 
V'max of transport mediated by the NET. The simplest explanation for this is 
that EIPA binds to the Na^ site of inwardly facing NETs and consequently 
causes the accumulation of the carrier at the inner surface of the membrane. 
As a result, the maximal initial transport rate (Vmax) of NE and the 
concentration of NE which half saturates transport (Km), decrease. The 
reduction in Km occurs as transporters that initially carry NE into the neuron 
become inhibited by EIPA and are unable to undergo reorientation (Schomig 
et al., 1989). In addition to inhibiting the influx of NE, EIPA significantly 
inhibits the binding of desipramine to isolated plasma membranes of PC I2 
cells. This is as expected as the binding of desipramine and other NET 
inhibitors is dependent on Na^ (Schomig and Bonisch, 1986). The Kj (~ 24 
pM) for the action of EIPA is considerably higher than that calculated for NET 
inhibitors such as desipramine, mazindol and cocaine. This is probably partly 
due to the high concentration of Na^, relative to NE that EIPA has to compete 
with compared to NET inhibitors which compete with NE for the substrate 
binding site (mM and nM - p.M, for Na^ and NE respectively).
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Figure 4. The structure of two inhibitors of the Na^-binding site of the 
norepinephrine transporter.
NH O NH,
Amiloride
3,5-Diamino-N-
(aminoiminomethyI)-6-
chloropyrazinecarboxamide
NH,
Amiloride, 5-(N-ethyl-N-isopropyl)-EIPA
3-Amino-N-(aminoinninomethyl)-6-chloro-5-
[ethyl(2-propyl)amino]-pyrazine-2-carboxamide
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1.4.3 Cloning and structural features of the norepinephrine transporter.
The cDNA for the hNET was first isolated by Pacholczyk et al., (1991) using 
an expression cloning strategy. They used the human SK-N-SH 
neuroblastoma cell line, which expresses multiple copies of the NET. Pools of 
clones from a SK-N-SH cDNA library were transfected into COS-1 cells. 
Transfectants expressing the hNET were identified by intracellular 
accumulation of the NE analogue, m-iodobenzylguanidine ([^^^l]mlBG), 
allowing autoradiographic visualization. A single clone was obtained by 
subdivision of DNA rescued from positive COS-1 transfectants. Sequence 
analysis of the cloned hNET predicted a protein of 617 amino acids with a 
relative molecular mass of -  69K. Similarly to other cloned Na^- and Cl'- 
dependent amine transporters, it has 12 regions of high hydrophobicity, in 
spans long enough to form transmembrane (TM) domains (see figure 5), with 
the N- and C-termini located intracellularly (Pacholczyk et al., 1991; Lingen et 
al., 1994; Bruss et al., 1997). The TM domains 1,2 and 4-8 show the highest 
degree of sequence identity between members of the neurotransmitter carrier 
family suggesting a possible important role for these regions in transport 
function (Blakely et al., 1994). An aspartate (Asp) residue in TM domain 1 is 
conserved in the NE, DA and serotonin transporters (Amara and Kuhar,
1993). As this residue is not present in the GABA transporter it was 
suggested that this residue could be critical for recognition of the 
catecholamine substrate. Mutagenesis studies (Kitayama et al., 1992; 
Ramamoorthy et al., 1993b) have confirmed the importance of this Asp
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residue and a serine residue in TM domain 7 for the transport process. 
Kitayama and coworkers proposed that charge-charge interactions between 
the TMD1 Asp residue and the protonated NH2 group of the CAs, and 
hydrogen bonding of catechol OH groups with TMD7 serine residues are 
responsible for substrate recognition. Recent work has demonstrated that 
although these serines (serine 354 and 357) are influential in inhibitor and 
substrate binding, uptake and efflux, they do not appear to be involved in a 
direct hydrogen bond interaction with the substrate (Danek Burgess and 
Justice, Jr., 1999). Delineation of structural domains influencing selectivity for 
NE, DA and MPP^ were made possible with the generation of a series of 
functional DA and NE chimeric transporters (Buck and Amara, 1994). It was 
found that TMD1-3 and TMD10-12 contribute to transporter specific substrate 
affinities, whereas TMD4-8 of the DAT appeared to influence the rate of 
substrate transport.
The majority of integral membrane proteins have charged residues bordering 
on hydrophobic regions that are thought to play a role in determining the 
correct positioning of the protein within the membrane. All of the cloned 
neurotransmitter transporters have focal clusters of 4-5 charged residues in 
the cytoplasmic loop immediately proceeding TM helix 9 (Amara and Kuhar,
1993). Conserved proline residues in 5 of the 12 TM domains (1, 2, 5, 11 and 
12), is another feature common to the cloned neurotransmitter transporters. A 
survey of integral membrane protein sequences provides evidence that, 
although proline residues are largely excluded from membrane-spanning
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segments in non-transport proteins, they are evenly distributed between 
aqueous and membrane domains in transport proteins (Brandi and Deber, 
1986). It has been suggested that proline residues may have several 
potential roles in membrane-spanning helices. Regulated cis-trans 
isomerization of membrane-buried X-proline peptide bonds (X = unspecified 
amino acid) of transport proteins may provide the conformational changes 
required for substrate translocation, as a result of the realignment of 
amphipathic helices, making a hydrophilic pore accessible to a substrate for 
transport. The formation of a pocket that may accommodate substrate or 
ligands could be facilitated by proline residues, which introduce bends into 
transmembrane helices.
The large hydrophilic loop between TMD 3 and 4 contains three consensus 
sites for A/-glycosyIation (see figure) that are conserved in the y-aminobutyric 
acid transporter. A/-glycosylation inhibitors reduce the protein stability, 
surface trafficking and transport activity of the hNET (Meiikian et al., 1996). 
These results were confirmed with the generation of a hNET mutant devoid of 
all canonical A/-glycosylation sites. When expressed in COS cells, a mutant 
hNET of a similar size to N-glycosylation-inhibited hNET expressing cells was 
produced. This non-A/-glycosylated protein is ~ 46 kDa compared to -  80 kDa 
for the /V-g lycosy lated form (Meiikian etal., 1996).
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Figure 5. A proposed model of the norepinephrine transporter.
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•  Residues that are divergent in rat NET but are conserved in the human and
bovine NETs. Potential sites for A/-glycolysation (CHO) and potential 
phosphorylation sites for protein kinase C (PKC) and for casein kinase II (CK 
II). Adapted from Paczkowski et al. (1999).
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1.4.4 Mechanism of substrate transport by the norepinephrine 
transporter.
The mechanism of ion-coupled NE transport via the NET is more complicated 
than that of ion channels. An ion channel can function merely by allowing its 
substrate ions to flow across the lipid bilayer. Transport of NE requires 
alternating access of the substrate and ion binding sites, to the outside and 
inside of the plasma membrane. This may be achieved by a central binding 
site for Na^, Cl" and NE, which can only be accessed by one face of the 
membrane at a given time (Rudnick and Clark, 1993). Translocation (influx or 
efflux) represents a conformational change so that the binding sites for Na^, 
c r  and NE are now exposed to the opposite side of the piasma membrane 
(Rudnick and Clark, 1993). A recent study with chimeric serotonin 
transporters (SERT) demonstrated that although the external loop regions of 
the SERT are not primary determinants of substrate and inhibitor binding 
sites, they are active elements responsible for maintaining the stability and 
conformational flexibility of the transporter (Smicun et a/., 1999). The precise 
mechanism of transport and the conformational changes that occur are still to 
be firmly elucidated.
Patch-clamp and amperometric recordings have predicted a channel mode of 
action for the NET in recombinant cell lines expressing the transporter (Galli 
et a i, 1996; Galli et a/., 1998). Currents generated by the transfected cell 
lines were much greater than that predicted for stoichiometric influx of NE.
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The current generated by NE influx was blocked by DMI and was dependent 
on Na’*' and Cl'. From the results of the study it was proposed that the NET 
can transport NE in two modes, an alternating access and channel mode. 
The channel mode of action occurs at a much lower probability, but results in 
a burst of NE influx (Galli etal., 1998).
1,4.5 Reversal of the norepinephrine transporter.
There are essentially two ways to elicit non-vesicular release of 
neurotransmitter from monoaminergic neurones. The first of these is via 
indirectly acting sympathomimetic amines, such as tyramine. As well as 
being a substrate for the NET, NE efflux induced by tyramine and other 
sympathomimetic amines is dependent on their ability to bind to the vesicular 
monoamine transporter and compete with NE for storage. Inhibition of the 
vesicular storage of NE increases the concentration of free cytoplasmic NE. 
Inward transport of any substrate of the NET alters the asymmetric distribution 
of the carrier, making it available to the intracellular side of the plasma 
membrane (Langeloh et al., 1987; Stute and Trendelenburg, 1984) where it 
can bind cytoplasmic CA and hence trigger outward transport. The 
appearance of the carrier on the inside of the axonal membrane, (facilitated 
exchange diffusion), is just one of the factors contributing to the outward 
transport of [^H]NE from preloaded sympathetic nerve endings. The co­
transport of Na'*' and Cl' lowers the Km for axoplasmic pH]NE at the inwardly 
facing NET (Bonisch, 1986; Friedrich and Bonisch, 1986). Furthermore,
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through competition for the outwardiy facing carriers, the reuptake of released 
[^H]NE will be reduced by the indirectly acting sympathomimetic amines, 
potentiating the releasing capacity of the extracellular substrate (Langeloh ef 
a/., 1987). Recently, the conventional facilitated exchange diffusion 
hypothesis has been questioned as the mechanism of substrate-induced 
biogenic amine release. It was demonstrated that although tyramine and 
amphetamine have considerably lower uptake rates than DA, the maximal 
releasing effect of these substrates is at least as high as DA (Sitte et a/., 
1998). Patch clamp recordings of these cells showed DAT-mediated currents 
in response to substrate exposure, as expected for this ion-coupled transport 
process. Despite similar Km values for uptake and the induction of ion 
currents (for each substrate tested), maximal effects differed significantly 
between patch-clamp and uptake experiments. It was shown that although 
the maximal uptake of DA was 20-times higher than amphetamine, the 
currents induced by saturating currents of each substrate differed by only 
25%, which is incompatible with the concept of a fixed ratio of ions co­
transported with each substrate molecule. In fact, such findings further 
support the idea of a substrate gated channel mode of CATs (see section 
1.4.4) (Galli et al., 1996; Galli et al., 1998). The releasing properties of 
transporter substrates correlated closer to their ability to induce ion currents 
than their actual rate of accumulation.
NET-mediated outward transport of NE can also be induced by changes in 
transmembrane ion gradients. This occurs during certain physiological and
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pathophysiological conditions, such as ischemia (Schomig et al., 1987; 
Schomig, 1990; Imamura et al., 1996; Kurz et al., 1996; Hatta et al., 1997). 
Any rise in neuronal Na^ concentration induces the outward transport of 
axoplasmic NE (Paton, 1973). Accumulation of intracellular Na'*' increases the 
availability of the NET to the inside of the axonal membrane and enhances 
the affinity of axoplasmic NE for the carrier (Sammet and Graefe, 1979). A 
study of the outward transport of axoplasmic NE from adrenergic nerve 
endings of the rat vas deferens (Stute and Trendelenburg, 1984), showed that 
inhibiting the membrane Na^,K^-ATPase with ouabain, results in an increase 
in NE efflux. The Na^,K^-ATPase maintains the high extracellular Na^ 
concentration by exchanging intracellular Na’*' for extracellular K'*'. Similar 
results were obtained with the voltage-sensitive Na'*' channel opener, 
veratridine (Stute and Trendelenburg, 1984). These conditions also caused 
an increase in the NE to DOPEG ratio. DOPEG is a metabolite of NE, 
produced by deamination of NE by MAO in the cytoplasm. Unlike NE, this 
metabolite is highly lipophilic and is able to cross the plasma membrane 
without the aid of a transport mechanism (Adler-Graschinsky etal., 1972).
A major process responsible for the influx of Na^ during ischemia, is activation 
of the Na^/H^ exchanger (NHE). The lowering of intracelluiar pH which occurs 
during ischemia, results in the exchange of internal H  ^ ions for external Na'*', 
via the NHE (Schomig, 1990; Schomig et al., 1991; Kubler and Strasser,
1994). Drugs that block the NHE (such as amiloride and its derivatives), 
greatly inhibit NE release during reperfusion after protracted myocardiai
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ischemia (Imamura et al., 1996; Hatta et al., 1997), demonstrating the 
importance of Na’*' entrance via NHE for carrier-mediated NE release (see 
chapter 6).
Since the cloning of the NET (Pacholczyk et al., 1991), it has become 
possible to study reverse transport in cellular systems that do not have the 
machinery for vesicular storage and contain only the transporter of interest. 
One such study using COS-7 cells transfected with the cloned human 
catecholamine transporters demonstrated an induction of cocaine sensitive 
carrier-mediated efflux of amines by low Na'*' or Cl" (PifI etal., 1997).
1.4.6 Regulation of catecholamine transporters.
To enable fine adjustments during neurotransmission, most aspects of 
chemical signaling at synapses are under tight control; from neurotransmitter 
biosynthesis and storage, to release and target responsiveness (De Lorenzo, 
1980; Kennedy, 1983; Nestler and Greengard, 1983). It is clear that the GA 
plasma membrane transporters are extremely important for terminating 
responses, recycling CAs and releasing neurotransmitter (reverse transport). 
Therefore, it would seem very likely that the uptake/efflux of CAs would also 
be subject to both acute and chronic regulation at the level of the transporter. 
Protein phosphorylation is a process by which rapid and reversible covalent 
modifications of proteins are made, regulating a diverse range of cellular 
functions. All of the biogenic amine piasma transporters cloned to date
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contain serine and threonine residues with the appropriate consensus 
sequences for phosphorylation by protein kinase C (PKC), cAMP-dependent 
protein kinase (PKA), and Ca^^-calmodulin kinase (Blakely et al., 1994; 
Pacholczyk et al., 1991; Hoffman et al., 1991; Bruss et al., 1997). These 
potential substrates for phosphorylation in the cytoplasmic amino- and/or 
carboxy-termini would allow the regulation of transporter activity by second 
messenger systems that become elevated during nervous transmission or 
receptor stimulation. Several studies have focussed on regulation of the DAT 
by phosphoryiation (Tian et al., 1994; Huff et al., 1997; Vaughan et al., 1997; 
Zhang et al., 1997; Kitayama et al., 1994; Vrindavanam et al., 1996). In one 
study (Huff et al., 1997) with LLC-PKi cells stably expressing the rat DAT, the 
uptake of DA was significantly inhibited by prior incubation of cells with the 
phorbol ester phorbol 12-myristate 13-acetate (PMA), an activator of PKC. In 
addition, a 3-fold increase in in vivo phosphorylation of the transporter after 
PMA treatment was demonstrated, suggesting a potential rapid regulatory 
mechanism of dopamine reuptake via direct phosphorylation of the transporter 
by PKC or a PKC-activated kinase. The results of this study differ to those 
obtained from an earlier investigation of the rat DA and y-aminobutyric 
(GABA) transporters in a rat striatal synaptosome preparation (Tian et al.,
1994). Agents that promote phosophorylation, such as okadaic acid (a 
protein phosphatase inhibitor) and forskoiin, inhibited GABA uptake but not 
dopamine uptake into rat striatal synaptosomes. These results suggest that 
structurally related plasma membrane transporters are subject to different 
post-translational regulation. The inability of the promoters of phosphorylation
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to inhibit the activity of the DAT in this study may be due to a requirement of 
PKC activation for phosphorylation of the DAT. A stimulant of PKC was not 
examined in this investigation. More recently, there have been studies 
demonstrating PKC-mediated regulation of the NET (Apparsundaram et al., 
1998a; Apparsundaram et a!., 1998b; Bonisch et a!., 1998). In a study with 
SK-N-SH cells, muscarinic receptor activation was shown to stimulate a PKC- 
dependent and -independent regulation of NET expression, leading to a 
diminished capacity for NE transport. Measurements of NET surface density 
in intact cells and isolated membrane fractions, revealed a redistribution of 
NET protein with muscarinic receptor stimulation (Apparsundaram et a!., 
1998a). In an accompanying study with stably transfected cells, a PKC- 
modulated protein trafficking of the NET was confirmed as a reguiatory 
mechanism of NET (Apparsundaram et a!., 1998b). A study prior to that of 
Apparsundaram and colleagues also demonstrated an inhibitory role for PKC- 
mediated phosphorylation on transporter activity (Bonisch et a!., 1998). 
However, when potential phosphorylation sites of the transporter were 
removed by point mutations, PKC stimulation still altered transporter activity to 
the same extent as that seen with the wild type NET. It is possible that the 
inhibitory effect of PKC on NET activity involves another regulatory protein, as 
has been suggested for the regulation of vesicular monoamine transporter 
activity by protein kinase A (Nakanishi et a!., 1995). Unlike the DAT (Huff et 
a/., 1997), there have been no studies which show a direct PKC-mediated 
phosphorylation of the NET.
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Although NET-mediated inward and outward transport of NE is not dependent 
on Ca^^, a recent study with PC 12 cells demonstrated that Ca^^ enhances 
[^H]NE uptake (Uchida et al., 1998). It was found that this was a result of the 
activation of calmodulin-dependent protein kinases and probably the 
stimulation of NET translocation to the plasma membrane and/or direct 
phosphorylation of the transporter itself (Uchida et al., 1998). A direct 
phosphorylation of the NET was not shown, however, a synthetic peptide 
consisting of a sequence contained within the NET was phosphorylated by 
purified brain calmodulin-dependent protein kinase II. It appears that NET 
translocation to the plasma membrane is regulated in a positive and negative 
way by calmodulin-dependent protein kinase II and PKC, respectively.
The elevation of the synaptic availability of NE resulting from blockade of NET 
function may contribute to the therapeutic effect of many antidepressant drugs 
in depressive disorders (Schildkraut, 1965). Treatment often requires chronic 
exposure to the NET inhibitors. This prompted studies of the effect of 
prolonged exposure of PC 12 cells (Zhu and Ordway, 1997) and recombinant 
cells expressing the NET (Zhu et a i, 1998), to the NET inhibitor desipramine. 
A 3-day exposure of PCI2 cells and HEK-293 cells stably transfected with 
hNET cDNA, resulted in a down-regulation of the transporter as demonstrated 
by reduced [^H]nisoxetine binding. It was shown that this was a consequence 
of a selective reduction in NET protein levels, presumably as a result of either 
a reduction in translation of NET mRNA or an enhanced degradation of hNET 
protein. The levels of NET mRNA were found to be unchanged.
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A study of NE release in the nonischemic and ischemic rat heart 
demonstrated an up regulation of the NET after electrical stimulation of the 
normoxic heart and after a 40-min period of stop flow ischemia (Ungerer et al., 
1996). The short time required for the upregulation of the NET during 
ischemia suggests that regulation of NET mRNA is improbable.
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1.5 Vesicular storage of norepinephrine.
Vesicular storage of NE ensures the maintenance of high-localized 
concentrations of neurotransmitter, in readiness for controlled release in 
response to stimuli. The storage of NE also protects the accumulated 
molecules from leakage or intraneuronal metabolism (see 1.2.1), and 
prevents possible toxic effects of the transmitter on the neuronal cell itself 
(Schuldiner, 1994). There are two vesicular membrane components that are 
responsible for the transport and concentration of cytosolic biogenic amines 
into storage vesicles. The first of these is a vacuolar ATP driven pump that 
acidifies the organelle interior, creating a transmembrane pH difference (ApH) 
and electricai potential difference {Ay/) (Johnson, 1988) which are the driving 
forces for biogenic amine accumulation into the storage vesicles (Njus et al., 
1986). The second component required for storage is the vesicular 
monamine transporter (VMAT). This transport system is common to several 
organelles including synaptic vesicles, adrenal chromaffin granules, platelet 
dense granules, mast cell and basophil secretory granules (Njus et al., 1986). 
VMAT exchanges two internal H  ^ ions with one molecule of cytoplasmic 
biogenic amine (Njus et al., 1986). It has been proposed that the high affinity 
form of the transporter is also a higher-energy form that requires H  ^
translocation for its formation. The energy invested in the transporter by H* 
flux may be released by ligand binding and converted into vectorial movement 
of a substrate molecule across the membrane (Rudnick et a i, 1990). The 
second H  ^ ion may be required to facilitate a conformational change of the
60
transporter, exposing the ligand-binding site to the vesicle interior or to allow 
release of the positively charged substrate from the protein (Rudnick et al., 
1990).
1.5.1 Inhibitors of the vesicular monoamine transporter.
Much of the knowledge gained on the vesicular storage process has arisen 
from studies using two potent and selective inhibitors of VMAT, reserpine and 
tetrabenazine (see figure 6). Reserpine, a natural analogue of serotonin, is 
thought to bind to the site of VMAT substrate recognition, as judged by the 
fact that VMAT substrates prevent reserpine binding in a concentration range 
similar to their apparent Km values (Scherman and Henry, 1984). Reserpine 
inhibits VMAT competitively in the subnanomolar range (Scherman and 
Henry, 1984; Darchen et al., 1989), with practically irreversible effects 
(Rudnick et al., 1990). Tetrabenazine does not irreversibly damage the 
transporter or inhibit VMAT at the site of substrate recognition (Henry and 
Scherman, 1989). Much higher concentrations of VMAT substrates are 
required to displace tetrabenazine binding than that for reserpine, suggesting 
that it binds at a site that overlaps with the substrate binding site (Henry and 
Scherman, 1989). Unlike the binding of reserpine to VMAT, the affinity of 
tetrabenazine for VMAT is not accelerated by ApH (Schuldiner, 1994).
Inhibition of VMAT by reserpine completely abolishes substrate accumulation 
into chromaffin granule membrane vesicles, suggesting that there is very little
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(if at all) un mediated transport into storage vesicles under physiological 
conditions (Schuldiner, 1994). The finding that vesicles loaded with serotonin, 
do not lose amine even when the extravesicular concentration of serotonin is 
diluted (Maron et al., 1983), illustrates the impermeability of the vesicular 
membrane to biogenic amines. An additional process is thought to contribute 
to the ability of storage vesicles to maintain a high concentration of biogenic 
amine. It has been suggested that a pH-dependent “gating” mechanism 
reversibly inactivates the transporter so that the amines do not leak even 
when the electrochemical gradient decreases, provided the intravesicular pH 
does not increase above a certain value (Maron et al., 1983). However, 
dissipation of the H  ^electrochemical gradient (AjaH+) induces a rapid efflux of 
amine from preloaded storage vesicles (Sulzer and Rayport, 1990). This is 
thought to be a consequence of the elimination of a kinetic barrier to flux 
reversal. One of the mechanisms by which amphetamine increases 
axoplasmic monoamine concentration is by acting as a weak base, dissipating 
ApH+ and consequently, an efflux of monoamine from vesicular stores is 
induced. Surprisingly, efflux triggered by conditions that dissipate A\ih+, is not 
blocked by inhibitors of VMAT (Floor et al., 1995), suggesting that a 
transporter-independent mechanism is operating. This probably accounts for 
the loss of NE from vesicular stores during protracted myocardial ischemia, in 
which the pH gradient across the vesicular membrane is lost (see chapter 6).
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Figure 6. The structure of two commonly used vesicular monoamine 
transporter inhibitors.
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1.5.2 Cloning and structural features of the vesicular monoamine 
transporter.
The vesicular transporters that have been cloned to date are almost identical, 
sharing essentially no sequence homology with the plasma membrane 
biogenic amine transporters (Liu et al., 1992; Erickson et al., 1992; Stern- 
Bach et al., 1992; Erickson et a!., 1996). One of the first vesicular 
transporters to be cloned was from PC 12 cells. Edwards and coworkers (Liu 
et al., 1992) were investigating the resistance shown by PC I2 cells to the 
neurotoxin N-methyl-4-phenylpyridnium (MPP^). When they transfected 
cDNA from PCI2 cells into a cell line normally sensitive to MPP^ (Chinese 
hamster ovary (CHO) fibroblasts), some transfectants became resistant to the 
neurotoxin and were able to concentrate dopamine into vesicular structures. 
Isolation and sequencing of the cDNA responsible predicted peptide 
sequences highly homologous to those of peptides derived from the purified 
chromaffin granule amine transporter. At about the same time, Hoffmans 
group (Erickson et al., 1992) were investigating cDNA from rat basophilic 
leukemia (RBL) cells mRNA. RBL cells have a plasma membrane serotonin 
transporter (SERT) and are able to store 5-HT via a vesicular transporter. 
They transfected RBL cDNA into CV-1 cells and looked for transfectants that 
conferred increased 5-HT uptake. Some of these clones encoded a vesicular 
transporter which functioned to accumulate 5-HT in acidic organelles. In both 
of the studies described, the vesicular transporters appear to localize in the 
membranes of acidic organelles. As a ApH already exists, the transporter is
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able to accumulate biogenic amine or MPP^ into the organelles. In the case 
of studies with the neurotoxin MPP* ,^ transfectant cells, which now express the 
vesicular transporter, show resistance to the toxin as it is stored in organelles 
(Stern-Bach et al., 1992).
Two isoforms of human VMAT have been cloned and characterized (Erickson 
et al., 1996). Inhibition of transport by tetrabenazine is a key feature in 
distinguishing VMAT1 and VMAT2. Tetrabenazine inhibits the uptake of 
pH]5-HT by VMAT2 with a K| of 100 nM, whereas concentrations of 
tetrabenazine as high as 20 pM had no effect on transport via VMAT 1. The 
two isoforms of human VMAT display an overall homology of 60%, with 
greatest identity within the putative 12 transmembrane (TM) regions 
(Schuldiner, 1994; Liu et a i, 1996a; Erickson et al., 1996). Three potential 
giycosylation sites are observed for VMAT1 in contrast to four sites in VMAT2 
(Liu et al., 1996a). Both the cytoplasmic N and C termini are poorly 
conserved between the two isoforms (Schuldiner, 1994; Liu et al., 1996a; 
Erickson et al., 1996). Catecholamine substrates show about a 3-fold higher 
affinity for VMAT2 than for VMAT1 (Erickson et al., 1996). Of all the VMAT 
substrates studied, histamine showed the greatest selectivity for VMAT 
isoforms. A 30-fold higher apparent affinity for VMAT2 than VMAT1 was seen 
with histamine. This corresponds well with the affinity of tetrabenazine for 
VMAT2 over VMAT1 and it has been suggested that histamine and 
tetrabenazine recognize the same binding site (Erickson et al., 1996). 
Evidence supporting this comes from a study in which it was found that
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histamine (a relatively low affinity substrate for VMATs) was unable to inhibit 
the binding of reserpine (Merickel and Edwards, 1996). The close similarity 
between VMATs suggested to one group that chimeric transporters would 
retain function and so enable the identification of residues that modulate 
substrate recognition and drug sensitivity, properties that differ between 
VMAT1 and VMAT2 (Peter et al., 1995). It was found that transmembrane 
domains 5-8 and 9-12 of VMAT2 are necessary for the high affinity substrate 
interactions. A surprising finding was the ability of the extreme amino 
terminus of VMAT2 to confer a partial VMAT2 phenotype in terms of both 
substrate recognition and drug inhibition (Peter et al., 1995). This is of 
particular interest in terms of regulatory mechanisms of VMAT activity.
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Figure 7. A proposed model of the vesicular monoamine transporter.
lu m e n
m e m b ra n e
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The bovine vesicular monoamine transporter is predicted to have 12 
transmembrane segments. The N- and C-terminal extremities are present in 
the cytoplasm and a large intravesicular loop bears 3 putative giycosylation 
sites.
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1.5.3 Regulation of the vesicular monoamine transporter.
In addition to inducing tyrosine hydroxylase, sustained depolarization by 
elevated (30 mM) increases VMAT expression in cultured sympathetic 
neurons from rat superior cervical ganglion (Desnos et al., 1990), as a 
consequence of transcriptional changes (Krejci et a i, 1993). The induction of 
the VMAT was shown to be dependent on Ca^^ entry through slow Ca^^ 
channels. Another group (Nakanishi et ai, 1995) investigated the 
involvement of cAMP-dependent signaling pathways on VMAT activity. They 
initially showed that dibutyryl cyclic AMP (dBcAMP) or other agents that 
elevate cellular cAMP, increase the extracellular CA level by inhibiting uptake 
by VMAT. Further investigation of the downregulation of VMAT activity by 
cAMP, revealed that this response is a consequence of protein 
phosphorylation. Inhibitors of protein kinases potentiated uptake of amines in 
whole and digitonin permeabilized cells. In contrast, inhibitors of protein 
phosphatases, such as okadaic acid, inhibited uptake of NE by VMAT. 
Vesicular amine transport and hence CA uptake activity of the cells is 
regulated by a balance of protein-phosphorylating and -dephosphorylating 
activities, or the level of phosphorylation of a certain protein(s) responsible for 
the control of vesicular amine transport. The target protein(s) are not yet 
known. Interestingly, both isoforms of VMAT contain consensus sequences 
for phosphorylation by protein kinase A in their cytoplasmic domains (Liu et 
ai, 1992; Surratt ef a/., 1993).
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1.5.4 An overview of norepinephrine exocytosis.
The uptake of NE by synaptic vesicles is just one step in a complex cascade 
of protein-protein interactions that constitutes the synaptic vesicle cycle 
(Sudhof, 1995). Once loaded with NE, synaptic vesicles translocate to a 
specialized area of the presynaptic membrane called the active zone, where 
docking is initiated (the first contact between the plasma and vesicular 
membranes). A maturation process (priming) then takes place, in which the 
synaptic vesicle becomes competent for fast Ca^^-triggered membrane fusion 
and exocytosis. Active zones are located in close proximity to Ca^^-channels 
and it has been suggested that these channels are also an important 
molecular element of the secretory machinery itself (Stanley, 1997). Only 
those vesicles apposed to the inner layer of the plasma membrane undergo 
exocytosis in response to a rise in intracellular Ca^ .^ Exocytosis occurs when 
the phospholipid bilayer of the docked synaptic vesicle becomes continuous 
with that of the plasma membrane, resulting in the release of the vesicular 
contents into the extracellular space. Several proteins associated with the 
plasma membrane and synaptic vesicle membrane have been implicated in 
the fast release (exocytosis) of NE from nerve endings. It is thought that an 
N-ethylmaleimide-sensitive fusion protein (NSF) forms a complex with soluble 
NSF attachment proteins (SNAPs) which binds to receptors (SNARES) on 
vesicular (e.g. synaptobrevin) and plasma membranes (e.g. syntaxin and 
SNAP-25) (Sollner et al., 1993). This fusion complex attaches vesicles to the 
plasma membrane and remains dormant until activated by the increase in
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intracellular Ca^^ that triggers exocytosis. A candidate for the Ca^^ switch is 
the vesicle associated protein synaptotagamin. Many other regulatory 
proteins are thought to be involved in the fusion and eventual exocytosis of 
NE, including the Rab-3A group of GTP-binding proteins (Geppert et al., 
1994). The synaptic vesicle cycle and in particular the arrangement of 
synaptic vesicles at active zones, facilitates rapid exocytosis by high local 
concentrations of Ca^^ during an action potential or in conditions of Ca^ '*' 
mobilization (e.g. via receptor-mediated pathways).
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1.6 The exchanger.
Several mammalian isoforms of NaVH^ exchanger (NHE) have been identified 
and characterized (Sardet et al., 1989; Orlowski et al., 1992; Wang et al., 
1993; Klanke et al., 1995; Tse et al., 1993). All are highly regulated 
(glyco)phosphoproteins derived from distinct genes that are dispersed 
throughout the mammalian genome (Orlowski and Grinstein, 1997). Studies 
based on the primary sequences of the different NHEs predicts a similar 
membrane topology with 1 0 - 1 2  membrane spanning regions and a large 
cytoplasmic domain at the C-terminus (Orlowski and Grinstein, 1997). The 
different isoforms known to date share -34-60% amino acid identity with 
molecular mass ranging between -81 and 93 kDa (Orlowski and Grinstein, 
1997). The most highly conserved regions of the NHEs are in the membrane 
spanning regions 6 and 7, which show -  95% identity (Orlowski and Grinstein, 
1997). This finding suggests that this is the region that participates in the 
actual transport of Na^ and H  ^across the membrane. The C-terminal region, 
which is oriented almost entirely to the cytosol, exhibits a much lower amount 
of sequence homology (Orlowski and Grinstein, 1997).
NHE1 mRNA is expressed in virtually all mammalian tissues and cells. It 
carries out what has been termed as the “housekeeping” functions within the 
cell, including the maintenance of cytosolic pH (pHi) and cellular volume 
(Wakabayashi et al., 1997). Like all isoforms of NHEs the most important 
functional feature of the antiporter is its exquisite sensitivity to the intracellular
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pH. Once the pHj drops below a given threshold level (which varies between 
isoforms of NHE) the exchanger is allosterically activated by cytosolic H  ^
resulting in rapid extrusion of acid (Aronson et al., 1982). Deletion 
mutagenesis studies with NHE1 suggest that the H  ^ sensor is located in the 
N-terminal transmembranous region and the C-terminal cytoplasmic domain 
modulates the value of this threshold set point (Wakabayashi et al., 1992).
The rate of NHE activity is dependent on the concentration of extracellular 
Na^. The NHE isoforms (1-3) show a hyperbolic dependence on extracellular 
Na^, with affinities for Na^ ranging from 5 to 50 mM (Orlowski and Grinstein, 
1997).
The sensitivity of NHEs to inhibition by the diuretic compound amiloride (and 
its analogs) (Kleyman and Cragoe, 1988) and by benzoyl guanidinium (e.g. 
HOE694) compounds (Counillon et al., 1993a) varies greatly between 
isoforms. In general, the sensitivity to these drugs is as follows, 
NHE1>NHE2»NHE3>NHE4. The extracellular Na^ concentration has a 
marked influence on the inhibitory power of both amiloride analogs and 
benzoyl guanidinium compounds (Orlowski, 1993; Counillon et al., 1993a; 
Orlowski and Kandasamy, 1996). A high extracellular Na^ concentration 
greatly reduces the inhibition of NHE by these compounds suggesting the site 
of action is close to that which binds Na^ (Counillon et al., 1993a). Recently it 
has been shown by mutagenesis studies that the Na^ and inhibitor binding 
sites are different. Residues in the transmembrane domain 4 and 9 regions
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contribute to drug sensitivity without effecting Na^ affinity of the exchanger 
(Counillon etal., 1993b).
Unlike many transport systems, NHE is not dependent on ATP for its activity 
(Wakabayashi et a/., 1997). The combined chemical gradients of Na"" and H* 
drive the exchange process without consuming metabolic energy directly. 
Despite this, procedures that drastically reduce intracellular ATP levels inhibit 
NHE in a variety of native systems. A possible mechanism for this 
observation is a reduction in affinity of the exchanger for intracellular pH 
(Wakabayashi etal., 1997).
1.6.1 Regulation of the exchanger.
The NHE isoforms are differentially regulated by a number of second 
messenger pathways including agents that target tyrosine kinases and 
agonists of serine/threonine kinases (e.g. PKA and PKC). Sequence analysis 
studies have revealed the existence of consensus sites for multiple protein 
kinases, including PKA, PKC, CAM kinase and proline-directed 
serine/threonine kinases (Fliegel and Frohlich, 1993). In resting cells, NHE1 
is constitutively phosphorylated. The addition of growth factors (GFs), phorbol 
esters or phosphatase inhibitors significantly increases the extent of NHE1 
phosphorylation. All of the potential phosphorylation sites identified in the 
NHE1 sequence are localized in the region of the cytosolic tail (Wakabayashi
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et al., 1997).
There is a large amount of evidence that suggests phosphorylation is not the 
sole regulatory mechanism of NHEs. This is best illustrated by studies with 
NHE1. Certain stimuli activate the exchanger without detectable changes in 
phosphorylation. Truncated mutants, which lack all known phosphorylation 
sites, can still be regulated by growth factors. This implies that NHEs are able 
to interact with other cellular components, which regulate their activity. 
Proteins that associate with particular isoforms of NHE have now been 
identified. Probably the best understood of these is calmodulin (CaM) 
(Bertrand et al., 1994). Two regions in the cytosolic tail of NHE1 have been 
identified as CaM binding sites (a high and low affinity site). Of these two 
sites, the high affinity CaM binding site (Kd -  20 nM) is important for regulating 
NHE1. Deletion of this region results in constitutive stimulation of the 
exchanger, resembling that of activation by processes that elevate cytosolic 
calcium. This finding has led to the hypothesis that the unoccupied CaM 
binding site in resting conditions exhibits an autoinhibitory effect on the 
exchanger, this inhibitory action is relieved upon ligand binding (Bertrand et 
al., 1994).
The regulation of NHE activity is of particular importance in myocardial 
ischemia. It has been demonstrated that in prolonged periods of cardiac 
energy depletion, intracellular acidosis stimulates the influx of Na^ via NHE 
activation (Schomig etal., 1991; Kubler and Strasser, 1994; Kurz et al., 1996;
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Imamura et al., 1996; Hatta et al., 1997). Influx of Na'^  triggers the massive 
carrier-mediated release of axoplasmic NE, which is readily associated with 
protracted myocardial ischemia (see chapter 6 ). As several receptor 
mediated pathways alter NHE activity, this is a key point for the regulation of 
NE overflow in protracted myocardial ischemia (Imamura etal., 1996; Hatta et 
al., 1997).
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1.7 An overview of cardiac action potentials.
The different phases of the cardiac action potential are associated with 
changes in the permeability of the cell membrane to Na^, and Ca^ .^ Like 
every cell In the body, the concentration of intracellular greatly exceeds the 
extracellular concentration in the resting cardiac myocyte. The reverse of 
this concentration gradient is true for Ca^^ and Na^. The resting plasma 
membrane is relatively permeable to K ,^ but considerably less so to Ca^^ and 
Na^. diffuses down its concentration gradient across the plasma 
membrane through voltage-regulated channels. The loss of positive ions 
from the cell results in the negative resting potential (the interior of the cardiac 
myocyte is about 90 mV lower than the surrounding medium). This negative 
electrostactic force opposes the outward diffusion of K ,^ and favors the influx 
of Na^. In fact, the steady influx of Na^ would gradually depolarize the resting 
cell membrane were it not for a metabolic pump that continuously extrudes 
Na^ from the cytoplasm in exchange for extracellular (the Na^,K^-ATPase).
Two types of action potential (AP) occur in cardiac tissue, the fast (see figure 
8 ) and slow response. Any process that alters the resting membrane potential 
beyond a critical value (called the threshold) triggers the fast response. Rapid 
depolarization (phase 0) of the plasma membrane is due almost exclusively to 
the inward flux of Na^ through specific tetrodotoxin- and voltage-sensitive 
channels. The influx of Na^ is extremely rapid as both the diffusion gradient 
and electrostatic force favors inward transport. In addition, more Na^
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channels open, as the potential difference (Vm) becomes less negative. When 
the Vm reaches 0 , there is no longer an electrostatic pull of Na^ into the cell, 
however, the Na^ gradient still favors influx, hence Vm becomes positive (this 
is known as overshoot). Termination of the influx of Na^ is mediated by a 
different set of Na^ channels that close in response to a reduction in negativity 
of Vm. Closing of this set of channels is much slower than the opening of Na^ 
channels. Partial repolarization (phase 1) is due to the opening of 
channels, which allows the efflux of K .^ In this instance, the electrostatic force 
(a negative cell exterior compared to the interior) also favors outward 
transport of K .^ The plateau (phase 2) of the AP is generated by the entrance 
of mainly Ca^  ^ and some Na^ through slow Ca^ "" channels (mainly L-type in 
the heart) that activate and inactivate much more slowly than the fast Na^ 
channels. The flat portion of phase 2 is the result of a counter loss of from 
the cell. Rapid repolarization occurs when the efflux of begins to exceed 
the influx of Ca^^ and Na .^ Ca^^ channels are inactivated after the start of the 
plateau so there is a gradual decrease in the inward current created by these 
channels. Ion pumps restore the intracellular ionic concentrations to the 
resting values. Of particular importance is the Na^, K^-ATPase and the 
Na^,Ca^^ exchanger which eliminate excess Na^ and Ca^^ respectively. 
Unlike the fast response, the initial rapid upstroke of phase 0 (mediated by the 
rapid influx of Na^) is absent in the slow response. Instead, the slow inward 
current of Ca^^ and Na^ achieves depolarization in the slow response. 
Another distinguishing and crucial feature of the slow response is 
spontaneous membrane depolarization. A slow depolarization occurs during
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phase 4 until threshold is attained and an action potential triggered. This is 
the basis of automaticity in the sinoatrial (SA) and atrioventricular (AV) nodes 
of the heart.
The slope of upstroke, anriplitude of the AP and the extent of the overshoot 
are lower in slow response APs than fast response APs. As the amplitude of 
AP and steepness of the upstroke are important determinants of propagation 
velocity, cardiac tissue is characterized by a much slower conduction velocity, 
which is more likely to be blocked than fast response APs, leading to rhythm 
disturbances.
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Figure 8. The fast response action potential.
^ase 1
phase 2
0 mV
phase 3
phase 0
phase 4
- 85 mV-
Outside i L ©Membrane t (i)Inside
Channel currents
Ca"N a'
"Lealc" currents
Changes in plasma membrane ion permeability during the 5 phases of the 
fast response cardiac AP. Involvement of (i) the Na^.K^-ATPase and (ii) the 
Na^,Ca^^ exchanger in restoring the resting intracellular ion concentration.
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1.8 Norepinephrine and myocardial arrhythmias.
Severe ventricular arrhythmias and sudden cardiac death are the main 
causes of mortality in acute myocardial infarction and in post infarct patients 
(Schomig etal., 1991). There is an increasing body of experimental evidence 
to suggest that NE has a pro-arrhythmic action on the reperfused ischemic 
heart. For example, chronic surgical cardiac sympathectomy abolishes NE 
overflow and the incidence of ventricular fibrillation in experimental myocardial 
infarction in the dog (Ebert et a/., 1970). Furthermore, ventricular arrhythmias 
can be induced in an electrically stable heart by pM concentrations of 
exogenous NE. This concentration range is comparable with the level of 
locally accumulated NE in myocardial ischemia (Schomig etal., 1991).
During protracted myocardial ischemia, non-exocytotic release of NE is 
mediated via a reversal of the Na^- and Cl'-dependent NET. Blockade of the 
transporter with desipramine, not only inhibits the ischemia-induced release of 
NE, but also significantly reduces the incidence of ventricular arrhythmias in 
isolated rat and guinea pig heart (Kurz et al., 1996; Imamura et al., 1996). 
The trigger for ischemia-induced carrier-mediated release of NE is the influx 
of Na^ in exchange for intracellular H ,^ via the activation of the Na"*, 
exchanger (NHE) (Schomig et al., 1991; Kubler and Strasser, 1994; Kurz et 
al., 1996; Imamura et al., 1996). Drugs that block the NHE, such as 
amiloride, markedly reduce both NE overflow and the duration of reperfusion
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ventricular arrhythmias (Imamura etal., 1996).
Sympathetic nerve endings possess many cell surface receptors that regulate 
the release of NE in the normoxic heart. In myocardial ischemia, a rise in the 
extracellular concentration of endogenous ligands (e.g. NE, adenosine, 
histamine, angiotensin and bradykinin), results in the activation of presynaptic 
receptors. In one study, blockade of a2-adrenergic receptors (ag-AR) with the 
specific Œ2-AR antagonist yohimbine, significantly reduced the release of NE 
and the incidence of ventricular fibrillation (VF) induced by protracted 
myocardial ischemia (Imamura et al., 1996). The augmentation of carrier- 
mediated NE release by a2-AR activation is contrary to the inhibitory role of 
these receptors in exocytotic NE release. In fact, presynaptic autoinhibitory 
Œ2-AR are regarded as the most effective modulators of depolarization-evoked 
CA release in the normoxic heart (Langer, 1977). It is thought that many 
presynaptic receptors control carrier-mediated NE release by regulating the 
NHE. Indeed, stimulation of both the adenosine Ai-receptor and the 
histamine H3-receptor has been shown to regulate the NHE in the ischemic 
guinea pig heart. Subthreshold concentrations of the adenosine Ai-receptor 
agonist A/®-cyclopentyladenosine and the NHE inhibitor 5-(A/-Ethyl-A/- 
isopropyl)-amiloride (ElPA) had no effect on NE overflow or VF alone. 
However, in combination, significant inhibition of both NE overflow and the 
incidence of VF induced by protracted myocardial ischemia, was observed 
(Imamura et al., 1996). Similar results were obtained for Hs-receptor 
stimulation. This suggests that stimulation of Ai- and Hs-receptors leads to
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inhibition of the NHE, implicating this exchanger as an important point of 
regulation for carrier-mediated release in protracted myocardial ischemia.
Although it is very apparent that NE released in myocardial ischemia 
contributes to ventricular arrhythmias, the mechanism(s) by which NE 
augments this deleterious response is not well understood. It has been 
known for several years that p-AR blocking compounds consistently reduce 
the sudden cardiac death rate (Yusuf et al., 1985), emphasizing the 
arrhythmogenic properties of NE acting at post-synaptic p-ARs in the ischemic 
heart. Exposure of the normoxic heart to p-agonists induces receptor 
desensitization. However, in the ischemic myocardium, an increased density 
of p-ARs in the plasma membranes has been observed, despite the large 
presence of endogenous ligand (i.e. NE) (Maisel et a!., 1985). One process 
responsible for this receptor externalization is the loss of high-energy 
phosphates in myocardial ischemia (Strasser et a/., 1990). Early ischemia 
also promotes a transiently increased sensitivity of adenylyl cyclase (AC), the 
effector enzyme of p-AR stimulation (Strasser et a!., 1990). The 
aforementioned changes lead to a super-sensitive p-AR-mediated pathway. 
In addition to the effects of p-AR stimulation, it has been reported that ai-ARs 
contribute to arrhythmias associated with ischemia and reperfusion (Sheridan, 
1986), whilst only playing a minor role in normal conditions of sympathetic NE 
release. The mechanisms underlying reperfusion arrhythmias are complex 
and are thought to involve changes in intracellular ion homeostasis.
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particularly Ca^^. Stimulation of ai-ARs results in the formation of inositol 
1,4,5-triphosphate (IP3) and diacylglycerol (DAG) (Summers and McMartin, 
1993). Recent evidence has demonstrated the transient release of IP3, via a i- 
AR stimulation, during early reperfusion of ischemic myocardium (Anderson et 
al., 1995). IP3 mediates the release of Ca^^ from the sarcoplasmic reticulum. 
Influx of Na^ via activation of the NHE, not only triggers carrier-mediated 
release of NE, but in addition, stimulates the influx of Ca^^ via an inhibition or 
reversal of the NaVCa^"  ^ exchanger (Kurz et ai, 1991). As DAG activates 
protein kinase C (PKC), it has been suggested that stimulation of ai-ARs may 
lead to further activation of NHE (PKC phosphorylates and enhances NHE 
activity) and consequently, influx of Ca^^ via the exchanger. It is
possible that NE, through its cell-surface receptors, interferes with various 
action potential components, such as amplitude, duration, refractoriness, and 
conduction velocity, resulting in arrhythmia. Under certain conditions, a 
cardiac impulse may reexcite a region through which it has just passed. This 
phenomenon is known as reentry and is responsible for many clinical 
disturbances of cardiac rhythm. Fibrillation is the principal example of random 
reentry. The likelihood of such rhythm disturbances in cardiac tissue is 
increased by the slow response action potentials found in the sinoatrial (SA) 
and atrioventricular (AV) nodes of the heart. The SA node is the natural 
pacemaker region of the heart and the AV node is a specialized tissue 
involved in conducting the cardiac impulse from atria to ventricles.
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CHAPTER 2 
MATERIALS AND METHODS
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2.1 Cell culture.
LLC-PKi cells stably transfected with cDNA for the human norepinephrine 
transporter (LLC-NET cells, donated by Dr G. Rudnick) were maintained in a- 
modified Eagles medium supplemented with 10% fetal bovine serum, 2 mM L- 
glutamine, 50 U/ml penicillin, 50 pg/ml streptomycin and 450 pg/ml of geneticin 
at 37°C, 5% CO2. Parent LLC-PK1 cells (donated by Dr G. Rudnick) were 
maintained in the same medium without geneticin. When confluent, cells were 
passaged 1 to 10 by trypsinization.
SK-N-SH neuroblastoma cells (originally from American Tissue Culture 
Collection) which endogenously express the NET (Richards and Sadee, 1986) 
were maintained in RPMI 1640 media supplemented with 10% fetal bovine 
serum, 2 mM glutamine, 50 U/ml penicillin and 50 pg/ml streptomycin. When 
confluent, cells were passaged 1 to 10 by trypsinization.
SKNMC cells were maintained in the same medium as LLC-PK1 cells.
LLC-NET and SK-N-SH cells were used between passage numbers 50-65
and 30-45, respectively.
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2.1.1 Transient expression of SKNMC cells with hNET oDNA.
Calcium phosphate-mediated transfection of SKNMC cells was performed as 
follows. Cells were plated on 100-mm culture dishes at ~ 40% confluence 
and grown overnight. Three hours prior to the transfection procedure the cell 
media was changed and replaced with 10 ml of the same complete media. 
For each dish -  10 pg of plasmid DNA (pCMV5-NET) in 0.438 ml of sterile de­
ionized H2O was mixed with 62 pi of a sterile 2M CaCL solution (prepared 
freshly). The DNA/CaCL solution was then added dropwise to 0.5 ml of 2x 
MBS buffer and allowed to stand at room temperature for 30 min to facilitate 
the development of a fine calcium-phosphate precipitate. The calcium- 
phosphate-DNA precipitate was then added dropwise to the cells and mixed 
by gentle swirling. Subsequently cells were incubated overnight (-  16 hours) 
at 37°C, 5% CO2. Media was removed and after rinsing once with PBS, fresh 
media was added to the cells. 24 hours later SKNMC cells were plated in 24- 
well tissue culture plates and incubated at 37°C overnight. Transport assays 
were performed following this overnight incubation period.
2.1.2 Influx studies.
LLC-PK1, LLC-NET, SKNMC and SKNMC-NET cells were grown in 24-well 
plates at 37°C until confluent, which was usually 48 hours after plating. SK-N- 
SH cells, which exhibit a longer doubling time, were used 4-5 days after plating. 
After rinsing once with HEPES buffer ((in mM) 25 HEPES, 125 NaCI, 2.6 CaCL,
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1.2 MgS0 4 , 1.2 KH2PO4, 4.8 KCI and 5.6 glucose, pH 7.4), cells were incubated 
at 37°C for 15 min (or other stated time) in 0.45 ml of HEPES buffer in the 
presence or absence of various ligands. Influx of [^H]substrate was initiated by 
aspirating the HEPES buffer and incubating the cells with 0.23 ml of HEPES 
buffer containing 40 nM [^H]NE, 40 nM [^H]DA or 20 nM [^H]IVIPP ,^ unless 
otherwise stated. Drugs used during the pre-incubation period were used 
throughout the influx period. In ion-dependence experiments Na^ was replaced 
with LF and Cl" was replaced with isethionate. After a given period of uptake, 
[^H]substrate containing buffer was rapidly removed by aspiration and cells were 
rinsed twice with 1 ml of ice-cold HEPES buffer. Cells were then lysed with 0.45 
ml of 0.3% Triton X-100 for 30 min. A 0.3 ml aliquot of cell lysate was then 
counted in 4 ml of Bio-Safe II scintillation cocktail in a scintillation counter 
(Beckman LS 6000) for 3 min.
2.1.3 Carrier-mediated efflux studies.
LLC-NET and SK-N-SH cells were grown as described for the influx studies. 
After rinsing once with HEPES buffer, cells were incubated at 37°C for 60 min in 
0.23 ml of HEPES buffer containing 40 nM [^H]NE, 40 nM [^H]DA or 20 nM 
[^H]MPP^. In some experiments, the COMT inhibitors, tropolone or Ro 41-0960, 
were used during the loading period and throughout the rest of the experiment. 
At the end of the incubation period, cells were aspirated and washed twice 
rapidly with pre-warmed oxygenated HEPES buffer. Cells were then incubated 
for up to 30 min in HEPES buffer containing various drugs of interest. Carrier-
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mediated release of [^H]substrates was stimulated by exposing the preloaded 
cells to HEPES buffer with a modified Na^ concentration, tyramine, ouabain, 
nigericin, gramidicin or proprionate. A 0.3 ml aliquot of buffer containing 
released radiolabel was removed from each well and transferred to a scintillation 
vial containing 4 ml of scintillation cocktail. The remainder of the release buffer 
was immediately removed from each well and the amount of radiolabel 
remaining was determined by lysing the cells with 0.45 ml of 0.3% Triton X-100 
(for 30 min). A 0.3 ml aliquot of cell lysate was transferred to a scintillation vial 
containing 4 ml of scintillation cocktail. The release buffer and cell lysate were 
counted in a scintillation counter (Beckman LS 6000) for 3 min. The amount of 
radiolabel released from LLC-NET cells was calculated as a percentage of the 
total content of radiolabel.
2.1.4 Exocytotic NE release.
SK-N-SH cells were grown as described for the influx studies. After 60 min of 
loading with [^H]substrate (see 2.2.2), cells were incubated with various 
ligands for 30 min. Exocytosis was triggered by switching the physiological 
HEPES buffer with a HEPES buffer containing an increased K  ^concentration. 
The NaCI concentration was reduced in this HEPES buffer to maintain 
osmolarity. Cells were usually exposed to the high K  ^ buffer for 5 or 10 min. 
Termination of the release period, sampling, measurement of the intracellular 
[^H]substrate contents and calculation of the percentage of pHjsubstrate
released were as described in 2.2.5.
2.1.6 Protein determination.
In some experiments the amount of protein in each well was determined by a 
modified method of Lowry (Lowry et al., 1951). A 50 pi sample of cell lysate 
was diluted 1 to 1 with Triton X-100, this 100 pi sample was then used for 
each protein measurement. Two reagents, A (2.0% Na2C0 3 , 0.4% NaOH, 
0.16% sodium tartrate and 1% sodium dodecyl sulfate) and B (4% CUSO4) 
were made up separately and then mixed 100 parts A to 1 part B. 300 pi of 
reagent A+B was then added to each 100 pi sample and to each bovine 
serum albumin (BSA) standard (prepared in a 0.3% Triton X-100). After 
vortexing, the samples and standards were left for 15 min, prior to the addition 
of 30 pi of folin reagent (previously diluted 1 to 1 with distilled H2O). 45-min 
later, 200 pi of each sample and standard was transferred to a 96-well plate 
for an absorbance reading at 650 nM with a spectrophotometer (Molecular 
Devices Vmax Kinetic Microplate Reader). The amount of protein in each 
initial 50 pi sample was calculated from the known BSA standards which were 
used to produce a linear regression plot of BSA concentration vs absorbance. 
As the cells were initially lysed in 450 pi of Triton X-100, the amount of protein 
per well was taken to be 9-times the value obtained for the 50 pi sample.
2.1.6 Lineweaver-Burk Plots.
Influx studies (2 min) were performed with a fixed extracellular Na^ 
concentration and a varied [^H]NE or [^H]IVIPP  ^concentration. The reciprocal 
experiments with fixed pH]substrate concentrations were also performed. 
Lineweaver-Burk plots of 1/[Na^] vs 1 / v n e  and 1/[NE] vs 1 /v N a +  were then 
generated. Corresponding plots for [^H]IVIPP  ^were also produced. The initial 
velocities were calculated as pmols of substrate per mg of protein per min of 
influx (pmol/mg/min). The dpm count measured for each influx experiment 
was converted into a pmol concentration by measuring a known concentration 
of [^H]substrate. This usually involved measuring a small sample of the 
HEPES buffer used for the actual influx study, e.g. 25 pi of the 40 nM [^H]NE 
containing buffer. Lineweaver-Burk plots were used to display the data and 
demonstrate the order of substrate and Na^ binding. Kinetic calculations of 
Km and Vmax Were made by nonlinear regression analysis.
2.1.7 Drugs.
[^H]MPP^ (82.0 Ci/mmol) was purchased from NEN Life Science Products 
(Boston, MA). [^H]DA (47.0 Ci/mmol) and pH]NE (32.0 Ci/mmol) were 
purchased from Amersham (Arlington Heights, IL). Desipramine hydrochloride 
(DMI) and Idazoxan were purchased from Research Biochemicals International 
(Natick, MA). Gramicidin, mazindol, nigericin, pargyline, reserpine.
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teterodotoxin, tropolone, tyramine and verapamil were purchased from Sigma- 
Aldrich Chemical Co (St. Louis, MO). Rilmenidine hemifumurate was purchased 
from Tocris-Cookson (Ballwin, MO). Gramicidin and nigericin were dissolved in 
95% ethanol, mazindol was dissolved in 99.8% dimethyl sulfoxide (DMSO). 
Further dilutions of these drugs were made with HEPES buffer. At the 
concentration used (I.e., < 0.1 %), DMSO and ethanol had no effect on influx 
studies. All other drugs were initially dissolved in distilled water.
2.1.8 Data analysis and statistics.
Graphical presentation of data was performed using the GraphPad Prism 
program (Graphpad Software, Inc., San Diego CA). Data analysis of nonlinear 
regression, for the determination of kinetic parameters of norepinephrine 
transporter-mediated transport, and EC50 and IC50 values, were also performed 
using the GraphPad Prism program.
Values are expressed as mean + S.E.M. Student’s t test was performed for 
experiments with two groups. Comparison of more than two groups was 
performed by one way analysis of variance (ANOVA), with the Bonferroni t test 
used for post hoc analysis (GraphPad Instat). A value of P<.05 was considered 
statistically significant.
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CHAPTER 3
SUBSTRATE KINETICS, INHIBITOR SENSITIVITY AND ION 
DEPENDENCE OF THE HUMAN NOREPINEPHRINE 
TRANSPORTER EXPRESSED IN A RECOMBINANT CELL LINE
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3.1 INTRODUCTION.
The earliest studies of the neuronal NE uptake system involved monitoring the 
influx of exogenous NE into tissues with a high degree of sympathetic 
innervation, such as the heart (Iversen and Kravitz, 1966). Studies of this 
kind provided the first evidence for Na^ dependency of NE uptake by 
sympathetic nerve terminals and further supported the idea of an active 
transport system for NE. Although the removal of Na^ from the buffer 
markedly reduced heart perfusion rates (due to failure of the heart to beat), 
this alone did not account for the dramatic reduction in uptake of exogenous 
NE, compared to that observed in the presence of Na^ (Iversen and Kravitz, 
1966).
A definitive role for Cl" and the active transport of NE occurred later than that 
for Na"", again utilizing heart tissue as the source of sympathetic nerves 
(Sanchez-Armass and Orrego, 1977). Similarly to that seen for Na’*’, no active 
transport of NE occurred in the absence of Cl". It was found that maximal 
uptake of NE occurred at 50 mM Cl", whilst the concentration of Cl" which 
produced the half-maximal rate of influx was -  6 mM (Sanchez-Armass and 
Orrego, 1977).
The earliest studies of the ion dependence of NE uptake, such as those just 
described, did not determine whether Na^ and/or Cl" are co-transported with 
NE, or are simply required for the binding of NE to the transporter. The role 
played by extracellular Na"" in the active neuronal uptake of NE became
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clearer with a study of reserpine treated rat vas deferens (Sammet and 
Graefe, 1979). The initial rates of neuronal uptake were determined with 
various concentrations of pH]NE and Na^ in the extracellular buffer. 
Irrespective of whether [^H]NE or Na^ was taken to represent the variable 
substrate, the Vmax increased and the apparent Km of the system decreased 
with increasing concentrations of the other substrate (Sammet and Graefe, 
1979). This demonstrated for the first time that NE and Na^ are mutually 
cooperative at the NET, i.e. Na^is co-transported with NE.
The identification of the NET in PC12 cells (Bonisch, 1984) prompted further 
investigation of the ion-dependence of the NET. An extensive study by 
Friedrich and Bonisch (1986) revealed that Cl' in addition to Na^ is co­
transported by the NET during NE uptake. The study also confirmed the 
order in which Na ,^ Cl' and NE bind to the transporter (Friedrich and Bonisch, 
1986), Na^ is the leading substrate, followed by Cl" and then NE or other 
protonated substrate (e.g. DA).
Since the cloning of the NE, DA and 5-HT transporters (Pacholczyk et al., 
1991; Kilty et al., 1991; Hoffman et al., 1991), the ion dependence of the NET 
has been confirmed in recombinant cell lines stably expressing the NET (Gu 
et al., 1994; Gu et al., 1996). Initial rates of transport showed a simple 
hyperbolic dependence on Na^ and Cl" consistent with a Na^:CI":NE 
stoichiometry of 1:1:1.
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The Na^- and Cl'-dependent transporters differ in their sensitivities to a 
number of transporter inhibitors (Gu et al., 1994), which compete for the 
substrate binding site of the transporter (Schomig et al., 1988a; Chen and 
Justice, 1998). For example, the DA and NE transporters share similar 
sensitivities to cocaine and mazindol, however, tricyclic antidepressants, such 
as desipramine, have a much higher affinity for the NET than the DAT (see 
table 8).
In addition to the endogenous CAs (NE and DA), the NE and DA transporters 
carry a number of substrates, including tyramine (Bonisch, 1986; Wayment et 
al., 1998), amphetamine (Wall et al., 1995; Bonisch, 1984) and the 
neurotoxin, A/-methyl-4-phenylpyridnium (MPP^) (PifI et al., 1993). Similar to 
that seen with inhibitors, the NE and DA transporters display different 
transport kinetics for various substrates. Whilst the DAT carries NE and DA at 
a higher maximal rate (Vmax ), the NET has a higher affinity (lower Km,) for the 
two endogenous substrates (Gu etal., 1994).
Initial experiments in this study were performed to confirm the documented 
substrate kinetics, inhibitor sensitivity and ion dependence of the NET stably 
expressed in LLC-PKi cells.
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3.2 RESULTS
3.2.1 Uptake of f  H]NE, [®H]DA and f  H]MPP* by LLC-NET cells.
LLC-PKi cells stably transfected with hNET cDNA (LLC-NET cells) transported 
[^H]NE, [^H]DA and f  HIMPP"  ^ (figure 9) in an inward direction under normal 
physiological conditions. As shown in figure 9, uptake of all three pH]substrates 
was abolished by pre-incubation of LLC-NET cells with the neuronal uptake 
inhibitors DMI (100 nM) and mazindol (300 nM), or when experiments were 
performed in a modified HEPEs buffer in which Na^ was replaced with LP. 
Removal of Cl" from the HEPES buffer markedly attenuated pHjsubstrate 
uptake. Reserpine (100 nM), an inhibitor of the vesicular monoamine 
transporter (VMAT), had no inhibitory action on either fH]NE, [^H]DA or 
[^H]MPP^ influx.
3.2.2 Drug inhibition profiles.
As shown in figure 10, uptake of all three pHjsubstrates was inhibited in a dose- 
related manner by the neuronal uptake blockers, DMI and mazindol. The IC50 
values for DMI calculated from the dose-response studies were ~ 17, 66 and 40 
nM for [^H]NE, [^H]DA and [^H]MPP^ respectively. The corresponding values for 
mazindol were ~ 65, 64 and 40 nM. The maximal inhibition of uptake by DMI 
and mazindol resulted in negligible transport of all three pHJsubstrates. The 
amiloride derivative El PA, which competes for the Na^ binding site of the NET, 
dose-dependently inhibited pH]substrate influx. The IC50 values for El PA were
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-  80, 80 and 65 pM for [^H]NE, [^H]DA and pH]MPP^ respectively.
3.2.3 Time-dependent influx of f  H]NE, f  H]DA and f  HjWlPP*.
The uptake and accumulation of [^H]NE, [^H]DA and [^H]MPP^ by LLC-NET 
cells was linear for ~ 5 min and approached a maximum after 30 min (figure 11).
3.2.4 The kinetics of f  H]substrate influx.
Saturation experiments of substrate influx revealed a similar maximal transport 
rate (Vmax) and affinity (Km) of the NET for [^H]NE, [^H]DA and [^H]IVIPP  ^(figure 
12). The Vmax values of uptake calculated by nonlinear regression were -36, 43 
and 40 pmol/min/mg protein for [^H]NE, [^H]DA and [^H]MPP^, respectively. The 
corresponding Km values were -0.54, 0.45 and 0.59 pM.
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Figure 9. Norepinephrine transporter-mediated influx of [^H]NE, 
[^H]DA and [^H]MPP  ^by LLC-NET cells.
o  10
control DMI maz Q Na* 0 Cl' reserp 
300 nM 300 nM 100 nM
Uptake of A) [^H]NE, B) [^H]DA and C) [^H]MPP^ by LLC-NET cells. Bars 
are mean ± S.E.M. values of [®H]NE [^H]DA and [^H]MPP* influx 
(expressed in DPM) during a 5-min period, (n = 4; *** P < .001 from 
control by ANOVA followed by post hoc Bonferroni’s test).
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Figure 10. Dose-dependent inhibition of LLC-NET-mediated influx of 
fH]NE, fH]DA and [^H]WIPP  ^ by the norepinephrine transporter 
inhibitors DMI, mazindol and EIPA.
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Points are mean ± S.E.M. values of [^H]NE, pH]DA or [^H]MPP"  ^influx into 
LLC-NET cells during a 10-min period in the presence of the concentration 
of A) DMI, B) mazindol or 0) EIPA indicated by the abscissa (n = 4-6).
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Figure 11. Time course of [^H]NE, [^H]DA and [®H]MPP  ^ influx by
LLC-NET cells
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Points are mean ± S.E.M. values of [^H]NE, [^H]DA or [^H]MPP'' influx into 
LLC-NET cells during the time point indicated by the abscissa (n = 4). For 
each time point, control rates in the presence of DMI (1 m-M) were 
subtracted to give the net rates shown.
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Figure 12. Saturation curves of substrate transport rate into LLC- 
NET ceils.
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Points are mean ± S.E.M. values of NE, DA or MPP^ influx into LLC-NET 
cells at the concentration of substrate indicated by the abscissa (n = 4-6). 
Transport was measured using 3-min incubations, 40 nM of [^H]substrate 
was used for concentrations of substrate above 40 nM plus sufficient 
unlabeled substrate to give the indicated total concentration. For each 
concentration, control rates in the presence of DMI (1 pM) were subtracted 
to give the net rates shown.
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3.2.5 Na*-dependence of [®H]NE, fH]DA and fH p P P * influx by LLC-NET 
cells.
In the presence of a fixed Cl" concentration (125 mM) the influx of pH]NE, 
pH]DA and pHjMPP'" increased progressively with increasing concentrations of 
Na^. Uptake curves for the pHjsubstrates approximated rectangular 
hyperbolae when the concentration of Na^ was increased (figure 13). The 
concentrations of Na'*' that half maximally stimulated (apparent KmNa+) the 
uptake of pH]substrates during a 10-min period, were ~ 40, 52, and 53 mM, for 
pH]NE, pH]DA and pH]MPP'*', respectively.
3.2.6 Cl -dependence of pH]NE, pHJDA and pHjMPP^ influx by LLC-NET 
cells.
In the presence of a fixed Na^ concentration (125 mM) the influx of pH]NE, 
pH]DA and pH]MPP^ increased progressively with increasing concentrations of 
or. Uptake curves for the pH]substrates approximated rectangular hyperbolae 
when the concentration of Cl" was increased (figure 14). The concentrations of 
o r  that half maximally stimulated (apparent Kmci-) the uptake of pH]substrates 
during a 10-min period, were ~ 3, 0.4, and 7 mM, for pH]NE, pH]DA and 
pH]MPP\ respectively.
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Figure 13. The Na*-dependence of norepinephrine transporter- 
mediated influx of [®H]NE, [^H]DA and f  H]MPP^
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Points are mean ± S.E.M. values of A) [^H]NE, B) [^H]DA and C) [^H]MPP^ 
influx (expressed in dpm; n = 4-6) by LLC-NET cells during a 10-min 
period. Na^CI' was replaced with Li^CI" to achieve the concentration of 
Na^ indicated by the abscissa.
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Figure 14. The Cl -dependence of norepinephrine transporter- 
mediated influx of [^H]NE, [^H]DA and [^H]IViPP\
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Points are mean ± S.E.M. values of A) [^H]NE, B) pH]DA and C) [^H]MPP^ 
influx (expressed in dpm; n = 4-6) by LLC-NET cells during a 10-min 
period. Na^CI' was replaced with Na^ isethionate to achieve the 
concentration of Cl" indicated by the abscissa.
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3.2.7 Lineweaver-Burk analysis of [^H]NE and f  H]MPP* influx.
Lineweaver-Burk plots of 1/Vj vs 1/[Na^] at several fixed concentrations of 
[^H]NE were linear and intersected at a common point to the left of the 
abscissa (figure 15A). The reciprocal plots with fixed Na^ concentrations were 
also linear but intercepted at the abscissa (figure 15B). Similar results were 
seen when [^H]IVIPP  ^was used as the [^H]substrate (figure 15C and D).
3.2.8 Inhibition of fH]NE, fH]DA and fH]IVIPP^ influx by the Na\K"^- 
ATPase inhibitor ouabain.
Exposure of LLC-NET cells to ouabain (100 |iM) during the influx period, had 
no effect on total [^H]NE uptake during a 10 min period (figure 16). However, 
pre-incubation of LLC-NET cells with ouabain (60 min) significantly inhibited 
NET-mediated influx of [^H]NE, pH]DA and [^HJMPP'  ^ by ~ 63, 57 and 40%, 
respectively (figure 16).
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Figure 15. Lineweaver-Burk analysis of the kinetics of interaction
between [^H]substrate and Na  ^ in uptake into LLC-NET cells.
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Lineweaver-Burk analysis of the kinetics of interaction between NE and 
Na^ (A and B), and MPP'*' and Na'*' (C and D) in NET-mediated uptake. 
Transport was measured using 3-min incubations, 40 nM of pH]substrate 
was used for concentrations of substrate above 40 nM, plus sufficient 
unlabeled substrate to give the indicated total concentration. For each 
concentration, control rates in the presence of DMI (1 pM) were subtracted 
to give the net rate of uptake. 1/v (v = initial rate of carrier-mediated 
uptake of [^H]NE or [^H]MPP^ in pmol/min/mg of protein). 1/NE or 1/MPP^ 
(NE or MPP'*' = the concentration of NE or MPP^ in the incubation buffer in 
nmol/l): 1/Na'*' (Na'*' = the concentration of Na'*' in the incubation buffer in 
mmol/l).
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Figure 16. Inhibition of norepinephrine transporter-mediated uptake
of fH]NE, [^H]DA and [®H]MPP* by the Na*,K*-ATPase inhibitor,
ouabain.
« 15
X 50
3  10
control ouabain pre-ouabain
LLC-NET cells were incubated with ouabain (100 |liM) during or prior (60 
min) to [^H]substrate uptake. Bars are mean ± S.E.M. values of A) 
[^H]NE, B) [^H]DA and C) [^H]MPP^ influx (expressed in DPM) during a 
10-min period, (n = 4; *** P < .001 from control by A NOVA followed by 
post hoc Bonferroni’s test).
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3.3 DISCUSSION.
The findings presented here demonstrate that LLC-PKi cells stably 
transfected with hNET cDNA (LLC-NET cells) inherit the ability to transport 
[^H]NE, [^H]DA and [^H]MPP^ in an inward direction under physiological 
conditions (high extracellular Na"" and Cl). Inward transport of all three 
[^H]substrates was exclusively NET-mediated, as demonstrated by its 
dependence on extracellular Na'' (Iversen and Kravitz, 1966) and Cl" (Sammet 
and Graefe, 1979), its complete blockade by the NET inhibitors DMI and 
mazindol (Gu et al., 1994), and its insensitivity to the vesicular monoamine 
transporter inhibitor, reserpine (Scherman and Henry, 1984).
Two NET inhibitors, mazindol and DMI dose-dependently inhibited uptake of all 
three [^H]substrates with similar IC50 values. The IC50 values calculated for DMI 
in this study are higher than those calculated in previous studies of NET- 
mediated [^H]substrate influx, using LLC-NET cells, SK-N-SH cells and 
synaptosomes (Gu et a!., 1994; Lameh et a!., 1992; Javitch et a!., 1984). The 
IC50 values and/or inhibitor constants (K,) for DMI approximated to 5-10 nM in 
these previous studies. It is difficult to account for the discrepancies in inhibitor 
sensitivities calculated in the present study, with previous findings, particularly 
as substrate affinities were found to be comparable (see below).
Next the ability of El PA, an inhibitor of the NaVH^ exchanger, to block the 
uptake of pHJNE, pH]DA and [^HjMPP^ was determined. EIPA has previously 
been demonstrated to inhibit the influx of NE into PCI2 cells, by competing for
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the Na^-binding site of the NET (Schomig et al., 1989). For a more detailed 
discussion of the inhibitory action of EIPA, see section 1.4.2. The IC50 value of 
~ 80 pM calculated for EIPA is considerably higher than that determined for DMI 
and mazindol. This is in accordance with the study of Schomig et al. (1989), 
who calculated a Kj value of -  24 for EIPA. The use of EIPA as an 
alternative to classical inhibitors of the NET was assessed so that NET- 
mediated transport could be confirmed In subsequent studies in which the use of 
DMI or mazindol was not possible, such as inhibitor-induced transport (see 
chapter 5). It was also important to assess whether lower concentrations of 
EIPA, which inhibit the NHE, interfere with NET-mediated transport of NE. EIPA 
was used to inhibit NHE and subsequent [^H]MPP^ efflux in experiments used to 
develop a model of carrier-mediated NE release in myocardial ischemia (see 
chapter 6). At a concentration of 10 pM (which was used to inhibit the NHE), 
EIPA had little inhibitory effect on [^H]substrate uptake (less than 20%).
The simple hyperbolic relationship for [^HJsubstrate uptake with increasing Na^ 
or Cr concentration is indicative of substrate transport being dependent on 1 
Na^ and 1 Cl' ion. This is consistent with the Na'^iCl'isubstrate stoichiometry of 
1:1:1 calculated for the NET (Friedrich and Bonisch, 1986; Ramamoorthy et al., 
1993a; Gu et al., 1994; Gu et al., 1996). The DAT has a stoichiometry of 2:1:1 
for Na^:CI":substrate (Gu et al., 1994), increasing the Na^ concentration with a 
fixed o r concentration results in a sigmoidal pattern of substrate uptake. As 
seen with the NET, increasing the Cl' concentration with a fixed Na^ 
concentration produces a hyperbolic pattern of uptake with the DAT (Gu et al..
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1994).
The concentration of Cl" required to produce half maxinnal influx of 
[^H]substrates was considerably lower than that calculated for Na\ The values 
determined for Cl" here, are similar to previous studies of NE uptake by LLC- 
NET cells (~ 5.7 mM) (Gu et al., 1994) and adrenergic nerves of the rat heart (~ 
6 mM) (Sanchez-Armass and Orrego, 1977). However, in a study of a cocaine- 
sensitive NET in human placental syncytiotrophoblasts, the Km for Cl" was 
considerably higher, ~ 160 mM (Ramamoorthy et al., 1993a). It had been 
suggested that the differences in Km calculated for Cl" from studies of 
syncytiotrophoblasts and LLC-NET cells maybe due to improper expression of 
NET cDNA. However, the fact that a similar Km value has been calculated for 
adrenergic nerves of the rat heart (Sanchez-Armass and Orrego, 1977), 
suggests otherwise. It may simply be that in the environment of placental 
syncytiotrophoblasts, a higher Cl" concentration is required for half maximal 
transport of NE, or alternatively, the NET itself is different from that of SK-N-SH 
cells (from where the NET transporter used in this study was originally cloned). 
As yet there have been no studies of the syncytiotrophoblast NET in 
recombinant cell lines. Such studies would help resolve the marked disparity in 
Cl" dependence for the NET in these different systems (LLC-NET cells and 
placental syncytiotrophoblasts). The low Kmci- of LLC-NET cells compared to 
the KmNa+, suggests that a reduction in the inwardly directed Na’*’ gradient will 
have a greater effect on transport than alteration of the Cl" gradient.
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Nonlinear regression analysis of saturation studies of substrate influx revealed 
similar kinetic parameters for each fH]substrate used. The maximal transport 
rate of ~ 40 pmol/min/mg protein is similar to that seen with DA in a previous 
study with LLC-NET cells (Gu et al., 1994). However, in the present study, a 
significant difference between the maximal transport rate of NE and DA, was not 
seen. In the aforementioned study, DA was found to be the preferential 
substrate in terms of maximal transport rate and affinity (Km). Again, in the 
present study, concentrations of substrate which produce half maximal transport 
were comparable to that calculated before, but there was no significant 
difference between NE and DA. In different recombinant cell lines expressing 
the NET, NE has been found to be transported at a higher Vmax than DA (PifI et 
al., 1996; see table 7). The values calculated in this study do reflect the general 
kinetic properties of the NET rather than that of the DAT which has considerably 
higher Vmax and Km values for substrate uptake (Gu et al., 1994; see table 7).
Lineweaver-Burk plots were generated to display data, but were not used to 
calculate kinetic parameters (nonlinear regression was used for this, see above). 
The Lineweaver-Burk plots show that Na^ and [^H]substrate are mutually 
cooperative at the NET, furthermore, that plots of 1/Vj vs 1/[Na^] at several fixed 
concentrations of [^H]NE intersected at a common point to the left of the 
abscissa demonstrates that Na^ binds to the transporter before [^H]NE 
(Friedrich and Bonisch, 1986). The corresponding plots with Cl' were not 
produced due to the very low Kmc\- calculated from experiments determining the 
dependence on 01“ of transport.
I l l
One of the most important plasma membrane components for maintaining the 
high extracellular Na^ concentration and therefore the inwardly directed Na^- 
gradient, is the Na^,K^-ATPase. Although the plasma membrane is relatively 
impermeable to N a\ there is a gradual influx of Na^ that would result in 
membrane depolarization if it was not for the action of the Na^,K^-ATPase, 
which exchanges intracellular Na^ for extracellular (Stute and 
Trendelenburg, 1984). Blockade of the Na^,K^-ATPase leads to an increase in 
intracellular Na^ concentration and therefore, a diminished inwardly directed 
Na^ gradient. In experiments in which LLC-NET cells were exposed to the 
Na^,K^-ATPase inhibitor, ouabain, simultaneously with [^H]substrate, there 
was no significant blockade of [^H]substrate influx, suggesting that ouabain does 
not have a direct effect on the NET. When LLC-NET cells were pre-incubated 
with ouabain for 60 min, influx of all three pH]substrates was markedly inhibited, 
reflecting a gradual rise in intracellular Na^ and consequently a reduced 
inwardly directed Na^ gradient with prolonged Na^,K^-ATPase inhibition. 
Inhibition of Na^,K^-ATPase activity is also a contributing factor to Ca^^- 
independent NE release in myocardial ischemia when ATP levels are 
depleted (see chapter 6).
Although some discrepancies with the literature were found in this study, the 
initial studies presented here demonstrate that stable expression of the NET 
in LLC-PKi cells generates a recombinant cell line which inherits the general 
properties of the native transporter expressed constitutively in sympathetic 
nerve endings and neuroblastoma cells.
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CHAPTER 4
METABOLISM OF NOREPINEPHRINE AND DOPAMINE BY 
LLC-NET, SKNMG-NET AND SK-N-SH CELLS
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4.1 INTRODUCTION
Since the cloning of the cocaine-sensitive NE and DA transporters 
(Pachoiczyk et al., 1991; Kilty et a!., 1991), there have been many studies 
utilizing cell lines transiently or stably transfected with catecholamine 
tarnsporter (CAT). Recombinant cell lines stably expressing CATs have 
proven extremely valuable for studying the kinetics, stoichiometry and 
substrate/inhibitor sensitivities of the Na^- and Cl'-dependent transporter 
family (Gu et a!., 1994; Gu et a!., 1996; Tatsumi et al., 1997) (see chapter 3). 
The cell types used for the heterologous expression of CATs are usually very 
different from those cells that constitutively express them, such as PC I2 cells 
(Bruss et al., 1997; Friedrich and Bonisch, 1986) and SK-N-SH 
neuroblastoma cells (Richards and Sadee, 1986; Apparsundaram et a i, 
1998a). One of the most notable differences is the inability of recombinant 
cell lines to store CAs within synaptic vesicles, a process that requires specific 
cellular machinery (see chapter 1.5), such as the vesicular monoamine 
transporter (Liu et a i, 1996b). Vesicular storage of CAs is not only a 
prerequisite for exocytotic release, it also protects CAs from intracellular 
metabolism (Schuldiner, 1994). There are two principal enzymes responsible 
for the metabolism of CAs (see section 1.3) monoamine oxidase (MAO) and 
catechol-0-methyl transferase (COMT). When one studies the uptake or 
release of CAs by neuronal cell lines or synaptosomal preparations, it is of 
standard practice to block the action of MAO (Seyedi et a i, 1997; 
Apparsundaram et a i, 1998a). Inhibitors of COMT are rarely used in these 
preparations. Commonly used cell lines for the heterologous expression of
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CATs are human embryonic kidney (HEK 293) (Apparsundaram et al., 
1998b), COS (Pachoiczyk et al., 1991) and LLC-PKi cells (Gu etal., 1996; Gu 
et al., 1994), all of which are of kidney origin. COMT is expressed abundantly 
in the kidneys (Guldberg and Marsden, 1975), and would therefore be 
expected to be of major importance for the metabolism of CAs in kidney 
derived recombinant cell lines. Furthermore, in the absence of vesicular 
storage, CAs will be continuously exposed to COMT, greatly enhancing the 
capacity for their metabolism.
The metabolism of CAs by MAO and/or COMT is of particular relevance when 
radiolabeled substrates are used. With intracellular and extracellular (efflux 
studies) radiolabel measurements, no discrimination is made between the 
parent pHjCA and [^Hjmetabolites, both will carry the radiolabel and are 
hence, detected together. Although this in itself is a potential problem, of 
more striking significance are the increased lipophilic properties of the 
metabolites compared to the parent compounds (NE and DA). Metabolites of 
NE and DA have a far greater capacity to passively cross the plasma 
membrane (Eshleman et al., 1997), reducing the intracellular contents of 
radiolabel. The loss of [^Hjmetabolites from recombinant cells might alter the 
kinetic parameters calculated for the uptake of pH]NE and [^H]DA. Indeed, 
several investigators have found that the apparent uptake and affinity (Km) of 
[^H]NE and/or [^H]DA is significantly lower in recombinant cell lines 
expressing the CATs than in synaptosomal preparations or neuronal cell lines 
which endogenously express the NE or DA transporter (Eshleman et al.,
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1995; PifI et al., 1993; Horn, 1990). In addition to altering the kinetic 
properties calculated for the transporters, spontaneous CAT-independent 
release of [^H]metabolites from preloaded recombinant cells, could interfere or 
prevent studies of carrier-mediated efflux of the [^HJCAs.
Recently, in a study using HEK 293 and C6 glioma cells stably transfected 
with DAT or NET cDNA, it was demonstrated that COMT inhibitors 
significantly increase the retention of both [^H]NE and pH]DA (Eshleman et 
al., 1997). In addition, the apparent affinity (Km) of [^H]DA transport was 
increased in the presence of COMT inhibitors. The amount of COMT activity 
and therefore the potential to affect the apparent uptake and retention of 
[^H]CAs may vary greatly with the cell line of choice. Although the 
spontaneous loss of radiolabel from [^H]NE and f  H]DA preloaded LLC-NET 
cells has previously been reported (Wall et al., 1995), the influence of COMT 
and MAO activity on NET-mediated transport of [^H]NE and [^H]DA, has not 
been investigated in this recombinant cell line. The purpose of the present 
study was to evaluate COMT and MAO activity in LLC-NET cells, and more 
importantly the contribution these enzymes make to the apparent uptake and 
retention of pH]CAs. In addition, the influence of COMT and MAO activity on 
uptake by transiently transfected SKNMC cells (SKNMC-NET) and SK-N-SH 
cells (which endogenously express the NET) is assessed.
Reversal of the NET is an important mechanism of NE release, therefore, 
specific experiments to address the Influence of COMT and/or MAO activity
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on the potential to study carrier-mediated release of [^H]CAs from LLC-NET
cells, are made and discussed.
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4.2 RESULTS.
4.2.1 The effect of catecholamine-O-methyltransferase inhibition on the 
time course of f  H]NE, f  H]DA and [^H]MPP* uptake by LLC-NET, SKNMC- 
NET and SK-N-SH ceils.
LLC-NET cells transported [^H]NE, [^H]DA and [^H]MPP^ in an inward direction 
under normal physiological conditions. The COMT inhibitor tropolone (ImM) 
significantly potentiated the apparent uptake of pH]NE and pH]DA (figure 17A 
and B), but had no effect on the influx of [^H]MPP^ (figure 17C), a stable 
substrate of the CATs that is not metabolized by COMT. Whilst tropolone did 
not significantly enhance the apparent uptake of [^H]NE during 5 min, the 30 min 
influx period was potentiated by ~ 16%. The effect of COMT inhibition on 
[^H]DA uptake, was considerabiy greater than that seen for [^H]NE uptake by 
LLC-NET cells. Tropolone significantly augmented both the early (5 min; ~ 
15%) and prolonged (30 min; -  60%) [^H]DA uptake. Similar results were 
observed with transiently transfected SKNMC (SKNMC-NET) cells (figure 18) 
and SK-N-SH cells (figure 19), which endogenously express the NET. 
Tropolone potentiated the apparent uptake of [^H]DA by ~ 65 and 120% for 
SKNMC-NET and SK-N-SH cells, respectively.
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Figure 17. The effect of COMT inhibition on the time course of
[»H]NE, [®H]DA and [’H]MPP* uptake by LLC-NET cells.
• control 
o trop (ImM)oX  20-
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40.
o
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O' 40-
g: 30-
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minutes
Potentiation of the apparent uptake of A) [^H]NE and B) pH]DA, but not C) 
[^H]IVIPP ,^ by the COMT inhibitor tropolone (trop; 1 mM). Points are mean 
+ S.E.M. values of fh i] radiolabel uptake (expressed in DPM) by LLC-NET 
cells, at the times indicated on the abscissa (n = 4; * P < 0.05 and *** P < 
0.01 from control by Student’s f test).
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Figure 18. The effect of COMT inhibition on the time course of
[^HJNE and [^H]DA uptake by SKNMC-NET cells.
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o trop ( 1mM)oX 15.
CL
Û
z
IX
CO
"o
1
BO 15-
10 -
co
M—
3025
minutes
Potentiation of the apparent uptake of A) [^H]NE and B) pH]DA, by the 
COMT inhibitor tropolone (trop; 1 mM). Points are mean ± S.E.M. values 
of pH] radiolabel uptake (expressed in dpm) by SKNMC-NET cells at the 
times indicated on the abscissa (n = 4; * P < 0.05 and *** P < 0.01 from 
control by Student’s f test).
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Figure 19. The effect of COMT inhibition on the time course of pH]NE
and [^H|DA uptake by SK-N-SH cells.
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Potentiation of the apparent uptake of A) [^H]NE and B) f  H]DA, by the 
COMT inhibitor tropolone (trop; 1 mM). Points are mean ± S.E.M. values 
of [^H] radiolabel uptake (expressed in DPM) by SK-N-SH cells at the 
times indicated on the abscissa (n = 4; ** P < 0.01 and *** P < 0.01 from 
control by Student’s f test).
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4.2.2 Dose-dependent effect of the catecholamine-O-methyltransferase
inhibitors tropolone and Ro 41-0960 on [^H]DA uptake by LLC-NET cells.
Tropolone had a dose dependent effect on the apparent uptake of [^H]DA by 
LLC-NET cells (figure 20). In a 20 min influx period, the maximal effect of 
tropolone (1 mM) on [^H]DA uptake was an ~ 60% increase above the control 
(i.e. in the absence of tropolone). The EC50 calculated from dose-response 
studies was -  13 pM. Similar experiments performed with Ro 41-0960 
revealed an EC50 value of -  1 nM (figure 20). The relatively small increase in 
the apparent uptake of [^H]NE in the presence of tropolone during a 20 min 
period prevented an accurate calculation of the EC50 value for tropolone and 
[^H]NE uptake (figure 17A).
4.2.3 The effect of the monoamine oxidase inhibitor pargyline on the 
apparent uptake of E^ H]NE, f  H]DA and f  H]MPP^ by LLC-NET and SK-N- 
SH.
Unlike tropolone and Ro 41-0960, the MAO inhibitor pargyline did not potentiate 
the apparent uptake of [^H]NE, [^H]DA or pHJMPP’*' into LLC-NET cells (figure 
21). The uptake of [^H]NE, [^H]DA and [^H]MPP^ was markedly inhibited by 
pargyline in a dose-dependent manner. The IC50 values calculated for pargyline 
were ~ 0.4, 1.6 and 0.6 mM for [^H]NE, [^H]DA and [^H]MPP^ uptake, 
respectively. Concentrations of pargyline which produced maximal inhibition of
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[^H]NE, pH]DA and f  H]MPP^ uptake, reduced transport by -  80%. Similarly to 
its effect on LLC-NET cells, pargyline (0.2 mM) markedly inhibited the uptake of 
[^H]NE, [^H]DA and [^H]MPP^ by SK-N-SH cells (figure 22).
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Figure 20. Dose-response curves for the effect of the COMT 
inhibitors tropolone and Ro 41-0960 on the apparent uptake of 
[^H]DA by LLC-NET cells.
70
□ tropolone 
▼ Ro 41-0960^  60-
20 -
^  10 -
inh ib ito r (M )
Points are mean ± S.E.M. values of [^H] radiolabel uptake (percent 
increase above control) by LLC-NET cells during a 20-min period in the 
presence of the concentration of COMT inhibitor indicated on the abscissa 
(n = 4-6).
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Figure 21. Dose-dependent inhibition of LLC-NET-mediated fH]NE,
f  H]DA and [^H]IVIPP  ^uptake by the MAO inhibitor pargyline.
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Points are mean ± S.E.M. values of [^H]substrate uptake by LLC-NET 
cells (percent of maximum uptake), during a 30-min influx period in the 
presence of the concentration of pargyline indicated on the abscissa (n = 
4).
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Figure 22. The effect of the COMT inhibitor tropolone and the MAO
inhibitor pargyline on [^H]NE and [^H]DA uptake by SK-N-SH cells.
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***
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30 minutes 60 minutes
The potentiation and attenuation by tropolone (trop; 1 mM) and pargyline 
(parg; 0.2 mM), respectively, of the apparent uptake of A) [^H]NE and B) 
[^H]DA by SK-N-SH cells. Bars are mean ± S.E.M. values of [^H] 
radiolabel uptake (expressed in dpm) during a 30- or 60-min period (n = 4; 
* P < 0.05, ** P < 0.01 and *** P < 0.001 from control; t t t  < 0.001 from 
tropolone by AN OVA followed by post hoc Bonferroni’s test).
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4.2.4 The effect of catecholamine-O-methyltransferase inhibition on the 
retention of [^H]NE, [^H]DA and f  H]MPP^ by LLC-NET cells.
Tropolone (1 mM) markedly augmented the amount of radiolabel retained by 
LLC-NET cells loaded with [^H]NE or pH]DA. After 60 min of uptake (loading) 
and 30 min of washout, inhibition of COMT with tropolone (1 mM) or Ro 41-0960 
(1 pM) increased the retention of radiolabel by -  3 and ~ 25 fold, for [^H]NE and 
[^H]DA respectively (figure 23). COMT inhibition had no significant effect on 
[^H]MPP^ retention, a large amount of radiolabel was maintained by preloaded 
LLC-NET cells in the absence or presence of tropolone or Ro 41-0960 (figure 
23). Dose response studies with tropolone revealed EC50 values of ~ 31 and 96 
pM for [^H]NE and [^H]DA radiolabel retention, respectively (figure 24A). The 
corresponding EC50 values for Ro 41-0960 were -1 .7  and 3.9 nM (figure 24B).
The time-dependent spontaneous loss of radiolabel from LLC-NET cells 
preloaded with [^H]NE or [^H]DA, was markedly reduced with tropolone (figure 
25). In the absence of tropolone or Ro 41-0960, the spontaneous loss of 
radiolabel from preloaded LLC-NET cells was greater for [^H]DA than [^H]NE. 
During 20 min incubation in normal HEPES buffer, ~ 50 and 30%, ([^H]DA and 
[^H]NE, respectively) of the total radiolabel remaining in preloaded (60 min 
influx) LLC-NET cells was spontaneously released into the extracellular buffer. 
During a 30 min period, dose-response studies with tropolone revealed an EC50 
value of -  26 and 35 pM for the attenuation of the spontaneous loss of
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radiolabel from [^H]NE and [^H]DA preloaded LLC-NET cells, respectively (figure 
26A). The corresponding values for Ro 41-0960 were -  1.5 nM for both [^H]NE 
and pH]DA (figure 26B). The NET inhibitors DMI (1 pM) and mazindol (1 pM) 
had no effect on the spontaneous release of radiolabel from [^H]NE or [^H]DA 
preloaded LLC-NET cells (data not shown).
4.2.5 The effect of tropolone on low Na^-induced release of [^H]NE and 
[^H]DA from preloaded LLC-NET cells.
In the presence of tropolone (1 mM), exposure of preloaded LLC-NET cells to a 
reduced Na^ buffer (5 mM) stimulated a large efflux of [^H]CAs that was 
significantly blocked by DMI (1 pM) (figure 27). In the absence of tropolone, 
stimulated efflux was only slightly greater than the spontaneous release of [^H] 
radiolabel and this release was not significantly blocked by DMI.
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Figure 23. The effect of COMT inhibition on [^H]NE, [^H]DA and
[^H]MPP* retention by LLC-NET cells.
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Potentiation of [^H]NE and [^H]DA retention but not [^H]MPP^ by the 
COMT inhibitors A) tropolone (trop; 1 mM) and B) Ro 41-0960 (Ro; 1 pM). 
Bars are mean ± S.E.M. values of [^H] radiolabel retention (percent of 
maximal) by preloaded (60 min) LLC-NET cells during a 30-min release 
period, in the presence or absence of tropolone or Ro 41-0960 (n = 4; *** 
P < 0.001 from COMT inhibitor by AN OVA followed by post hoc 
Bonferroni’s test).
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Figure 24. Dose-dependent effects of the COMT inhibitors tropolone 
and Ro 41-0960 on [^H] radiolabel retention by LLC-NET cells 
preloaded with pH]NE or [^H]DA.
£  100 - II  80-
o 60-
c? 40- 
O 20 .
10 100 
tropolone (|aM)
1000
100 -II 80-
E
60- 
e
i  40-
CO
-  20 -
‘o
0.1 100 1000
Ro 41-0960 (nM)
Dose-dependent potentiation of pH]NE and pH]DA retention by the COMT 
inhibitors A) tropolone and B) Ro 41-0960. Points are mean ± S.E.M. 
values of pH] radiolabel retention (percent of total taken up) by preloaded 
LLC-NET cells during a 30-min release period in the presence of the 
concentration of COMT inhibitor indicated on the abscissa (n = 4-6).
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Figure 25. The effect of COMT inhibition on the time course of 
spontaneous loss of radiolabel from pH]NE and [^H]DA preloaded 
LLC-NET cells.
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Inhibition of the spontaneous loss of [^H] radiolabel from A) [^H]NE 
and B) [^H]DA preloaded LLC-NET cells by the COMT inhibitor 
tropolone (trop; 1 mM). Points are mean ± S.E.M. values of 
spontaneous [^H] radiolabel efflux (percent release of total) at the 
times indicated on the abscissa (n = 4).
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Figure 26. Dose-dependent inhibition of the spontaneous loss of [^H] 
radiolabel from preloaded LLC-NET cells, by the COMT-inhibitors 
tropolone and Ro 41-0980.
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LLC-NET cells were loaded with [^H]NE or [^H]DA (60 min) in the 
presence of the concentration of the COMT inhibitor A) tropolone or B) Ro 
41-0960 indicated on the abscissa. Points are mean ± S.E.M. values of 
[^H] radiolabel spontaneously released (percent of total taken up), during a 
30-min period in the presence of the concentration of COMT inhibitor 
indicated on the abscissa (n = 4-6).
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Figure 27. The effect of the COMT inhibitor tropolone on low Na*- 
induced efflux of f  H]NE and [^H]DA from LLC-NET cells.
80-
□  control 
■  SmM Mb '"
5 mM Na^ + DMI
A
***
100
IX
CO
w—OX3
%
80-
60-
40-
□  control 
®  5 mM Na"^
^ 5  mM Na^ + DMI
B
tropolone (1 mM)
Tropolone (1 mM) markedly potentiates the specific NET-mediated, low 
Na^-induced efflux of A) [^H]NE and B) pH]DA. Bars are mean ± S.E.M. 
values of [^H]substrate efflux (percent release of total) during a 40-min 
period (n = 4; ** P < 0.01 and *** P < 0.001 from control; t t t  P < 0.001 
from 5 mM Na"" by ANOVA followed by post hoc Bonferroni’s test).
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4.3 DISCUSSION.
Kidney derived LLC-NET cells possess abundant COMT activity, which 
markedly alters the apparent uptake and retention of [^H]CAs. The inability of 
an inhibitor of MAO to increase the apparent uptake or retention of pH]CAs, 
suggests that this CA metabolizing enzyme does not have significant activity in 
LLC-NET cells. However, pargyline, an inhibitor of MAO, markedly attenuated 
NET-mediated influx of [^H]substrates.
The apparent uptake of f  H]NE and [^H]DA by LLC-NET cells was significantly 
increased in the presence of the COMT inhibitors, tropolone and Ro 41-0960. 
Unlike the pH]CAs, influx of [^H]MPP^ was unaffected by COMT inhibitors. 
Although [^H]MPP^ is a substrate for CATs (Buck and Amara, 1994; PifI et al., 
1996), this neurotoxin lacks a catechol hydroxyl group which is necessary for the 
methyl substitution, and is therefore insensitive to metabolism by COMT. In the 
presence of COMT inhibitors, the increase in the apparent uptake of both 
pH]NE and [^H]DA, is best interpreted as a reduced loss of radiolabel from LLC- 
NET cells, as the production of intracellular pH]metabolites is decreased. The 
plasma membrane is not an impermeable barrier to the relatively lipophilic CA 
metabolites, consequently, radiolabel carried by the [^H]metabolites, will be 
spontaneously lost from LLC-NET cells. In the continuous presence of 
extracellular pH]CAs, COMT inhibition had a more pronounced effect on [^H]DA 
uptake than [^H]NE uptake. Whereas COMT inhibition with tropolone (1 mM) 
increased the apparent uptake of [^H]NE by ~ 15%, [^H]DA influx was
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potentiated by ~ 60%, during a 30 min period. Furthermore, significant 
increases in the apparent uptake of [^H]DA occurred during earlier time points, 
than that seen with [^H]NE. Influx of [^H]DA, but not pH]NE, was significantly 
increased by COMT inhibitors during 10 min exposure to the [^H]CAs. Two 
possible explanations could account for these differences. COMT may 
preferentially metabolize [^H]DA, or alternatively, the product of [^H]DA 
metabolism may be more lipophilic than the corresponding [^H]NE metabolite. 
In either case, a larger amount of radiolabel will be lost from LLC-NET cells 
loaded with pH]DA, and consequently, COMT inhibitors enhance the apparent 
uptake of [^H]DA by a greater degree than pH]NE. The metabolites of [^H]NE 
and fH]DA produced by COMT are pH]normetanephrine and 3- 
[^H]methoxytyramine, respectively (see section 1.3). In a previous study, 3- 
pH]methoxytyramine was calculated, by the FRAGMENT method, to be more 
lipophilic than [^Hjnormetanephrine (Eshleman et al., 1997). The greater effect 
of COMT inhibitors on the apparent uptake of [^H]DA, compared to [^H]NE, 
probably reflects the difference in lipophilicity of pHjnormetanephrine and 3- 
[^Hjmethoxytyramine. Although both [^H]CAs are avidly metabolized by COMT, 
more radiolabel will be lost from LLC-NET cells containing [^H]DA, as 3- 
[^HJmethoxytyramine, passively crosses the plasma membrane with greater 
ease than pHJnormetanephrine. Although a significant amount of 
[^Hjnormetanephrine produced by COMT action on intracellular [^H]NE, diffuses 
out of LLC-NET cells, a greater amount, compared to [^H]methoxytyramine, will 
be retained within the cytoplasm. Intracellular pH]normetanephrine and [^H]NE, 
will be detected together when radiolabel measurements of the lysed cells are
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made, hence COMT inhibitors appear to have less effect on [^H]NE than [^H]DA 
uptake. This has been demonstrated by HPLC measurements of NE taken up 
by C6  glioma cells stably expressing CATs (Eshleman et al., 1997). Direct NE 
measurements revealed that the apparent uptake of NE is actually much greater 
in the presence of COMT inhibitors than that calculated with radiolabel 
measurements.
The EC50 value calculated from dose-response studies for the action of 
tropolone on the apparent uptake of [^H]DA in the present study ( -  13.3 jiM), is 
similar to the IC50 value of COMT inhibition by tropolone -  22 ^iM (Guldberg and 
Marsden, 1975). The structurally different COMT inhibitor, Ro 41-0960 had 
similar effects to tropolone on the apparent uptake of pH]DA. The only 
difference between the two COMT inhibitors, were the calculated potencies of 
tropolone and Ro 41-0960 for enhancing the apparent uptake of [^H]DA. Ro 41- 
0960 (EC50 value of ~ 1.2 nM) was ~ 10000 times more potent than tropolone. 
The maximal effect was similar for each inhibitor demonstrating a specific action 
of these compounds on COMT.
The uptake of [^H]DA by a second recombinant cell line expressing the NET 
(transiently transfected SKNMC cells) was also potentiated by tropolone. 
SKNMC cells are of brain tissue origin, which also abundantly expresses COMT 
(Guldberg and Marsden, 1975).
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To determine if the use of COMT inhibitors is warranted in uptake studies of 
pH]CAs using cell lines that endogenously express the NET, experiments were 
performed with SK-N-SH neuroblastoma cells. Similarly to that seen with LLC- 
NET cells, tropolone (1 mM) potentiated the apparent uptake of [^H]NE and 
[^H]DA by SK-N-SH cells. The pattern of potentiation was also dependent on 
the [^H]CA of study, pH]DA uptake being significantly augmented at earlier time 
points and by a greater degree than [^H]NE. This clearly demonstrates that 
although SK-N-SH cells perform vesicular storage, the use of a COMT inhibitor 
is warranted during uptake studies and subsequent release studies.
The MAO inhibitor pargyline had no augmentary effect on the apparent uptake 
of pH]CAs by LLC-NET cells. In fact, pargyline significantly inhibited the 
apparent uptake of [^H]NE and [^H]DA, suggesting that whilst MAO probably 
does not metabolize [^H]CAs in this cell line, pargyline, a derivative of CAs, 
competes with pH]NE and [^H]DA for the NET. To further investigate the 
possible inhibitory action of pargyline on NET-mediated transport, dose- 
response studies with pargyline were performed on pH]MPP^ uptake. Pargyline 
markedly and dose-dependently inhibited the uptake (20 min) of [^H]MPP"‘ by 
LLC-NET cells. Although the concentration of pargyline which produced 
significant inhibitory effects on pH]NE, pH]DA and f  H]MPP^ uptake were high 
compared to the classical NET inhibitors (e.g. DMI, cocaine and mazindol), high 
pM to low mM concentrations of this MAO inhibitor are commonly used 
(Apparsundaram et a/., 1998a; Seyedi et al., 1997). Of particular 
interest/relevance was the inhibitory action of pargyline (0.2 mM) on the uptake
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of [^H]CAs by SK-N-SH cells. Pargyline markedly inhibited the uptake of both 
[^H]NE and [^H]DA in the absence or presence of tropolone. This implies that 
the use of pargyline to inhibit MAO maybe disadvantageous when uptake 
experiments with exogenous CAs are performed. A previous study with 
Chinese hamster ovary (CHO) cells stably expressing the NET also 
demonstrated an inhibitory action of MAO inhibitors (including clorgyline and 
phenelzine) on [^H]NE uptake (Percy et a/., 1999). Although a reason for this 
inhibitory action was not proposed, similar to the findings with pargyline in this 
study, it most likely reflects an action of MAO inhibitors at the NET.
To study the carrier-mediated release of [^H]CAs from recombinant cell lines, it 
is first necessary to load the cells with [^H]NE or f  H]DA. After a relatively long 
period of pH]NE or [^H]DA uptake (60 min), preloaded cells are incubated in a 
CA free physiological buffer, prior to exposure to CAT substrates, ionophores or 
modified buffers with a reduced Na^ or Cl" concentration (see chapters 5 and 6). 
To evaluate the contribution of COMT to the spontaneous loss of radiolabel from 
preloaded LLC-NET cells, studies were performed in which LLC-NET cells were 
loaded for 60 min with [^H]NE or [^H]DA, in the absence or presence of 
tropolone (1 mM). After this loading period, cells were washed and then 
incubated in CA free HEPEs buffer with or without the COMT inhibitor. Similarly 
to its effect on the apparent uptake of pH]NE and pH]DA, tropolone markedly 
increased the retention of pH]CAs. The length of time that accumulated 
pHJCAs were exposed to COMT, was considerably greater for these studies 
than those used to measure the apparent uptake of pHJCAs by LLC-NET cells.
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Therefore, the potential for metabolism and production of pH]normetanephrine 
and 3-pH]methoxytyramine is greatly increased. Additionally, the lost 
intracellular pHjmetabolites cannot be replaced by extracellular pH]CAs, as 
LLC-NET cells are incubated in a pH]CA free HEPES buffer after the loading 
period. The amount of radiolabel retained by LLC-NET cells in the absence of 
COMT inhibition was significantly greater for pH]NE than pH]DA preloaded LLC- 
NET cells. To compare the retention of the two pH]CAs/pH]metabolites, the 
amount of radiolabel remaining in LLC-NET cells in the absence of tropolone, 
was expressed as a percentage of that retained in the presence of the COMT 
inhibitor. After 60 min of loading and 30 min washout, ~ 40 and 5% (for pH]NE 
and pH]DA, respectively) of the radiolabel retained by LLC-NET cells incubated 
with tropolone (1 mM), remained in LLC-NET cells in the absence of the COMT 
inhibitor. Similar values were obtained with Ro 41-0960 (1 juM). Analogous to 
the apparent uptake of pH]NE and pH]DA by LLC-NET cells, dose-response 
experiments performed with the two COMT inhibitors, revealed a much greater 
potency of Ro 41-0960 than tropolone, on radiolabel retention.
To elucidate the dependence or independence of the NET on the spontaneous 
loss of radiolabel from preloaded LLC-NET cells, experiments were performed in 
which the pH]CA loaded LLC-NET cells were incubated in a physiological 
HEPES buffer in the absence or presence of the NET inhibitor DMI. DMI 
potently blocks the inward and outward transport of NET substrates (see 
sections 3, 5 and 6). DMI (1 |liM) had no effect on the spontaneous loss of 
radiolabel from LLC-NET cells preloaded with pH]NE or pH]DA, indicating that
139
the spontaneous loss of pH]metabolites is independent of the NET. In fact, it 
would have been very surprising if the NET had been found to mediate the 
spontaneous loss of radiolabel from preloaded LLC-NET cells incubated in a 
physiological HEPES buffer. In the absence of extracellular NET substrates, the 
high extracellular Na^ concentration will maintain an asymmetric distribution of 
the transporters across the plasma membrane (Trendelenburg, 1991). A far 
greater number of transporters will be in the outward facing conformation, and 
therefore, unavailable to transport the intracellular CAs. In accordance with the 
inability of DMI and mazindol to block the spontaneous release of pH] radiolabel 
from preloaded LLC-NET cells, pHjnormetanephrine has been shown to have a 
very low affinity for the NET (Paton, 1973).
One method used to induce NET-mediated outward transport of pHjCas from 
recombinant cell lines, is to reverse the Na^ gradient by incubating the 
preloaded cells in a reduced Na^ buffer (PifI et al., 1997). When preloaded LLC- 
NET cells were incubated in a modified HEPES buffer containing 5 mM Na ,^ the 
release of radiolabel was slightly, but significantly increased for pHjNE. In 
similar experiments performed in the presence of tropolone, the release of 
radiolabel from pH]NE or pHjDA preloaded cells was markedly increased with 
Na^-gradient reversal. More importantly, the NET inhibitor DMI blocked this 
stimulated release, demonstrating the dependence of the NET on low Na^ 
induced efflux of pH]CAs. In the absence of tropolone, DMI had no significant 
effect on the slight increase in radiolabel produced by Na^-gradient reversal. 
Therefore, inhibition of COMT activity is essential for carrier-mediated efflux
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studies of [ H]NE and pH]DA from preloaded LLC-NET cells.
This and other recent studies with recombinant cells expressing the CATs 
(Eshleman et ai, 1997; Percy et ai, 1999) suggest that whilst these 
heterologous expression systems provide an important tool for exploring the 
functional properties of the CATs, the ability of the host cell to metabolize 
pH]CAs should be determined. The existence of COMT activity in many of the 
cell lines tested warrants the routine use of COMT inhibitors in studies with 
recombinant and endogenously expressing CAT cell lines. Furthermore, the 
very apparent inhibitory action of the MAO inhibitor pargyline on NET substrate 
uptake may distort the calculation of kinetic parameters, hence alternative MAO 
inhibitors which lack NET inhibitory properties should be determined and used 
where possible.
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CHAPTER 5
INHIBITORS OR SUBSTRATES? DESIPRAMINE AND 
MAZINDOL-INDUCED EFFLUX OF NOREPINEPHRINE 
TRANSPORTER SUBSTRATES
142
5.1 INTRODUCTION.
As well as being responsible for the reuptake of released NE, similar to other 
members of the Na^- and CP-dependent transporter family, the NET mediates 
the outward transport of free axoplasmic NE (reverse transport). This occurs 
with the inward transport of a substrate, so that the NET is now in the inward- 
facing conformation where it can bind free axoplasmic NE (Chen and Justice, 
1998; Langeloh et a/., 1991; Levi and Raiteri, 1993) or when the 
transmembrane Na^ gradient is altered, such as with Na^,K^-ATPase 
inhibition (Stute and Trendelenburg, 1984; Sweadner, 1985) or Na^-H^ 
exchanger activation, as seen in myocardial ischemia (Schomig et al., 1991; 
Schomig et al., 1988b; Imamura et al., 1996; Hatta et al., 1997).
A number of therapeutic compounds, such as mazindol (Inoue, 1995) and 
tricyclic antidepressants (Bruss etal., 1993), and drugs of abuse (e.g. cocaine 
and amphetamines) (Schomig and Bonisch, 1986; Ritz et al., 1987; Wall et 
al., 1995) elicit their pharmacological action by inhibiting the uptake of 
catecholamines (CAs), thus increasing the synaptic CA concentration. 
Despite inhibiting the uptake of catecholamine transporter (CAT) substrates, 
the interaction of inhibitors with the dopamine transporter (DAT) was found to 
be more complex, than one of simple blockade (Johnson et al., 1998). In C6- 
glioma cells stably expressing the DAT (C6-DAT), it was discovered that 
cocaine and other transporter inhibitors actually stimulate the release of f\-\]N- 
methyl-4-phenylpyridinium ([^H]MPP'*'), a stable substrate of the CATs (Buck 
and Amara, 1994; PifI et al., 1996), from p re loaded cells. The high
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spontaneous release of radiolabel from [^H]DA loaded C6-DAT cells, even in 
the presence of a COMT inhibitor, prevented the investigation of inhibitor- 
induced efflux of the endogenous CA substrates (NE and DA). In another 
study, differences between spontaneous and inhibitor-induced efflux of pH]DA 
and [^H]MPP^ were demonstrated in COS cells expressing the DAT, 
suggesting that the substrate of study may influence the findings (potency and 
efficacy) made with transporter inhibitors (Kitayama et al., 1996).
To date, there have been no studies to assess whether the NET can mediate 
inhibitor-induced efflux of CAT substrates. Chimeric studies of the NE and DA 
transporters revealed discrete structural domains that contribute to the 
pharmacological and kinetic characteristics of each transporter for substrate 
and inhibitor recognition (Buck and Amara, 1994; Buck and Amara, 1995). 
The discrete differences in structural domains of the NE and DA transporters 
may contribute to inhibitor-induced efflux of CAT substrates, therefore, the 
purpose of the present study was to investigate the possible stimulatory action 
of CAT inhibitors on [^H]NE, [^H]DA and [^H]MPP* effiux via the NET. Uniike 
C6-DAT cells (Eshleman et al., 1997), but similarly to COS-DAT cells 
(Kitayama et al., 1996), LLC-NET cells maintain high levels of intracellular 
[^H]NE and [^H]DA in the presence of a COMT inhibitor (e.g. tropolone; see 
chapter 4) making efflux studies of [^H]NE and [^H]DA, in addition to 
[^H]MPP^, possible.
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5.2 RESULTS.
5.2.1 Low Na*-induced efflux of fH]NE, [®H]DA and [^H]MPP  ^ from
preloaded LLC-NET cells.
Incubation of preloaded LLC-NET cells in a modified HEPES buffer containing 5 
mM Na'*' resulted in a significant time-dependent efflux of [^H]NE, pH]DA and 
[^H]MPP^ (figure 28). The maximal amount of pH]substrate released by Na^- 
g rad lent reversal and the extent of inhibition by DMI and mazindol, differed 
between substrates (figures 29 and 30). 30 min exposure of preloaded LLC- 
NET cells to 5 mM Na^ resulted in ~ 40, 50 and 70% release of the total 
contents of [^H] radiolabel, for [^H]NE, pH]DA and [^H]MPP^, respectively. 
Incubation of LLC-NET cells with DMI or mazindol attenuated the low Na^- 
induced efflux of all three [^Hjsubstrates in a dose-dependent manner. The 
calculated IC50 values for DMI were -  32, 70 and 55 nM, for [^H]NE, pH]DA and 
[^H]MPP^, respectively (figure 29). The maximal inhibitory effect of DMI and 
mazindol on low Na^-induced efflux was ~ 75, 60 and 30% for pH]NE, pH]DA 
and pH]MPP^, respectively. Incubation of preloaded LLC-NET cells with the 
amiloride derivative, 5-(A/-ethyl-A/-isopropyl)-amiloride (ElPA; 100 pM), during 
the release period, markedly attenuated the low Na^-induced release of all three 
pH]substrates (figure 30B). Furthermore, incubation of preloaded LLC-NET 
cells with El PA (30 min), prior to Na^-gradient reversal, significantly enhanced 
the inhibitory action of El PA on pH]DA and f  HJMPP"^  release (from -  40 to 70% 
and ~ 70 to 90% for pH]DA and [^H]MPP^, respectively), but not f  H]NE.
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Figure 28. Time-dependent, low Na^-induced release of pH]NE,
pH]DA and f  H]MPP* from preloaded LLC-NET cells.
■ NE 
A DA 
• MPP
-H-<
_o
40-
coM—
20 -
20
m inutes
30 40
Points are mean ± S.E.M. values of low Na^- (5mM) induced [^HJsubstrate 
efflux from [^H]NE, pH]DA and [^H]MPP+ preloaded LLC-NET cells 
(percent release of total, corrected for basal release) at the times indicated 
on the abscissa (n = 4).
146
Figure 29. Dose-dependent inhibition of low Na^-induced efflux of 
fH]NE, [^H]DA and [^H]MPP  ^ from LLC-NET cells by the 
norepinephrine transporter inhibitor, DMI.
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Points are mean ± S.E.M. values of low Na^- (5mM) induced [^H]substrate 
efflux from [^H]NE. [^H]DA and [^H]MPP’^  preloaded LLC-NET cells 
(percent release of maximal) in the presence of the concentration of DMI 
indicated on the abscissa during a 30-min period (n = 4).
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Figure 30. inhibition of low Na^-induced efflux of [^H]NE, [^H]DA and
f  H]MPP* from LLC-NET cells by DMI, mazindol and EIPA.
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Bars are mean ± S.E.M. values of low Na"^ - (5 mM) induced [^H]substrate 
efflux from [^H]NE, [^H]DA and [^H]MPP^ preloaded LLC-NET cells 
(percent release of total) in the absence or presence of DMI (1 pM), 
mazindol (maz; 1 pM) or EIPA (100 pM) during a 30-min period (n = 4; *** 
P < .001 from control; t t t  < 001 from low Na""; t t t  P < .001 from low Na'^  
+ EIPA, respectively, by ANOVA followed by post hoc Bonferroni’s test).
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5.2.2 Tyramîne-înduced effiux of fH]NE, fH]DA and pH]MPP^ from
preloaded LLC-NET cells.
Tyramine induced a time- and dose-dependent efflux of [^Hjsubstrates from 
preloaded LLC-NET cells (figures 31 and 32). Similar to the efflux induced by 
Na^-gradient reversal, the maximal amount of pH]substrate released by 
tyramine, and the extent of inhibition by DMI and mazindol differed between 
substrates. After a 30-min incubation period with tyramine (10 pM) ~ 25, 50 and 
65% of the total cellular content of [^H]NE, [^H]DA and f  H]MPP^ was released 
into the extracellular buffer, respectively (figure 33). The EC50 values calculated 
for tyramine were -  3.4, 4.8 and 1.7 pM for pH]NE, [^H]DA and [^H]MPP^ 
release, respectively (figure 32). DMI (1 pM) and mazindol (1 pM), significantly 
reduced the amount of tyramine-induced [^H]substrate efflux (figure 33A). As 
seen with low Na^nduced [^H]substrate efflux, the inhibitory action of DMI and 
mazindol was greatest for pH]NE. EIPA (100 pM) markedly attenuated the 
tyramine-induced release of all three [^H]substrates (figure 33B). The inhibitory 
action of EIPA was augmented when preloaded LLC-NET cells were pre­
incubated with EIPA. Noticeably, unlike low Na^-induced pH]substrate efflux, 
pH]NE release in addition to [^H]DA and [^H]MPP^ was further augmented by 
pre-incubation with EIPA.
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Figure 31. Time-dependent, tyramine-induced efflux of pH]NE,
[^H]DA and pHlWIPP  ^from preloaded LLC-NET cells.
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Points are mean ± S.E.M. values of tyramine- (10 i^M) induced 
[^H]substrate efflux from [^H]NE, [^H]DA and [^H]MPP^ preloaded LLC- 
NET cells (percent release of total, corrected for basal release) at the 
times indicated on the abscissa (n = 4).
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Figure 32. Dose-dependent, tyramine-induced effiux of [^H]NE,
[^H]DA and [^H]iVIPP* from preioaded LLC-NET ceiis.
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Points are mean ± S.E.M values of [^H]NE, [^H]DA [^H]MPP^ effiux (% 
release of total) at the concentration of tyramine indicated on the abscissa 
during a 10-min period (n = 4).
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Figure 33. Inhibition of tyramine-induced efflux of fH]NE, [^H]DA
and [^H]MPP  ^from LLC-NET cells by DMI, mazindol and EIPA.
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Bars are mean ± S.E.M. values of tyramine- (tyr; 10 pM) induced 
[^H]substrate efflux from pH]NE, [^H]DA and pHlMPP"" preloaded LLC- 
NET cells (percent release of total) in the absence or presence of DMI (1 
pM), mazindol (maz; 1 pM) or EIPA (100 pM) during a 30-min period (n = 
4; *** P < .001 from control; t t t  < .001 from tyramine; t  P < .05, t t  P < 
.01 and t t t  P < .001 from tyr + EIPA, respectively, by ANOVA followed by 
post hoc Bonferroni’s test).
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5.2.3 DMI and maztndol-induced efflux of fH]NE, [^H]DA and [^H]MPP*
from LLC-NET cells.
The NET inhibitors DMI and mazindol induced a time- and dose-dependent 
efflux of pHJsubstrate from preloaded LLC-NET cells (figures 34 and 35). The 
maximal amount of inhibitor-induced [^HJsubstrate efflux was considerably 
higher for [^HjMPP^ than [^H]DA and pH]NE. During a 30-min period, DMI (1 
pM) and mazindol (1 pM) induced ~ 8.5, 13.4 and 32.0% efflux of the total 
cellular content of [^H]NE, [^H]DA and [^H]MPP^, respectively, into the 
extracellular buffer above that of spontaneous release (figure 34). The 
corresponding control values (basal efflux) were ~ 5.0, 5.3 and 2.9%. The EC50 
values calculated for DMI-induced efflux of the pH]substrates were 60, 245 and 
85 nM for [^H]NE, [^H]DA and [^H]MPP^, respectively (figure 35). The 
corresponding values for mazindol were ~ 60, 170 and 95 nM. EIPA (100 pM), 
which competes for the Na^ binding site of the NET, did not induce [^Hjsubstrate 
efflux from preloaded LLC-NET cells (data not shown). Similar to its inhibitory 
action on low Na^- and tyramine-induced [^HJsubstrate efflux, EIPA markedly 
attenuated the DMI and mazindol-induced efflux of all three [^H]substrates 
(figures 36 and 37).
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Figure 34. Time course for inhibitor-induced effiux of [^H]NE, [^H]DA
and [^H]iViPP* from LLC-NET ceiis.
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Points are mean ± S.E.M. values of [^HJsubstrate efflux induced by DMI (1 
j^M) or mazindol (1 juM) (percent release of total, corrected for basal 
release) at the times indicated on the abscissa (n = 4).
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Figure 35. Dose-dependent inhibitor-induced efflux of f  H]NE, [^H]DA
and f  H]MPP^ from LLC-NET cells.
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Dose-dependent release of A) [^H]NE, B) [^H]DA and C) [^H]MPP'‘ from 
preloaded LLC-NET cells by the NET inhibitors DMI and mazindol. Points 
are mean ± S.E.M. values of [^HJsubstrate efflux (percent release of total) 
elicited by DMI or mazindol at the concentration indicated on the abscissa 
during a 30-min period (n = 4).
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Figure 36. Inhibition of DMI- and mazindol-induced efflux of [^H]NE
and [^H]DA from LLC-NET cells by EIPA.
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Bars are mean ± S.E.M. values of A) DMI (1 pM) and B) mazindol (maz; 1 
pM) induced efflux of [^H]NE and [^H]DA (% release of total) from 
preloaded LLC-NET cells in the absence or presence of EIPA (100 pM), 
during a 90-min period (n = 4; *** P < .001 from control; t t t  < .001 from 
DMI or maz, by ANOVA followed by post hoc Bonferroni’s test).
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Figure 37. Inhibition of DMI- and mazindoi-induced efflux of
[^H]MPP* from LLC-NET ceils by EiPA.
EIPA (100 nM)
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Bars are mean ± S.E.M. values of DMI (1 pM) and mazindol (maz; 1 pM) 
induced efflux of [^H]MPP^ (% release of total) from preloaded LLC-NET 
cells in the absence or presence of EIPA (100 pM), during a 30-min period 
(n = 4; *** P < .001 from control; f t t  < 001 from DMI or maz, by AN OVA 
followed by post hoc Bonferroni’s test).
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5.3 DISCUSSION.
The findings presented here demonstrate that preloaded LLC-NET cells 
transport [^H]NE, [^H]DA and pHlMPR"" in an outward direction when exposed to 
a NET substrate (i.e. tyramine) or when the inwardly directed Na^ gradient is 
reversed. Although the NET inhibitors DMI and mazindol abolished influx of all 
three fH]substrates with similar IC50 values (see section 3), the maximal 
inhibitory action of DMI and mazindol on stimulated efflux (Na^-gradient reversal 
or tyramine-induced release) differed significantly between the [^H]substrates. 
In addition to blocking the influx and efflux of pH]substrates, both DMI and 
mazindol induced a time- and dose-dependent efflux of [^H]substrates that was 
sensitive to EIPA. The degree of inhibitor-induced [^Hjsubstrate efflux, differed 
greatly among pH]NE, pH]DA and [^H]MPP^ suggesting that the specific 
substrate to NET interaction determines the sensitivity of a particular substrate 
to inhibitor-induced efflux.
Preloaded LLC-NET cells maintained high levels of [^H]NE, [^H]DA and 
pHJMPP’^  during all the time points tested (up to 90 min). The use of a COMT 
inhibitor (tropolone, 1 mM) was required for the retention of [^H]NE and pH]DA 
(see section 4). Maintenance of high intracellular levels of pH]NE, f  H]DA and 
[^H]MPP^ is a prerequisite for studying substrate-specific characteristics of NET- 
mediated efflux. Efflux of pH]NE, pH]DA and pH]MPP^ induced by Na^- 
gradient reversal, revealed significant differences between the [^H]substrates. 
Firstly, the maximal amount of [^Hjsubstrate released by Na^-g rad lent reversal
158
was greatest for [^H]IVIPP .^ Whilst the initial release of [^H]DA and [^H]MPP^ 
was similar (5 min time point), during prolonged exposure to low N a\ 
[^H]MPP’^  efflux increased to a higher maximal value. [^H]NE efflux was 
noticeably lower than [^H]DA and [^H]MPP^ during all the time points tested, 
the largest difference being at 5 min. Not only was there considerably less 
[^H]NE released during 5 min exposure to low Na*, the actual percentage of 
maximal [^HJsubstrate efflux was markedly lower for [^H]NE than for [^H]DA 
and f  H]MPP^. Differences in the kinetic parameters of the NET for [^H]NE, 
[^H]DA and [^H]MPP‘^  may explain this. The NET has been reported to have a 
higher apparent affinity (K^) for DA and IVIPP^  than for NE (0.42, 0.64 and 
1.92 pM, respectively; (PifI et a i, 1996). However, earlier influx experiments 
with LLC-NET cells (see section 3) did not demonstrate significant differences 
in the affinity of the NET for each substrate. Despite this, it is possible that 
differences in kinetic properties between substrates exist in the intracellular 
environment where the Na^ concentration is low and the NET is in the inward- 
facing conformation. It is well documented that prior loading of the NET with 
Na^ increases the affinity of the transporter for substrate (Trendelenburg, 
1991), a characteristic which may differ for each substrate.
Although the NET inhibitors DMI and mazindol abolished influx of all three 
[^H]substrates (see section 3), inhibition of low Na^-induced outward transport 
by DMI and mazindol varied between pH]NE, pH]DA and [^H]MPP^. 
Concentrations of DMI and mazindol that produced a maximal inhibitory 
action (i.e. 1 pM), significantly blocked a greater amount of low Na^-induced
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efflux of [^H]NE than [^H]DA and [^H]MPP^. In the efflux experiments, 
preloaded LLC-NET cells were exposed to a reduced Na^ HEPES buffer, 
simultaneously with DMI or mazindol. There was no pre-incubation period 
with the NET inhibitors as they may alter the intracellular contents of 
[^H]substrates (Johnson et al., 1998). It is very probable that the greater 
inhibitory action of DMI and mazindol on [^H]NE release is due to a lower 
affinity of the NET for NE in the intracellular environment. In addition, a 
notably inferior initial rate of pH]NE efflux compared to [^H]DA and [^H]MPP^, 
was observed. Both of these characteristics of [^H]NE transport, enable a 
greater number of NETs to be inhibited by DMI and mazindol prior to the 
induction of outward transport. To further clarify this hypothesis, experiments 
were performed with the amiloride derivative, EIPA. Unlike classical NET 
inhibitors, such as DMI, cocaine and mazindol, EIPA inhibits the NET by 
competing for the Na^ binding site of the transporter (Schomig et a!., 1989). 
EIPA markedly inhibited the efflux of all three [^Hjsubstrates. Despite this 
finding, similar to the NET inhibitors DMI and mazindol, EIPA blocked the 
efflux of [^H]NE by a greater degree than [^H]DA and pH]MPP'*’. EIPA is a 
very lipophilic compound and it is thought to compete for the inwardly facing 
NET, where the Na^ concentration is much lower (Schomig et al., 1989; 
Trendelenburg, 1991). Unlike DMI and mazindol, incubation of preloaded 
LLC-NET cells with EIPA did not alter the intracellular concentration of 
[^Hjsubstrates. If the affinity of the NET and initial rate of efflux for each 
[^H]substrate determines the potential for attenuation by NET inhibitors, pre­
incubation of LLC-NET cells with EIPA should produce a similar degree of
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efflux inhibition for [^H]NE, [^H]DA and [^H]MPP^. Indeed, pre-incubation of 
LLC-NET cells with EIPA significantly enhanced the inhibitory action of EIPA 
on low Na^-induced pH]DA and fHJMPP"^ efflux. This supports the 
suggestion that the NET has a lower affinity for intracellular [^H]NE than 
[^H]DA and [^H]MPP^, which in turn could account for the increased inhibition 
of [^H]NE by DMI and mazindol.
Comparable results to those obtained with low Na^ were observed when the 
NET substrate tyramine, was used as the stimulant for pHJsubstrate efflux 
from preloaded LLC-NET cells. Time-course and dose-response studies with 
tyramine, once again demonstrated that the amount of [^H]substrate released 
for a given time or concentration of tyramine was least for [^H]NE. The initial 
efflux of all three pHJsubstrates was less rapid than that seen with Na^- 
gradient reversal, this most likely reflects the time for association and 
dissociation of tyramine with the NET. Despite the reduced initial rate of efflux 
compared to Na^-g rad lent reversal, DMI and mazindol (simultaneous 
incubation with tyramine) had a far less pronounced effect on pH]DA and 
[^H]MPP^ efflux, than [^H]NE. One would assume that a significant amount of 
the inhibition of tyramine-induced efflux of [^H]substrates, by DMI and 
mazindol, would in fact be a result of blockade of tyramine uptake. Although 
this is probably a contributing factor, it appears that the most important 
determinant for the inhibitory action of DMI and mazindol on tyramine-induced 
efflux, is the specific kinetic properties of the intracellular [^H]substrate. 
Analogous to efflux experiments with a reduced Na^ buffer, pre-incubation of
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preloaded LLC-NET cells with EIPA, augmented its inhibitory action on 
tyramine-induced efflux of [^H]DA and [^H]MPP^. In addition, pre-incubation 
with EIPA potentiated the inhibitory action of EIPA on tyramine-induced 
[^H]NE release. This may reflect an increased inhibition of tyramine uptake 
with EIPA pre-incubation. Low Na^-induced efflux of [^H]substrates does not 
depend on the initial uptake of a substrate (e.g. tyramine), hence pre­
incubation with EIPA has no effect on [^H]NE efflux induced by Na^-gradient 
reversal.
Next the ability of DMI and mazindol to stimulate the efflux of [^H]substrates 
from preloaded LLC-NET cells was assessed. Both DMI and mazindol were 
found to induce a significant time- and dose-dependent efflux of all three 
[^Hjsubstrates. That the stimulatory action of DMI and mazindol was 
mediated via the NET, is clearly demonstrated with experiments performed in 
the presence of EIPA. EIPA markedly attenuated the inhibitor-induced efflux 
of [^H]NE, [^H]DA and [^H]MPP^, consistent with transport being dependent 
on the NET. The amount of inhibitor-induced [^H]substrate release 
(percentage of the total cell content taken up) differed greatly for [^H]NE, 
[^H]DA and [^H]MPP^. DMI and mazindol were least effective in stimulating 
the release of [^H]NE. Even after 2 hours exposure to DMI or mazindol, there 
was less than a 10% release of [^H]NE above that of the spontaneous efflux. 
Although stimulated efflux (low Na^ and tyramine-induced) of [^H]DA and 
[^H]MPP^ was similar, inhibitor-induced efflux of these 2 pH]substrates 
differed markedly. For a given dose or incubation time with DMI and
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mazindol, pH]MPP^ release was far greater than [^H]DA. 2 hours exposure of 
preloaded LLC-NET cells to the NET inhibitors resulted in more than 70% of 
the total intracellular contents of [^H]MPP"' being released into the 
extracellular buffer. When pH]DA was used as the NET substrate, ~ 30% of 
the intracellular content of [^H]DA was released in a 2 hour incubation period. 
In a previous study with LLC-NET cells, in which [^H]MPP'*‘ was used as the 
NET substrate (Wall et a/., 1995), it was shown that mazindol appeared to 
increase the spontaneous release of [^H]MPP‘*'. However, this observation 
was thought to be independent of a stimulatory effect of mazindol on the 
transporter. Instead it was suggested that the potentiation of [^HjlVIPP^ 
release in the presence of mazindol was a result of the blockade of [^HjlVIPP^ 
reuptake. The authors speculated that there may be a loss of [^H]MPP^ from 
preloaded LLC-NET cells that is independent of the transporter. In the 
absence of mazindol, this [^H]MPP^ is taken back up into the cells via the 
NET. Inhibition of the NET with mazindol prevents the reuptake of [^H]IVIPP*, 
hence just the NET-independent spontaneous loss of [^H]MPP^ occurs 
resulting in an increase of extracellular [^H]MPP^ concentration. Although this 
may contribute to the stimulatory effect of mazindol and DMI, the marked 
attenuation of inhibitor-induced pH]MPP^ efflux by EIPA, clearly demonstrates 
that this is a NET-mediated event. Additionally, it should be reiterated that 
EIPA alone, had no stimulatory effect on [^H]MPP^ efflux. If the DMI- and 
mazindoi-induced efflux of [^HjMPP^ was simply due to a blockade of the 
reuptake of pHjMPP^, EIPA would also increase the release of pHjMPP^ from 
preloaded LLC-NET cells.
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The much greater stimulatory properties of DMI and mazindol on [^H]MPP^ 
release compared to [^H]NE and [^HjDA, may contribute to the reduced 
inhibitory power of these two NET inhibitors on low Na^- and tyramine-induced 
[^HJMPP-  ^efflux.
In conclusion, this study demonstrates marked substrate-specific differences 
in the NET-mediated efflux of pH]NE, [^H]DA and [^H]MPP\ The specific 
kinetic parameters of each [^H]substrate appears to determine the 
susceptibility of preloaded LLC-NET cells to Na^-g rad lent reversal and 
tyramine-induced efflux. Despite blocking stimulated efflux of all three 
[^H]substrates (by varying degrees), DMI and mazindol induced a NET- 
mediated efflux of [^H]NE, pH]DA and [^H]MPP^ from preloaded LLC-NET 
cells incubated in a physiological HEPES buffer. Unlike that of low Na^- and 
tyramine-induced efflux, other factors than the kinetic parameters appear to 
contribute to the much greater release of [^H]MPP^ compared to [^H]NE and 
[^H]DA. The smaller but significant DMI and mazindol induced efflux of the 
endogenous substrates, implies that inhibitor-induced efflux of CAs may 
contribute to the therapeutic and abusive properties of CAT inhibitors.
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CHAPTER 6
DEVELOPMENT OF A FUNCTIONAL MODEL OF CARRIER- 
MEDIATED NOREPINEPHRINE RELEASE IN PROTRACTED
MYOCARDIAL ISCHEMIA
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6.1 INTRODUCTION
Exocytosis is the major physiological mechanism for NE release from synaptic 
vesicles of sympathetic nerve endings. The simplest way to determine if a 
release process is exocytotic is to investigate the Ca^^-dependence of 
transmitter efflux. Exocytosis of NE is dependent on an increase in
intracellular Ca^^ concentration (Sudhof, 1995), which usually arises from the 
influx of extracellular Ca^  ^ through voltage-gated ion channels or the 
mobilization of Ca^^ from intracellular stores (via IP3 production).
Unlike tightly controlled exocytosis, a second mechanism of NE release, 
carrier-mediated efflux, is Ca^^-independent and results in a far greater 
release of NE via a reversal of the NET (Kubler and Strasser, 1994; Schomig 
et a/., 1991; Imamura et al., 1996; Hatta et al., 1997). Any condition, 
physiological or pathophysiological, that causes an increase in adrenergic 
neuronal Na^ concentration can trigger the reversal of the NET (Paton, 1973). 
Accumulation of intracellular Na^ increases the availability of the NET to the 
inside of the axonal membrane and enhances the affinity of axoplasmic NE for 
the carrier (Sammet and Graefe, 1979). In protracted myocardial ischemia, 
extracellular Na^ enters the axoplasm of sympathetic nerve endings in 
exchange for intracellular via the NaVH^ exchanger (NHE). Several 
factors are responsible for the stimulation of this exchange process, and 
ultimately, the release of NE via a reversal of the neuronal uptake system 
(see figure 38).
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NE release under conditions of cardiac energy depletion (such as myocardial 
ischemia) can be described as a two-step process (see figure 38). The first 
step involves the loss of NE from storage vesicles of sympathetic nerve 
endings. In normoxic conditions the large majority of intracellular NE is stored 
in specialized vesicles where it is maintained in preparation for controlled 
release (Schuldiner, 1994). Storage of NE is dependent on a proton-driven 
vesicular monoamine transporter (VMAT), which exchanges 2 internal ions 
for cytoplasmic biogenic amine (Rudnick et a i, 1990). The transmembrane 
proton potential is created by a vacuolar ATP-dependent pump, which 
acidifies the interior of storage vesicles (Johnson, 1988). Lack of ATP in the 
ischemic heart prevents this process from maintaining a proton gradient 
between the axoplasm and synaptic vesicles. This not only inhibits the 
storage of cytoplasmic NE, but also causes the loss of stored NE to the 
axoplasm (Sulzer and Rayport, 1990). In normoxic conditions, enzymes 
present in the cytoplasm (e.g. monoamine oxidase; MAO) metabolize NE to 
dihydroxyphenylethyleneglycol (DOPEG) and related metabolites. DOPEG is 
a highly lipophilic metabolite that freely diffuses across the plasma membrane 
(Stute and Trendelenburg, 1984). Under anoxic conditions, lack of O2, of 
which MAO is dependent, prevents the breakdown of NE to its inactive 
metabolites (Schomig et al., 1987), thus, effectively enhancing the free 
axoplasmic NE concentration even further. The second essential step for 
non-exocytotic NE release is the influx of Na\ since the transport of NE Is 
critically dependent on the transmembrane Na^ gradient (Iversen and Kravitz, 
1966; Sanchez-Armass and Orrego, 1977). Ischemia-induced energy
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deprivation causes intracellular acidosis (due to lactate formation during 
anaerobic respiration), resulting in the activation of the NHE and therefore the 
influx ofNa* (Schomig etal., 1991; Kubler and Strasser, 1994; Imamura et a i, 
1996; Hatta et al., 1997). Failure of ATP-dependent pumps and exchangers, 
such as the Na^,K^-ATPase, which functions to remove intracellular Na^ in 
exchange for K ,^ potentiates the accumulation of axoplasmic Na"” in the 
ischemic heart. The processes described create a situation in which the 
sympathetic nerve endings contain a large amount of free axoplasmic NE and 
increased levels of intracellular N a\ In such conditions, many of the NETs 
will be immobilized and facing inwards, where they are able to bind Cl' and 
NE, re-inducing transporter mobility and hence outward transport of NE 
(Sammet and Graefe, 1979). In protracted myocardial ischemia, massive 
amounts of NE are released via this mechanism and there is much evidence 
to suggest a pro-arrhythmic action of this excess NE on the reperfused post 
ischemic heart (Ebert et al., 1970; Schomig et al., 1991) (see chapter 1.7).
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Figure 38. Scheme illustrating the events that trigger carrier-mediated 
NE release, and consequently the development of ventricular 
arrhythmias, in protracted myocardial ischemia.
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Legend for figure 38.
Lack of O2 results in a switch from aerobic respiration to anaerobic glycolysis. 
Consequently, ATP is depleted and axoplasmic pH is reduced (due to lactate 
production). This diminishes vesicular storage of NE, leading to a large 
increase in free axoplasmic NE. Compensatory activation of NHE by 
axoplasmic acidification causes the influx of Na* in exchange for H*. The 
resulting Na* accumulation triggers a massive release of free axoplasmic NE, 
via a reversal of the NET. Released NE acts on postsynaptic adrenoceptors 
on myocytes, pacemaker cells and conducting tissue. Stimulation of a i- and 
p-adrenoceptors results in an increased intracellular Ca^* concentration via 
IP3 production and increased Ca^* channel activity, respectively. Altered Ca^* 
homeostasis ultimately leads to the development of arrhythmias. Compounds 
that inhibit the NHE (e.g., EIPA) or NET (e.g., DMI) markedly attenuate 
carrier-mediated release of NE and consequently, the incidence of potentially 
fatal arrhythmias. Abbreviations: ARR, arrhythmias; DMI, desipramine; NET, 
norepinephrine transporter; NHE, Na*/H* exchanger; SNE, sympathetic nerve 
ending; VMAT, vesicular monoamine transporter.
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Previously, a direct correlation between the magnitude of NE overflow from 
guinea pig hearts subjected to global ischemia and the severity of reperfusion 
arrhythmias was demonstrated (Imamura et a!., 1996; Hatta et a/., 1999). A 
variety of agents that inhibit or potentiate NE overflow were shown to 
significantly reduce and prolong, respectively, the duration of ventricular 
fibrillation. Nonetheless, although isolated organ and tissue preparations 
allow the investigation of many regulatory processes of carrier-mediated NE 
release, the complexity of tissue responses to ischemia and reperfusion may 
mask important transductional processes involved in the outward transport of 
NE. Accordingly, the purpose of the present study was to develop a simpler 
cellular model of carrier-mediated transport. Cloning of the NET (Pacholczyk 
et al., 1991) has permitted the stable expression of NET cDNA in cell systems 
that are unequipped to store NE, allowing the investigation of the plasma 
membrane transporter without interference from vesicular storage. LLC-PKi 
cells are a rapidly growing, pig kidney-derived epithelial cell line (Haggerty et 
a i, 1985). In addition to being devoid of the machinery required for the 
uptake and vesicular storage of NE, LLC-PKi cells express two plasma 
membrane proteins that have pivotal roles in myocardial ischemia-induced 
carrier-mediated NE release, the Na*,K*-ATPase and an amiloride sensitive 
NHE (Chakraborty et a!., 1994). The findings presented here with a LLC-PKi 
cell line stably transfected with hNET cDNA demonstrate the potential of 
recombinant cell lines to study mechanisms and regulatory processes of 
carrier-mediated NE release, as seen in pathophysiological conditions, such 
as advanced myocardial ischemia.
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6.2 RESULTS.
6.2.1 High K*-induced exocytosis of [^H]NE from SK-N-SH cells.
K* induced the release of [^H]NE from preloaded SK-N-SH cells in a dose- 
dependent manner (figure 39A). The maximal release (% of total) was -  14.4%, 
compared to the basal efflux of -  5.3%. The calcium channel blockers, 
verapamil (5 iiM) and ro-conotoxin (100 nM) abolished depolarization (high K*) 
evoked release of pH]NE from SK-N-SH cells (figure 39B). Similar results were 
seen when a Ca^* free HEPES buffer was used during the release period. The 
NET inhibitor DMI had no significant effect on depolarization evoked release of 
[^H]NE.
Unlike exposure to a high K* HEPES buffer, incubation of preloaded SK-N-SH 
cells with a low Na* (5mM) buffer did not induce [^H]NE efflux above that of the 
basal release (figure 39C).
6.2.2 Carbachol-induced release of f  H]NE and [^H]MPP* from SK-N-SH 
cells.
Similarly to K*, the muscarinic agonist carbachol induced a dose-dependent 
release of pH]NE and [^H]MPP* from preloaded SK-N-SH cells (figure 40A). 
The maximal release of [^H]NE and [^H]MPP* was ~ 70 and 90% above that of 
basal efflux, respectively. The muscarinic antagonist atropine (10 p.M) blocked 
the carbachol-induced release of [^H]NE. (figure 40B)
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Figure 39. K*-evoked release of [^H]NE from preloaded SK-N-SH
cells.
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A) Points are mean ± S.E.M. values of [^H]NE efflux (percent release of 
total) elicited by the concentration of K* indicated on the abscissa. Bars 
are mean ± S.E.M. values of [^H]NE efflux (percent release of total) 
elicited by B) K* (100 mM) during a 5-min period and C) low Na* (5 mM) 
during a 5- and 30-min period (n = 4-6; *** P < .001 from control; f t t  P < 
.001 from 100 mM K* by AN OVA followed by post hoc Bonferroni’s test).
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Figure 40. Carbachol-induced release of [^H]NE from preloaded SK-
N-SH cells.
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A) Points are mean ± S.E.M. values of [^H]NE efflux (percent above basal) 
elicited by the concentration of carbachol indicated on the abscissa. B) 
Bars are mean ± S.E.M. values of [^H]NE efflux (percent release of total) 
elicited by carbachol (carb; 0.3 mM) in the absence or presence of 
atropine (atrop; 10 pM) (n = 4; *** P < .001 from control; f t t  P < .001 from 
carbachol by AN OVA followed by post hoc Bonferroni’s test).
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6.2.3 Low Na^-induced efflux of f  H]NE and f  H]MPP^ from LLC-NET cells.
The greater the degree of Na"‘-gradient reversal (by varying the extracellular Na"" 
concentration), the greater the efflux of [^H]NE and pHlMPR"*" from preloaded 
LLC-NET cells (figure 41). When compared in terms of percentage release of 
total [^H]substrate taken up, [^HJMPP'' efflux was more sensitive to gradual Na""- 
g rad lent reversal than [^H]NE.
6.2.4 Nigericin-induced f  H]W1PP"^  efflux from LLC-NET cells.
Nigericin (10 pM), a ionophore, induced a time- and dose-dependent
efflux of [^H]MPP'*' from preloaded LLC-NET cells (figures 42 and 43). The 
Na"',K'"-ATPase inhibitor ouabain (100 pM), whilst having no effect of its own, 
significantly potentiated the nigericin-induced efflux of [^H]MPP^ from LLC-NET 
cells incubated in a modified HEPEs buffer (40 mM Na*) (figure 42). In both 
control and ouabain-treated conditions, efflux of [^H]MPP* from preloaded LLC- 
NET cells during a 20-min period, was -  20% of the total cellular content of 
[^H]MPP*. This value increased to -  40 and 50% in the presence of nigericin 
and nigericin + ouabain, respectively. In experiments performed in a 
physiological HEPES buffer (125 mM Na*), prolonged inhibition of the Na*,K*- 
ATPase with ouabain induced a significant efflux of pH]NE and [^H]MPP* (figure 
44).
DMI (100 nM) significantly potentiated the early phase (< 10 minutes; figure
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45A) of nigericin + ouabain induced efflux of [^H]MPP* from LLC-NET cells 
incubated in a physiological HEPEs buffer. DMI potentiated the release of 
[^H]MPP* induced by 5 min stimulation with nigericin + ouabain by more than 
100% (from ~ 6.1 to 12.7%). In contrast, DMI inhibited long term (> 10 min; 
figure 45B) nigericin + ouabain induced efflux of [^H]MPP*. Inhibition reached ~ 
70% at 30 min.
The maximal inhibitory action of DMI on nigericin + ouabain-induced [^H]MPP* 
efflux was greater when experiments were performed in a modified HEPES 
buffer (40 mM Na*) (figure 46)
The NHE inhibitor EIPA (10 pM) significantly inhibited both the early phase 
(figure 47A) and long term (figure 47B) nigericin + ouabain induced [^H]MPP* 
efflux from LLC-NET cells. During 5 and 30 min stimulation with nigericin + 
ouabain, EIPA inhibited [^H]MPP* efflux by ~ 60 and 45%, respectively. In 
contrast, the Na*-channel blocker tetrodotoxin (1 pM) caused only a slight 
inhibition of nigericin + ouabain induced release of pH]MPP* from LLC-NET 
cells (~ 10 % in a 30-min release period) (figure 48A).
The Na* ionophore gramicidin (10 pM) elicited [^H]MPP* efflux from preloaded 
LLC-NET cells. EIPA (10 pM) failed to inhibit gramicidin-induced pH]MPP* 
efflux (figure 48B).
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Figure 41. fH]NE and fH]MPP^ efflux from LLC-NET cells as a 
function of the extracellular Na* concentration.
40
NE
MPP+
_a
20 -
co
10 -
100
Preloaded LLC-NET cells were incubated in a modified HEPES buffer with 
an altered Na* concentration. Points are mean ± S.E.M values of [^H]NE 
and [^H]MPP* efflux (% release of total) during a 10-min period in the 
presence of the concentration of Na* indicated on the abscissa (n = 4).
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Figure 42. The effect of the Na^,K*-ATPase inhibitor ouabain on
nigericin-induced efflux of pH]MPP^ from preloaded LLC-NET cells.
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Points are mean ± S.E.M. values of nigericin (ngr; 10 i^M) induced 
[^H]MPP^ efflux from preloaded LLC-NET cells (% release of total) 
incubated in a 40 mM Na^ HEPES buffer in the presence or absence of 
ouabain (100 p,M), at the times indicated on the abscissa (n = 4; *** P < 
.001 from control; f  P < .05 and t t t  P < .001 from nigericin + ouabain, by 
AN OVA followed by post hoc Bonferroni’s test).
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Figure 43. Dose dependent increase in fH]MPP^ efflux from LLC- 
NET cells induced by the K*IH* ionophore nigericin.
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Points are mean ± S.E.M. values of [®H]MPP* efflux (% release of 
maximal) elicited by nigericin at the concentration indicated on the 
abscissa from preloaded LLC-NET cells incubated in a modified HEPES 
buffer containing 40 mM Na^ and 100 juM during a 30-min period (n = 4). 
Basal and maximal nigericin stimulated efflux were -  19 and 87% of the 
total cellular contents of [^H]MPP^, respectively.
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Figure 44. Ouabain evoked pH]NE and [^H]MPP* efflux from
preloaded LLC-NET cells.
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Bars are mean ± S.E.M. values of [^H]NE and [^H]MPP^ efflux (percent 
release of total) elicited by the Na^.K^-ATPase inhibitor ouabain (100 pM) 
during a 60-min period (n = 4; *** P < .001 from control by Student’s t 
test).
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Figure 45. The effect of the norepinephrine transporter inhibitor DMI 
on nigericin + ouabain-induced efflux of pH]MPP^ from LLC-NET 
cells.
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Points are mean ± S.E.M. values of nigericin (ngr; 10 ^M) + ouabain- 
(ouab; 100 |iM) induced [^H]MPP^ efflux from preloaded LLC-NET cells (% 
release of total) in the presence or absence of DMI (100 nM), at the times 
indicated on the abscissa (n = 4; ** P < .01 and *** P < .001 from control; 
t t  P < .01 and t t t  P < .001 from nigericin + ouabain, by AN OVA followed 
by post hoc Bonferroni’s test).
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Figure 46. Dose-dependent inhibition of nigericin + ouabain-induced 
[^H]MPP* efflux from LLC-NET cells, by the norepinephrine 
transporter inhibitor, DMI.
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Points are mean ± S.E.M. values of [^H]MPP^ efflux (percent release of 
total) elicited by nigericin (10 |aM) + ouabain (100 |j-M) during a 30-min 
period in the presence of the concentration of DMI indicated on the 
abscissa (n = 4).
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Figure 47. The effect of the Na^-H* exchanger inhibitor EIPA on 
nigericin + ouabain-induced efflux of [^H]iVIPP^  from LLC-NET cells.
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Points are mean ± S.E.M. values of nigericin (ngr; 10 pM) + ouabain- 
(ouab; 100 jiM) induced [^H]MPP^ efflux from preloaded LLC-NET cells (% 
release of total) in the presence or absence of EIPA (10 pM), at the times 
indicated on the abscissa (n = 4; * P < .05 and ***, and P < .001 from 
control; f  P < .01 and t t t  P < 001 from nigericin + ouabain, by AN OVA 
followed by post hoc Bonferroni’s test).
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Figure 48. The effect of the sodium channel blocker TTX on nigericin
+ ouabain-induced [^H]MPP  ^efflux from LLC-NET cells.
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Bars are mean ± S.E.M. values of [^H]MPP^ efflux during a 30-min period 
(percent release of total) elicited by A) nigericin + ouabain (10 pM) in the 
absence or presence of TTX (1 pM) or EIPA (10 pM) and B) gramicidin (n 
= 4; ** P < .01 and *** P < .001 from control; t  P < .05 and t t t  P < .001 
from nigericin + ouabain, respectively by ANOVA followed by post hoc 
Bonferroni’s test).
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6.2.5 Nigericin-induced f  H]MPP'  ^efflux from SK-N-SH cells.
Nigericin (10 pM) induced the efflux of pHlMPR"^ from preloaded SK-N-SH cells 
(figure 49). Similar to LLC-NET cells, the NET inhibitor DMI (100 nM) and the 
NHE blocker EIPA (10 pM), markedly attenuated the nigericin-induced efflux of 
I^H]MPPT
6.2.6 Proprionate-induced fH]-WIPP^ efflux from LLC-NET cells: 
modulation by EIPA, ouabain and imidazoline receptors.
As an alternative to nigericin, proprionate was used to stimulate carrier-mediated 
release of [^H]MPP^ from LLC-NET cells. As illustrated in figure 50, proprionate 
(25 mM) induced an efflux of [^H]MPP^ from LLC-NET cells. Proprionate- 
induced fHlMPP"^ efflux was potentiated by ouabain (100 pM) and inhibited by 
EIPA (10 pM). The imidazoline receptor agonist, rilmenidine, dose-dependently 
attenuated the proprionate-induced release of pH]MPP^ (figure 51 A). The 
inhibitory effect of rilmenidine was antagonized by the Imidazoline receptor 
blocker, idazoxan (10 pM) (figure 51B).
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Figure 49. Nigericin + ouabain-induced efflux of [^H]MPP* from
preloaded SK-N-SH cells.
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Bars are mean ± S.E.M. values of [^H]MPP^ efflux (percent release of 
total) elicited by nigericin (10 pM) + ouabain (100 pM) during a 30-min 
period in the absence or presence of DMI (100 nM) or EIPA (10 |iM) (n = 
4; *** P < .001 from control; f t  P < .01 and t t t  P < .001 from nigericin + 
ouabain, respectively, by ANOVA followed by post hoc Bonferroni’s test).
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Figure 50. Proprionate-induced efflux of [^H]MPP* from preloaded
LLC-NET ceils.
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Bars are mean ± S.E.M. values of [^H]MPP^ efflux (percent release of 
total) elicited by proprionate (25 mM) during a 10-min period in the 
absence or presence of ouabain (100 pM) and/or EIPA (10 pM) (n = 4; *** 
P < .001 from control; t t t  P < .001 from proprionate, respectively, by 
ANOVA followed by post hoc Bonferroni’s test).
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Figure 51. Inhibition of proprionate-induced [^H]MPP* efflux from 
LLC-NET cells by the imidazoline receptor agonist rilmenidine.
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A) Points are mean ± S.E.M. values of [^H]MPP^ efflux (percent release of 
total) elicited by proprionate (25 mM; 10-min) in the presence of the 
concentration of rilmenidine indicated on the abscissa. B) Bars are mean 
± S.E.M. values of [^HIMPP"" efflux (percent release of total) elicited by 
proprionate (25 mM) in the absence or presence of rilmenidine (rilm; 10 
pM) and/or the imidazoline antagonist, idazoxan (idaz; 10 pM) (n = 4; *** P 
< .001 from control; f t t  P < .001 from proprionate; t t t  P < .001 
proprionate + rilm by ANOVA followed by post hoc Bonferroni’s test).
188
6.3 DISCUSSION.
Analogous to carrier-mediated NE release in advanced myocardial ischemia, 
which is known to be NHE-dependent, the efflux of [^H]MPP‘^  from preloaded 
LLC-NET cells was stimulated by the KVH* ionophore nigericin, an action that 
was potentiated by ouabain, blocked by the NHE inhibitor EIPA, and sensitive 
to the NET inhibitor DMI. These findings suggest that LLC-NET cells 
represent a useful model for future studies of cellular processes involved in 
carrier-mediated NE release in protracted myocardial ischemia.
As reported by others (Apparsundaram et a i, 1998a; Richards and Sadee, 
1986), SK-N-SH neuroblastoma cells take up exogenous NE and other NET 
substrates (e.g. [^H]MPP^). Storage of these substrates in synaptic vesicles 
(via the VMAT) maintains high-localized concentrations of the substrate and 
enables controlled exocytosis. That a large amount of NE is stored within 
synaptic vesicles was indirectly demonstrated in this study by experiments in 
which preloaded SK-N-SH cells were exposed to a low Na^ HEPES buffer. 
Unlike that seen with preloaded LLC-NET cells (see chapters 4 and 5, and the 
discussion below), reversal of the Na^-g rad lent did not stimulate the efflux of 
[^H]NE from preloaded SK-N-SH cells above that of basal. This suggests that 
the free intracellular concentration of [^H]NE in SK-N-SH cells is relatively low 
and therefore little substrate is available for reverse transport. 
Depolarization-evoked release of [^H]NE from SK-N-SH cells was exocytotic 
in nature, as demonstrated by the dependence of the release process on
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extracellular Ca^^ (Sudhof, 1995). Furthermore, the Ca^  ^ channel blockers 
verapamil and w-conotoxin also abolished K^-induced release of [^H]NE, 
indicating that the opening of voltage gated Ca^"‘-channe!s and subsequently 
the influx of Ca^^ is the trigger for [^H]NE release. SK-N-SH cells possess 
both L- and N-type Ca^^ channels (Reuveny and Narahashi, 1993), both of 
which contribute to depolarization-evoked [^H]NE release. The NET inhibitor 
DMI (100 nM) did not inhibit K^'-induced release of [^H]NE, ruling out carrier- 
mediated NE release as a contributing mechanism to [^H]NE efflux under 
these conditions. In many situations, DMI actually potentiates exocytotic 
release of NE by preventing its reuptake by the sympathetic nerve endings 
(see chapter 1.4).
As demonstrated in chapters 4 and 5, NET-mediated efflux of both pH]NE and 
[^H]MPP^ from preloaded LLC-NET cells was stimulated by a reversal of the 
Na^-g rad lent. LLC-NET cells preloaded with [^H]NE or [^H]MPP^ were very 
sensitive to the extracellular Na^ concentration. Above 30 mM Na^, only a 
small amount of pH]substrate efflux was seen. Lower concentrations of Na^ 
induced a marked release of both [^H]substrates from LLC-NET cells. When 
the extracellular Na^ concentration is reduced below a critical value (< 30 mM 
in our model), fewer transporters are immobilized on the extracellular side of 
the plasma membrane, making more transporters freely mobile and available 
to the intracellular side. Reuptake of released [^Hjsubstrates will be less 
favorable in a reduced Na^ buffer, augmenting the release process.
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The most important trigger for carrier-mediated release of free axoplasmic NE 
in myocardial ischemia is activation of the NHE. Therefore, the ability to 
stimulate this exchange process (intracellular H  ^ for extracellular Na^) was 
assessed in LLC-NET cells.
A popular technique for acidifying cells and synaptosomal preparations, and 
subsequent NHE activation is NH4CI prepulsing (Chakraborty et al., 1994; 
Haggerty et al., 1985). This method requires incubating the cells or 
synaptosomes in a NaVree buffer containing a high concentration of NH4CI 
(e.g. 50 mM). After a given period (e.g. 30 min), cells are exposed to a NH4CI 
free buffer containing -  15 mM NaCI (Chakraborty et al., 1994) and the 
subsequent NHE-dependent influx of Na^ is measured. The use of this 
method was not possible for carrier-mediated efflux experiments of NET 
substrates in this study, as preloaded LLC-NET cells will lose large amounts 
of [^H]substrate when exposed to the Na^-free buffer. As an alternative 
method to NH4CI prepulsing, the KVH^ ionophore, nigericin was used to 
stimulate the NHE. Nigericin is a commonly used ionophore that mediates the 
exchange of external H  ^for internal (Erecinska et al., 1993). Incubation of 
cells with nigericin lowers both the intracellular pH (pHJ and concentration 
(Erecinska et al., 1993). Therefore, exposure of cells to nigericin results in a 
depolarization of the plasma membrane, triggering the opening of voltage- 
operated ion channels and the subsequent influx of Na^ and Ca^^ (Rodriguez 
and Sitges, 1996; Erecinska et al., 1993). The influx of Ca^ "" induced by 
nigericin has been shown to stimulate the exocytotic release of
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neurotransmitters (Rodriguez and Sitges, 1996; Erecinska et a i, 1993), whilst 
the nigericin-induced reduction in pH| has been demonstrated to activate the 
NHE (Erecinska et a i, 1993). The influx of Na^ via NHEs and voltage- 
sensitive Na^ channels could lead to the reversal of the NET and the release 
of axoplasmic substrate. Indeed, nigericin elicits a Ca^^-dependent and 
independent release of neurotransmitter from synaptosomes, neurons and C6 
glioma cells (Rodriguez and Sitges, 1996; Erecinska et a i, 1993), and has 
been shown to induce the release of MPP^ from preloaded platelets (Cesura 
et a i, 1987). In this study, nigericin induced a large increase in [^H]IVIPP  ^
release from preloaded LLC-NET cells, indicating that this compound does 
indeed stimulate the influx of Na^ and consequently a reversal of the NET.
In physiological conditions, Na‘*‘,K''-ATPase is responsible for maintaining the 
intracellular concentration of Na^ and by exchanging extracellular for 
intracellular Na^ (Stute and Trendelenburg, 1984). ATP depletion in various 
pathophysiological conditions (e.g. protracted myocardial ischemia) leads to 
an augmentation of intracellular Na^ accumulation, as Na^,K^-ATPase activity 
is inhibited. Inhibition of Na^,K^-ATPase with ouabain potentiated the 
nigericin-induced release of fH]MPP'^ from LLC-NET cells. These 
experiments were performed in a reduced-Na^ buffer to minimize the effect of 
ouabain alone. Prolonged inhibition of the Na^,K^-ATPase can itself, induce 
neurotransmitter release (Stute and Trendelenburg, 1984), as indeed was 
found in experiments with LLC-NET cells in a physiological HEPEs buffer in 
this study. In a 40 mM Na^ HEPEs buffer, ouabain did not stimulate [^H]MPP^
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efflux, but did potentiate the release induced by nigericin.
DMI inhibited the prolonged (>10 minutes) nigericin + ouabain-induced efflux 
of [^H]MPP^, clearly demonstrating that this release process is mediated by a 
reversal of the NET. However, DMI markedly potentiated the efflux of 
[^H]MPP^ during the early phase (<10 minutes) of the nigericin + ouabain- 
induced efflux. These experiments were performed in a physiological buffer, 
which has a high extracellular Na^ concentration. Accordingly, in the 
experiments with nigericin + ouabain alone, [^H]MPP^ released from LLC-NET 
cells will be subject to reuptake, as the high extracellular Na^ concentration 
favors inward transport. Because DMI inhibits the reuptake process, the 
concentration of extracellular [^H]MPP^ was higher than in the absence of 
DMI. An alternative explanation is the occurrence of inhibitor-induced efflux of 
[^H]MPP^ (see chapter 5) which will proceed until a significant outward 
transport of [^H]MPP^ is stimulated by the influx of Na^ as a consequence of 
NHE activation. It is possible that both of these processes contribute to an 
increased concentration of [^HjMPP^ in the extracellular buffer in the presence 
of DMI. With prolonged exposure to nigericin + ouabain, more Na^ 
accumulates within the cell, and thus the Na^ gradient favoring inward 
transport is reduced. In addition, more transporters will have been 
immobilized by DMI, reducing the number of transporters available for 
outward transport. Hence, DMI would be expected to reduce, as it did, the 
extracellular concentration of [^H]MPP^ during prolonged nigericin + ouabain 
treatment (>10 minutes).
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A recent study in brain synaptosomes demonstrated that at a low 
concentration (0.5 pM) nigericin behaves as a NaVH^ ionophore under 
physiological conditions (Rodriguez and Sitges, 1996). In that study, nigericin 
caused an increase in pHj (suggesting a loss of H^), Ca^"’ and Na"^ . It was 
concluded that the influx of Na^ was mediated through the ionophore itself. In 
our studies, no release of [^H]MPP^ was seen at concentrations of nigericin 
less than 3 pM. Furthermore, Rodriguez and Sitges used synaptosomes, 
rather than cells. It is probable that these different systems respond 
differently to the ionophore. In fact, in another study it was found that 5 pM 
nigericin caused a continuing increase of and thus lowered pH| in C6 
glioma and cultured neuron cells (Erecinska et ai, 1993). Our experiments 
with the amiloride derivative, EIPA (a potent inhibitor of NHE), clearly suggest 
that the nigericin + ouabain-induced efflux of [^H]MPP’^  from preloaded LLC- 
NET cells is a consequence of Na^ influx via the NHE. Unlike DMI, EIPA 
inhibited both the early and the late phase of the nigericin + ouabain-induced 
[^H]MPP^ efflux. This not only indicates an inhibitory action of EIPA at the 
NHE, but also eliminates the possibility that EIPA is acting at the NET. 
Indeed, if EIPA were to act at the NET, one would expect a potentiation of 
[^H]MPP^ release in the early phase of nigericin + ouabain-induced efflux. 
The inability of EIPA to inhibit gramicidin (a Na^ ionophore) induced [^H]MPP^ 
efflux, further supports an action of EIPA at the NHE.
To determine the influence of voltage-dependent Na^ channels on the
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nigericin + ouabain-induced efflux, release experiments in the presence of the 
Na^ channel blocker, TTX, were performed. TTX had very little effect on 
[^H]MPP^ efflux, suggesting that the opening of voltage-sensitive Na^ 
channels has only a minor role in stimulating [^H]MPP^ efflux in this model of 
carrier-mediated efflux.
The influx of Na^ via NHE activation is just one consequence of intracellular 
acidosis. Lowering of intracellular pH also results in the loss of NE from 
vesicular stores to the axoplasm, as the vesicular membrane pH gradient is 
diminished. The finding that nigericin also stimulated an EIPA- and DMI- 
sensitive release of [^H]MPP^ from SK-N-SH cells, implies that the reduction 
of intracellular pH triggered by nigericin causes the loss of [^HjMPP^ from 
vesicular stores. Only free cytoplasmic [^HjlVIPP  ^ will be subject to reverse 
transport, once Na^ enters in exchange for H .^ It should be reiterated that 
exposure of preloaded SK-N-SH cells to a low Na^ buffer did not stimulate 
pHjNE efflux above that of the basal.
To further assess the usefulness of LLC-NET cells as a model, and their 
potential to study receptor-mediated regulation of carrier-mediated NE 
release, a less powerful stimulant of reverse transport, namely proprionate, 
was used. Proprionate has previously been shown to stimulate the NHE in 
LLG-PKi cells (Schlatter et a/., 1997). Proprionate was found to elicit an efflux 
of [^HjlVIPP^ from pre-loaded LLC-NET cells. Similar to that seen with 
nigericin, the Na^,K^ATPase inhibitor ouabain (100 pM), potentiated
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proprionate-induced pH]MPP^ efflux. The NHE inhibitor EIPA (10 pM), 
inhibited proprionate-induced efflux, confirming the influx of Na^ via NHE 
activation with this compound. Imidazoline receptors are known to be coupled 
to the NHE in LLC-PKi cells (Schlatter et al., 1997). When these receptors 
were activated with rilmenidine, the proprionate-induced release of [^H]MPP‘^  
was markedly inhibited. The imidazoline receptor antagonist idazoxan 
blocked the inhibitory effect of rilmenidine, confirming the specificity of the 
rilmenidine response.
In conclusion, these data illustrate the potential of recombinant cell lines to 
study mechanisms and regulatory processes of carrier-mediated NE release. 
Similarly to that seen in advanced myocardial ischemia, carrier-mediated 
efflux of a NET substrate could be stimulated from LLC-NET cells by 
activating the NHE. Further, this release process could be modulated with 
inhibitors of the NET, NHE and via a receptor-operated pathway. Because 
excessive NE release contributes to severe, sometimes fatal myocardial 
arrhythmias, an improved understanding of the carrier-mediated NE release 
process will ultimately enhance the ability to intervene and prevent the 
deleterious effects of excessive NE release.
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CHAPTER 7
GENERAL DISCUSSION
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The plasma membrane CATs are integral membrane proteins whose first and 
foremost function is to terminate neurotransmission by a Na^- and Cl'- 
dependent reaccumulation of released CAs (Amara and Kuhar, 1993). Not 
only do these proteins contribute to the duration and extent of a transmitter 
response (the potential for receptor occupation), they are also vital for the 
recycling and storage of CAs within sympathetic nerve endings (Rudnick and 
Clark, 1993). As well as these critical physiological functions, the NET 
mediates the efflux of NE triggered by substrate influx (Langeloh et a/., 1987; 
Stute and Trendelenburg, 1984) and in conditions in which the intracellular 
Na^ homeostasis is perturbed, such as myocardial ischemia (Imamura et a!., 
1996; Hatta et al., 1997; Hatta et al., 1999; Kurz et al., 1996; Schomig et al., 
1988b).
Great advances in our understanding of the properties of the Na""- and CIn­
dependent transporter family has arisen from their cloning and expression in 
heterologous cell lines (Pacholczyk et al., 1991; Hoffman etal., 1991; Kilty et 
al., 1991). Initial studies focussed on differences between members of the 
Na^- and Cl'-dependent transporter family, particularly the ion dependence, 
substrate and inhibitor sensitivities (Gu et al., 1994; Gu et al., 1996). 
Expression of the different transporters in the same cellular background 
enables precise comparisons of the transporters, without interference from 
tissue or cell specific factors, problems encountered with synaptic 
preparations.
198
Initial work in this study confirmed the ion-dependence of the NET by 
measuring the uptake of fH]NE, [^H]DA and [^HjlVIPP  ^ in the presence of 
various concentrations of Na^ or Cl". The simple hyperbolic relationship seen 
with increasing concentrations of Na^ or Cl" and [^H]substrate uptake suggests 
that 1 Na"" and 1 Cl" ion is required for the transport of the f  H]substrate.
The KmNa+ and Kmci- for substrate uptake were comparable to previous studies 
of the NET expressed in LLC-PKi cells (Gu et al., 1994), with the Kmci- being 
considerably less than the KmNa+ (~ 4 and 50 mM, respectively). The greater 
dependence of NET-mediated transport on Na^ than Cl" suggests that 
alterations in the inwardly directed Na^-gradient may have a larger influence 
on transport than changes in the Cl"-gradient. Indeed, prolonged inhibition of 
the Na^,K^-ATPase with ouabain resulted in a marked inhibition of 
[^H]substrate influx.
The study presented here has demonstrated that the metabolism of NE and 
DA by COMT has an enormous influence on the apparent uptake of [^HJCAs 
by recombinant cell lines (LLC-NET and SKNMC-NET) and SK-N-SH 
neuroblastoma cells, which endogenously express the NET (Richards and 
Sadee, 1986). Two structurally dissimilar COMT inhibitors, tropolone and Ro 
41-0960 significantly potentiated the apparent uptake of [^H]NE and [^H]DA, 
but not the COMT resistant substrate, [^H]MPP^. This is similar to findings 
made recently with C6 glioma, L-M fibroblast and HEK293 cells stably 
transfected with either the DA or NE transporter (Eshleman et al., 1997). The
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effect of COMT inhibition on the apparent uptake was considerably greater for 
[^H]DA than [^H]NE. This reflects the greater degree of lipophilicity of 
methoxytyramine, a metabolite of DA, than normetanephrine, a metabolite of 
NE. The plasma membrane is an impermeable barrier to both NE and DA, 
therefore the loss of radiolabel from LLC-NET, SKNMC-NET and SK-N-SH 
cells in the absence of COMT inhibition, reflects the loss of [^H]metabolites 
from the cells. Indeed, in the absence of COMT inhibitors, HPLC studies of 
NE uptake by recombinant cell lines revealed a significantly lower actual 
intracellular NE concentration than that predicted by experiments with labeled 
NE (Eshleman et al., 1997). Whereas pHJmetabolites and [^H]NE are 
detected as one, HPLC measurements with electrochemical detection 
distinguishes NE from its metabolites (Eshleman et al., 1997). This study also 
revealed that COMT inhibition is required for carrier-mediated efflux studies of 
[^H]CAs. Only a slight increase in [^H]NE efflux with Na^-gradient reversal 
was seen in the absence of tropolone.
A somewhat surprising finding was the inhibitory action of the MAO inhibitor, 
pargyline, on [®H]NE, [^H]DA and f  H]MPP* uptake by LLC-NET and SK-N-SH 
cells. The obvious explanation for this response is an inhibitory action of 
pargyline at the NET. Pargyline is a derivative of CAs and appears to show a 
degree of affinity for the NET. A previous study with Chinese hamster ovary 
(CHO) cells stably expressing the NET also demonstrated an inhibitory action 
of MAO inhibitors (including clorgyline and phenelzine) on [^H]NE uptake 
(Percy et al., 1999). Although a reason for this inhibitory action was not
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proposed, similar to the findings with pargyline in this study, it most likely 
reflects an action of MAO inhibitors at the NET.
Inhibitors of the CATs are defined as such because they prevent the uptake of 
transporter substrates. These compounds have been shown to bind to 
transporters in a Na^-dependent manner (Schomig and Bonisch, 1986), but 
unlike substrates, were thought unable to induce transport of intracellular 
substrates (facilitated exchange diffusion). However, studies with the cloned 
DAT have demonstrated inhibitor-induced efflux of [^H]DA (Eshleman et a/., 
1994) and [^H]MPP^ (Johnson et al., 1998). In a different study, differences 
between the effect of inhibitors on [^H]substrate efflux, were seen between 
fH ]DA and fH]MPP^ (Kitayama et al., 1996). Whether this is a property 
shared by the NET has been investigated in this study. Influx of three 
[^H]substrates, [^H]NE, pH]DA and [^H]MPP^ was abolished by the NET 
inhibitors, DMI and mazindol. The degree of blockade of tyramine- of low 
Na^-induced efflux, exhibited by the two NET inhibitors, differed greatly 
between the [^Hjsubstrates. An explanation for this was proposed after 
experiments were performed with the amiloride derivative, EIPA, which at high 
p.M concentrations, competes for the Na^-binding site of the NET (Schomig et 
al., 1989; Trendelenburg, 1991), thus inhibiting transport. EIPA acts at the 
inward-facing conformation of the NET where the Na^ concentration is less, 
and must therefore first equilibrate across the plasma membrane. It was 
found that EIPA, similar to the NET inhibitors, blocked the efflux of [^H]NE 
induced by low Na^ or tyramine by a greater degree than it blocked [^H]DA or
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[^H]MPP^ efflux. Pre-incubation of preloaded LLC-NET cells with EIPA 
markedly potentiated the inhibitory action of EIPA on outward transport. This 
implies that differences in the kinetic properties of each intracellular 
[^H]substrate contributes to the differences in sensitivity of the [^H]substrate to 
inhibitors. Analogous to that seen with studies of the DAT, DMI and mazindol 
induced an efflux of [^H]NE, pH]DA and [^H]MPP^ from preloaded LLC-NET 
cells. The dependence of the NET on this process was demonstrated by 
inhibition studies with EIPA. The inhibitor-induced release of [^H]MPP^ was 
much greater than that of [^H]NE or pH]DA
In protracted myocardial ischemia, NHE activation is the major trigger for the 
efflux of free axoplasmic NE from sympathetic nerve endings. (Kubler and 
Strasser, 1994; Schomig et al., 1991; Imamura et al., 1996; Hatta et al.,
1997). Although carrier-mediated efflux of CAT substrates from recombinant 
cell lines has been demonstrated (Wall et al., 1995; PifI et al., 1997; Chen et 
al., 1998), this study is the first to manipulate NHE activation and Na^,K^- 
ATPase inhibition, to trigger reverse transport. Isolated tissue experiments 
have shown that NET and NHE inhibitors are extremely effective in 
attenuating ischemia-induced NE efflux, which is considerably greater than 
exocytotic NE release. Furthermore, the reperfusion arrhythmias associated 
with this massive NE release are alleviated with NET and NHE inhibitors. 
Although the NET is a target for regulation by second messengers 
(Apparsundaram et al., 1998a; Apparsundaram et al., 1998b; Uchida et al.,
1998), carrier-mediated efflux of NE during protracted myocardial ischemia
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appears to be regulated by modulation of the influx of Na"*", particularly via the 
NHE (Imamura et al., 1996; Hatta et al., 1997; Hatta et al., 1999; Kurz et al., 
1996; Schomig et al., 1988b) and in some cases, TTX-sensitive Na^ channels 
(Hatta et al., 1997). In this model of carrier-mediated NE release, an 
imidazoline receptor, which is known to negatively modulate NHE activity in 
LLC-PKi cells (Schlatter et al., 1997), was found to markedly augment 
proprionate-induced [^HJMPP"" release, from preloaded LLC-NET cells. The 
specificity of the receptor induced response was demonstrated by a reversal 
of the agonists action with the antagonist, idazoxan. This finding in itself 
implicates recombinant cell lines expressing the NET as useful functional 
models for studying the regulation of carrier-mediated release processes.
In summary, the studies reported in this thesis have established LLC-PKi cells 
stably expressing the NET as a suitable system for studying carrier-mediated 
influx and efflux of NET substrates. The NET retains its specific properties, 
such as ion-dependence and inhibitor sensitivity when expressed in this and 
other recombinant cell lines. The metabolism of [^H]CAs by COMT was found 
to be a major cause of radiolabel loss from LLC-NET cells and other cell lines 
expressing the NET. Inhibitors of COMT increased the apparent uptake of 
[^H]NE and [^H]DA. Furthermore, the use of COMT inhibitors was shown to 
be a prerequisite for carrier-mediated efflux studies. As has been 
demonstrated for the DAT, DMI and mazindol induced a time- and dose- 
dependent efflux of [^Hjsubstrates from LLC-NET cells. This inhibitor-induced 
efflux was dependent on the NET and varied markedly between
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[^H]substrates. Finally, LLC-NET cells were found to represent a functional 
model of carrier-mediated NE release in protracted myocardial ischemia.
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